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Whooping cough, the respiratory disease caused by the bacterium Bordetella pertussis, has been 
resurgent for the last thirty years. Several reasons have been suggested for this resurgence, including 
increased awareness and improved diagnosis techniques, waning immunity conferred by the 
whooping cough vaccine, and genetic shifts of circulating bacteria away from the vaccine strains. 
These genetic changes  may have been accelerated by the switch in many countries from a whole cell 
vaccine to an acellular vaccine containing just one to five B. pertussis antigens. Aside from certain key 
genes, however, variation between B. pertussis strains appears to be very limited on the level of single 
genes. Instead, in recent years, a picture of genome level inter-strain variation has been emerging, 
beginning with the revelation that genomic rearrangements, mediated by the numerous insertion 
sequence elements in the B. pertussis genome, are common. Investigations of whole genome 
variation, alongside classic molecular epidemiological studies, may therefore be important to our 
understanding of how genetic changes in B. pertussis are contributing to whooping cough resurgence.  
Many genome level changes may be observable only in closed genome sequences. The highly 
repetitive B. pertussis genome, which contains up to 300 identical copies of a 1,000 bp insertion 
sequence, has traditionally been difficult to resolve to the single-contig level, with most genomes 
assembled using Illumina sequencing data consisting of at least as many contigs as there are insertion 
sequence copies. Here, I first define a sequencing and data processing pipeline, utilising  nanopore 
long-read and Illumina short-read sequencing to enable the assembly of accurate, closed B. pertussis 
genome sequences. Using this hybrid sequencing pipeline, I then investigate the genomes of 66 B. 
pertussis strains isolated in New Zealand between 1982 and 2008. New Zealand commonly sees a 
higher rate of incidence of whooping cough than most other countries, and no isolates from the 
country had previously been sequenced. Several of the genomic features of the New Zealand isolates 
match those observed in many other countries, including a selective sweep from strains carrying the 
ptxP1 allele to the ptxP3 allele and a recent rapid increase in the number of strains which are unable 
to produce pertactin, one of the antigens usually included in the acellular vaccine. Nonetheless, the 
data also indicate that the strains circulating in New Zealand might be more genetically similar than 
those circulating in other countries, particularly in recent years, and particularly during whooping 
cough outbreaks. This strain screen is the first of its kind to use nanopore sequencing, and to include 
traditional analysis of genotypes with analysis of genome level variation, such as rearrangements and 
copy number variations. Next, I attempt to investigate an ultra-long genomic duplication identified 
whilst testing the hybrid assembly pipeline on five UK B. pertussis strains. This work ultimately shows 
that the complexity of the B. pertussis genome can make in vitro studies into the links between 
genotype and phenotype difficult. Finally, I use the closed genome sequences of every B. pertussis 
strain sequenced with long read technologies to investigate any recent changes in filamentous 
haemagglutinin, another of the antigens included in the acellular vaccine. Studies of the genes coding 
for this antigen have typically been limited by its length and repetitive nature, which have hindered 
attempts to assemble its whole sequence. This work reveals a homopolymeric locus which may be 
prone to slippage and which, under selective pressure, could therefore lead to an increase in the 
numbers of strains which are deficient in this vaccine antigen.  
Overall, the work in this thesis demonstrates how long-read sequencing can reveal previously 
unstudied or intractable aspects of B. pertussis biology, along with defining an affordable method for 
using nanopore long-read sequencing to assemble and study closed B. pertussis genomes. 
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“Sometimes, when it’s going badly, she wonders if what she believes to be a love of the written 
word is really just a fetish for stationary” 
- David Nicholls, One Day 
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1.1 Bordetella pertussis and whooping cough 
The Bordetellae 
The Bordetella genus contains a growing number of gram-negative coccobacilli. There are currently 
16 named species in the genus, with many additional “Bordetella sp.” and “Bordetella genomosp.” 
members which have yet to be characterised and named (see Table 1.1 for further details and 
references). Bordetella species occupy diverse ecological niches, including soil, water, plants and 
animals, having been isolated from a wide variety of settings, from human wounds to mural paintings 
in an ancient tomb. Phylogenies based on 16S rRNA for all species found so far suggest that the origins 
of the genus were likely environmental (Hamidou Soumana, Linz and Harvill, 2017). Figure 1.1 shows a 
simple phylogeny based on representative 16S rRNA sequences for the 16 named species and, indeed, 
the environmental species are found throughout the tree, whereas the animal-adapted species are 
restricted to one major branch. Recently, metagenomic studies have resulted in a surge in the number 
of environmental Bordetella identified, with new findings reported in the literature regularly (for 
example: Calon et al., 2019; Qi et al., 2019; Zheng, X. et al., 2019). The species which are currently best 
characterised, however, are the mammal-adapted classical Bordetellae: Bordetella bronchiseptica, 
Bordetella pertussis and Bordetella parapertussis. 
 





Originally isolated from Primary Host(s) Key publication 
ansorpii 288768 Human epidermal cyst Humans Ko et al. (2005) 
avium 521 Turkeys with respiratory disease Poultry Kersters et al. 
(1984) 
bronchialis 463025 Respiratory samples from cystic 
fibrosis patients 
Humans Vandamme et al. 
(2015) 
bronchiseptica 518 Dogs with respiratory disease Various animals, 
including humans 
Ferry (1912) 
flabilis 463014 Respiratory samples from cystic 
fibrosis patients 
Humans Vandamme et al. 
(2015) 
hinzii 103855 Immunocompromised humans and 
poultry with respiratory disease 
Humans, poultry, 
rabbits 
Vandamme et al. 
(1995) 
holmesii 35814 Humans with blood infection Human Weyant et al. 
(1995) 
muralis 1649130 Environmental (tomb mural 
painting) 
Environmental Tazato et al. (2015)  
parapertussis 519 Humans with respiratory disease Humans, sheep Eldering and 
Kendrick (1938) 
pertussis 520 Humans with respiratory disease Humans Bordet and Gengou 
(1906) 





et al. (2001) 
pseudohinzii 1331258 Mice with respiratory disease,  Mice Ivanov et al. (2016) 
sputigena 1416810 Respiratory samples from cystic 
fibrosis patients 
Humans Vandamme et al. 
(2015) 
trematum 123899 Humans with wounds or otitis media Humans Vandamme et al. 
(1996) 
tumbae 1649139 Environmental (tomb mural 
painting) 
Environmental Tazato et al. (2015) 
tumulicola 1649133 Environmental (tomb mural 
painting) 
Environmental Tazato et al. (2015) 
3 
 
All three classical Bordetella species can cause respiratory disease. B. bronchiseptica was first isolated 
in 1911, when it was identified as a cause of distemper (specifically, kennel cough) in dogs (Ferry, 
1912). B. bronchiseptica has subsequently been found to be capable of infecting numerous different 
mammals, including cats, rabbits, pigs, horses, seals, koalas and, rarely, humans (McGowan, 1911; 
Gallagher, 1965; Fisk and Soave, 1973; McKenzie, Wood and Blackall, 1979; Goodnow, 1980; Baker 
and Ross, 1992; Bjornstad and Harvill, 2005). In contrast, both B. pertussis and B. parapertussis are 
highly niche-restricted. Two distinct lineages of B. parapertussis have been identified, one which 
infects sheep and one which causes a mild form of whooping cough in humans (Heininger et al., 1994; 
van der Zee, Groenendijk, et al., 1996). B. pertussis is found only in the human nasopharynx, where it 
is responsible for causing the vast majority of cases of whooping cough. 
Whooping cough infection has three distinctive stages 
Whooping cough, also known as pertussis, is a respiratory disease which most severely affects infants 
younger than 12 months, but which can affect anyone of any age.  Recent estimates suggest that 24.1 
million children are infected with whooping cough annually, resulting in almost 161,000 deaths (Yeung 
et al., 2017). A typical case of whooping cough follows a distinctive pattern, comprising three clinically-
defined stages. The catarrhal stage, which includes symptoms much like the common cold such as a 
sore throat, runny nose and a non-productive cough, lasts around two weeks. The catarrhal stage is 
followed by the spasmodic stage, which is characterised by regular lengthy episodes of paroxysmal 
coughing which can cause cyanosis, and which typically end with a deep inspiration accompanied by 
the classic “whooping” sound and, often, vomiting. After around two weeks of this acute stage, the 
convalescent stage gradually develops. During the convalescent stage, coughing episodes slowly 
decrease in frequency as the body recovers, although complications such as  secondary infections 
leading to pneumonia or, more rarely, seizures and encephalopathy, can still occur (Lauria and Zabbo, 
2020). Convalescence can last from two weeks up to several months (Cherry, 1999; Kent and Heath, 
2014). 
Figure 1.1 The phylogenetic relationships between the 16 named Bordetella species according to NCBI’s Taxonomy 
Browser (as of July 2020), with Achromobacter xylosoxidans (also from the family Alcaligenaceae) as an outgroup. The 
classical Bordetellae cluster together, along with B. holmesii. Clustal W was used to align the 16S rRNA sequence for each 
species, a tree was constructed with IQ-Tree 2, and the tree was visualised with iTOL, with up to 2000x bootstrapping 
(Thompson, Higgins and Gibson, 1994; Letunic and Bork, 2019; Minh et al., 2020). A phylogeny constructed from whole 
genome sequences may show slightly different relationships, particularly between species which are found on the same 
branches; however, for some of the lesser-studied Bordetellae, only 16S rRNA sequences are currently available. 
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Whooping cough is rarely diagnosed during its earliest stage, because the symptoms are so 
reminiscent of less serious illnesses. Diagnosis therefore tends to occur during the spasmodic or 
convalescent stages, by which time culture testing is unlikely to be positive because most bacteria 
have already been cleared by the host. Diagnosis by polymerase chain reaction (PCR) or serology is 
therefore recognised as more sensitive, although the specificity of serology can be affected by the age 
of the patient: infants under three months may not develop detectable antibodies, resulting in false 
negatives, whilst testing within one year of immunisation can produce false positives (Kent and Heath, 
2014). Antibiotics can be prescribed for whooping cough infection, but often do not alter the clinical 
course of the infection, likely due to the common delay in diagnosis (Altunaiji et al., 2007).  
Whooping cough in the pre-vaccine era 
Whooping cough appears to be a relatively young disease. Writings which describe any illness with 
the distinctive symptoms of whooping cough are largely absent from historical records until the 1400s. 
Reports from Persia seem to describe the first outbreaks of a disease which sounds very similar to 
modern day whooping cough in the late 1400s, whilst a paper by Nils Rosen von Rosenstein from the 
18th century claims the first cases occurred in France in 1414 (Mattoo and Cherry, 2005; Aslanabadi et 
al., 2015). Less than a century later, Guillaume de Baillou produced what has long been considered to 
be the first description of a whooping cough epidemic, in Paris in 1578 (Hardy, 1993). Further 
outbreaks were reported regularly in Europe from then onwards, and the disease was named 
“pertussis”, meaning violent cough, in 1679 (Mattoo and Cherry, 2005). The etiological agent behind 
pertussis, however, remained a mystery until the beginning of the 20th century. 
The bacterium B. pertussis was first identified by Dr Jules Bordet at the Pasteur Institute in Paris in 
1900, when he observed a “small ovoid Gram-negative bacterium” in expectorate sampled from 
Bordet’s own five month-old daughter, who was suffering from pertussis. Six years later in Brussels, 
Bordet and Octave Gengou used a medium they had developed themselves, Bordet-Gengou (BG) 
medium, to isolate bacteria from expectorate from Bordet’s son, Paul, who had also developed the 
disease (Cavaillon, Sansonetti and Goldman, 2019). Bordet and Gengou’s medium was prepared from 
potatoes, serum, agar and blood, and is still widely used to grow Bordetella species. The bacterium 
was originally named Haemophilus pertussis due to the observation that freshly isolated bacteria were 
haemolytic, although it was also noted that after in vitro culture, the bacteria were no longer 
haemolytic. The genus was eventually renamed Bordetella in honour of Bordet later in the twentieth 
century, after more species, B. bronchiseptica and B. parapertussis, were isolated, and the species 
were collectively found to differ sufficiently from other Haemophilus to be reclassified (Bordet and 
Gengou, 1906; Howson, Howe and Fineberg, 1991; Guiso, 2009). 
Whole cell vaccination reduced global whooping cough incidence, but was associated with 
reactogenicity 
Once the bacterium responsible for whooping cough had been identified, efforts to develop an 
effective whooping cough vaccine began. Thorsvald Madsen described the first large-scale use of a 
whooping cough vaccine containing whole B. pertussis cells in 1925. Although somewhat successful in 
controlling a whooping cough outbreak in Europe, the vaccine had potential serious adverse effects, 
with two infant deaths occurring within 48 hours of immunisation (Madsen, 1933; Howson, Howe and 
Fineberg, 1991). Throughout the 1930s, further experimental vaccines were used to both prevent 
whooping cough and to treat ongoing infections, with varying levels of efficaciousness (Cherry, 1996; 
5 
 
Mattoo and Cherry, 2005). By the 1940s and 1950s, however, more fully developed whole-cell 
vaccines (WCVs), containing chemically killed bacteria, were deployed and widely used in many 
countries, usually combined with vaccines for diphtheria and tetanus (collectively called the DTwP 
vaccine). 
As seen in Figure 1.2, in the pre-vaccine era the average yearly incidence of reported whooping cough 
was 157 per 100,000 people in the United States, and 230 per 100,000 people in the United Kingdom, 
although it was suspected that fewer than 20% of cases were diagnosed, suggesting the true incidence 
was much higher. Pertussis infection was endemic; in an average year, up to 150,000 people were 
affected and around 300 deaths were linked with whooping cough infection in the United Kingdom.  
In addition, epidemics occurred on average every three years (Cherry, 1984; Mattoo and Cherry, 2005; 
Amirthalingam, Gupta and Campbell, 2013). The introduction of the DTwP appeared to be effective: 
for example, in England and Wales the incidence in infants under 1 year fell from 12.1 per 1,000 
population in 1954-1957 to only 1.6 per 1,000 population in 1970-1973 (Amirthalingam, Gupta and 
Campbell, 2013). However, the three-yearly epidemic cycle continued, albeit with greatly reduced 
infection rates (Fine and Clarkson, 1982).  
A perception grew over several decades that the pertussis component of the DTwP was responsible 
for side effects ranging from vaccine-site soreness and swelling to encephalopathy or even death. This 
perception peaked in the 1970s, leading to a dramatic decrease in DTwP uptake (Byers and Moll, 1948; 
Cody et al., 1981). In the United Kingdom, it was estimated that the rate of uptake fell from around 
80% to as low as 9% in some areas of the country (British Medical Journal, 1981). Contemporary and 
subsequent research has shown that the most severe adverse effects were likely not caused by the 
vaccine itself; rather, the vaccine was given at around the same time that such illnesses would have 
occurred in the affected infants anyway (Cherry, 1990, 1992; Blumberg et al., 1993; Cherry et al., 1993; 
Cherry, 1996; Moore et al., 2004). Nonetheless, public confidence in the vaccine had been damaged. 
Acellular vaccination replaced WCV in many countries throughout the 1990s and 2000s 
Although uptake of the DTwP stabilised somewhat after the scare in the 1970s, throughout the 1980s 
and 1990s a new type of whooping cough vaccine was developed. The new vaccine does not contain 
Figure 1.2 Whooping cough incidence in the USA, 1922-2017. The whole cell vaccine, labelled DTwP here, was made widely 
available from 1948 and was replaced by the acellular vaccine, labelled DTaP, in 1996. Annual notification data from Centers 
for Disease Control (CDC) Surveillance and Reporting website, annual population data from US Census Bureau. Inset shows 
years of resurgence only. 
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whole bacterial cells; instead it contains one to five purified B. pertussis antigenic proteins. As such, 
the new vaccine is termed the acellular pertussis vaccine (ACV). The antigens included in the ACV are 
summarised in Table 1.2, whilst Table 1.3 shows which versions of the pertussis vaccine are in use in 
the countries from which data is considered in this thesis. Compared to the WCV, the ACV results in 
fewer adverse effects such as fever, site soreness and inflammation, although the frequency of each 
of these events still increases with each subsequent vaccine dose (Mattoo and Cherry, 2005).  
Like the WCV before it, the ACV is usually given in combination with diphtheria and tetanus toxoids 
(DTaP) and sometimes also with polio, Haemophilus influenzae type b and hepatitis B (the “6-in-1”, 
DTaP-IPV-Hib-HepB vaccine) (Chen, Z. and He, 2017). In the UK, the three- or five-pertussis antigen 
DTaP vaccine is administered to infants at 8, 12, and 16 weeks, followed by a pre-school booster 
between 3 and 5 years. A further booster vaccine, the Tdap, is available for adolescents and adults; 
the Tdap contains lower doses of the B. pertussis antigens, to mitigate the adverse effects observed 
from repeated doses of pertussis vaccines (Amirthalingam, Gupta and Campbell, 2013). Since the 2012 
whooping cough outbreak, a Tdap booster has been recommended for pregnant women in the UK  
(PHE, 2018). Figure 1.3 shows the distribution of vaccine uptake across the globe: in general, most 
developed countries have coverage higher than 90%, whereas developing countries tend to be slightly 
lower. Similarly, most developed countries now use the ACV, whilst many developing countries have 
continued to use the WCV, likely due to the increased expense associated with producing the purified 
antigens for the ACV compared to killed whole bacteria for the WCV (Chen, Z. and He, 2017).  
One to five B. pertussis virulence factors are included in the acellular pertussis vaccine 
Most formulations of the ACV contain pertactin (PRN). Pertactin is a 69 kDa autotransporter protein. 
Due to an Arg-Gly-Asp-binding motif in the N-terminal domain, PRN is thought to be an adhesin 
(Mattoo and Cherry, 2005). The N-terminal domain is transported across the B. pertussis cell 
membrane by the C-terminal domain, which takes the form of a transmembrane β-barrel (Henderson, 
I.R. and Nataro, 2001). Outside of the membrane, the N-terminal domain is thought to play a part in 
adherence to host cells; this has been shown to be likely in Salmonella and Escherichia coli (Charles et 
al., 1989; Emsley et al., 1996; Everest et al., 1996). Although Δprn deletions have not been shown to 
have any effect on adherence in vitro or in vivo, it was noted during early trials of the ACV that anti-
PRN antibodies are important during infection, hence PRN is included in many ACV formulations (see 
Table 1.3) (Lipscombe et al., 1991; Roberts et al., 1991; Cherry et al., 1998; Storsaeter et al., 1998).  
Table 1.2 Antigens included in the acellular pertussis vaccine, and their characteristics 







Gene IDs Frequency of 
inclusion in ACV 
Pertactin PRN Adhesin 69 prn BP1054 Most 












Fimbrial 2 Fim2 Adhesin 22 
(monomer) 
fim2, fimB-D BP1119, 
BP1881-3 
Some 
Fimbrial 3 Fim3 Adhesin 22 
(monomer) 






Table 1.3 Current pertussis vaccination strategies in all countries considered in this thesis 




PT PRN FHA Fim2 and 
Fim3 
Vaccine coverage 
(three dose)* /% 
Source 
Belgium 1950s 1999-2002   ? X 98 Barkoff et al. (2019) 
Denmark 1961 1997  X X X 97 Barkoff et al. (2019) 
Finland 1952 2005    X 91 Barkoff et al. (2019) 
France 1959 2004  ?  X 96 Barkoff et al. (2019) 
Italy 1961 1995    X 95 Barkoff et al. (2019) 
Netherlands 1953 2005    ? 93 Barkoff et al. (2019) 
Norway 1952 1998    X 94 Barkoff et al. (2019) 
Sweden† 1953 1996  ?  X 98 Barkoff et al. (2019) 
UK  1957 2004    ? 94 Barkoff et al. (2019) 
USA 1948 1996    ? 94 Klein (2014) 
Canada 1943 1997    ? 91 Canadian Public Health Association 
(2019) 
Australia 1953 1999    ? 95 Pillsbury, Quinn and McIntyre (2014) 
Poland 1960 NA - - - - 95 Gzyl et al.  (2004)  
Japan 1947 1981     99 Noble et al. (1987) 
China 1973 2009  X  X 99 Zheng, Y. et al. (2018) 
New Zealand 1945 2000    X 93 Reid (2006) 
Israel 1957 2002    X 98 Stein-Zamir et al. (2010) 
Brazil 1950 NA - - - - 83 Domingues, Teixeira and Carvalho 
(2012); Guimarães, Carneiro and 
Carvalho-Costa (2015) 
Mexico 1960 2007  X  X 88 Aquino-Andrade et al. (2017); 
Carrillo (2017) 
* Coverage statistics from WHO (WHO, 2019b)                                                                                                                              † Sweden ceased Pertussis vaccination between 1979 and 1996 
 Antigen included in ACV                                                                                                                                                                  X Antigen not included in ACV 







Figure 1.3 Estimated global coverage of three DTP (DTwP/DTaP) doses as of 2016. Many countries now have greater than 90% coverage (WHO, 2019a).  
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Every formulation of the ACV contains pertussis toxin (PT), which is a 105 kDa ADP-ribosylating toxin. 
The mature protein is comprised of five proteins subunits, S1 to S5, which are coded for by the ptxA 
to ptxE genes. PT is an A-B toxin, in which S1 (the ptxA protein) forms the A subunit and the remaining 
proteins form a pentameric ring-shaped B subunit including one copy of S2, S3 and S5, and two copies 
of S4 (Tamura et al., 1983; Locht and Keith, 1986; Nicosia et al., 1986). The B subunit binds to, and 
delivers the A subunit into, eukaryotic host cells (Kaslow and Burns, 1992; Xu, Y. and Barbieri, 1995, 
1996). Once delivered, the A subunit transfers an ADP-ribose to GTP-binding proteins, thereby 
disrupting the normal function of G proteins in G protein-coupled cell signalling and transport (Katada, 
Tamura and Ui, 1983; Hoshino et al., 1990; Shinoda, Katada and Ui, 1990). This disruption of G protein 
activity results in a number of deleterious effects within the host cell, including upset electrolyte and 
fluid balance, and a reduced ability to recruit neutrophils and macrophages (Meade et al., 1984; 
Carbonetti, 2007; Andreasen and Carbonetti, 2008). These effects, particularly immune supression, 
are thought to play a vital role during infection establishment, and also appear to be the cause of many 
of the symptoms of whooping cough, such as leucocytosis (Carbonetti, 2010). Some questions over 
the functions of PT during whooping cough infection remain. For example, PT is only expressed in B. 
pertussis; although the gene is present in the genomes of both B. bronchiseptica and B. parapertussis, 
mutations in the promoter region (ptxP) are thought to prevent expression (Arico and Rappuoli, 1987). 
Yet, even without PT, B. parapertussis can also cause whooping cough, albeit less severely than B. 
pertussis (Heininger et al., 1994). Nevertheless, PT can be considered the major virulence factor of B. 
pertussis and, indeed, some formulations of the ACV contain only PT and are still effective at 
preventing whooping cough. 
Like pertactin, filamentous haemagglutinin (FHA) is included in most formulations of the ACV around 
the world.  Most of what we know about FHA has been learned by studying the FHA protein of B. 
bronchiseptica in mammals other than humans; however, the protein and its mechanisms are thought 
to behave the same way in B. pertussis as in B. bronchiseptica (Nash and Cotter, 2019). FHA is a 
secreted protein which acts as a membrane-bound adhesin via the same Arg-Gly-Asp motif as PRN, as 
well as being released. As an adhesin it has been shown that FHA alone is sufficient for the adherence 
of bacterial cells to eukaryotic host epithelial cells in culture, whilst as a released protein it contributes 
to the evasion of the host’s immune response (Urisu, Cowell and Manclark, 1986; Relman et al., 1989; 
Cotter et al., 1998; Melvin et al., 2015). Knockout studies in a variety of mammals have shown that 
FHA is required, but not sufficient, to establish Bordetella infection in mammalian respiratory tracts 
(Inatsuka, Julio and Cotter, 2005; Julio et al., 2009; Henderson, M.W. et al., 2012; Melvin et al., 2015). 
FHA is known as a prototypical member of the two-partner-secretion (TPS) pathway family of proteins, 
the two partners being FHA and FhaC (Nash and Cotter, 2019). FHA, coded for by the 10 kbp fhaB 
gene, is initially synthesised as a 370 kDa precursor protein, FhaB. The transmembrane, β-barrel, FhaC 
protein facilitates the translocation of FhaB across the bacterial membrane, and along the way the C-
terminal prodomain of FhaB is proteolytically cleaved to produce the final 220 kDa FHA protein. Nash 
and Cotter (2019) proposed the most comprehensive mechanism yet for the processing of FhaB into 
FHA. The proposed mechanism involves sequential, multi-step cleavage and degradation of the 
prodomain by an unknown periplasmic protease, periplasmic CtpA, and extracellular SphB1. The 
process culminates in the release of the mature, highly immunogenic, 220 kDa FHA protein from the 
membrane, triggered by a currently unknown signal. As with pertussis toxin, questions about the 
biology of FHA remain. For example, Nash and Cotter (2019) also speculate that another, as yet largely 
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undefined, role for the full length FhaB protein exists, potentially related to immune suppression and 
the binding of adenylate cyclase toxin (ACT), another Bordetella virulence factor.  
The final two components of the ACV, Fim2 and Fim3, are included less frequently than the others. 
The fimbriae are members of the type 1 pili family, which are long, hair-like structures on the cell 
surface, composed of thousands of pilin subunits (Scheller and Cotter, 2015). B. pertussis strains can 
express Fim2 fimbriae alone (serotype 1-2), Fim3 fimbriae alone (serotype 1-3), or a combination of 
both fimbriae (serotype 1-2-3) (Ashworth, Irons and Dowsett, 1982). The most heavily studied type 1 
pili mechanism is that of uropathogenic E. coli, and Bordetella pili biogenesis is thought to proceed by 
the same mechanism (Busch, Phan and Waksman, 2015). A variety of proteins are involved in the 
biogenesis of these structures, including FimB, FimC and FimD, which are believed to act as a 
periplasmic chaperone, outer membrane usher and tip adhesin, respectively (Willems, van der Heide 
and Mooi, 1992). The pilin subunits are delivered sequentially to the transmembrane β-barrel usher 
protein (FimC) by the chaperone (FimB) and, as the chain of pilin subunits grows, it is translocated 
across the outer membrane into the extracellular space. Each chain has a tip adhesin protein, FimD, 
at the extracellular end, which is thought to be involved in the adherence of Bordetella cells to 
eukaryotic epithelial cells and monocytes. Genes for other pilin subunits, FimA, FimN and FimX, are 
also found in the B. bronchiseptica and B. pertussis genomes, but their proteins are not believed to be 
produced in either species (Scheller and Cotter, 2015). Interestingly, in B. pertussis and B. 
bronchiseptica, many of the Fim genes are found on an operon between the FHA genes FhaB and FhaC, 
but fim2 and fim3 are both found elsewhere, separately, in the genome. As a result of their co-
translation with the Fha genes, experimental investigation of the fimbriae in Bordetella has not been 
an easy task. However, although experimental evidence for the role of the fimbriae in Bordetella 
adherence to eukaryotic cells is limited, and despite their relatively rare inclusion in the ACV, the 
presence of Fim2 and Fim3 has been shown to significantly enhance vaccine-mediated protection (Olin 
et al., 1997; Geuijen et al., 1998; Scheller and Cotter, 2015).  
B. pertussis virulence depends on the BvgAS two-component system 
Lacey (1960) described three distinct phenotypic phases in which the classical Bordetella species could 
exist. These distinct phases were designated the X, I and C modes, and the bacteria could seemingly 
modulate between different phases according to their environmental signals (Mattoo and Cherry, 
2005). It is now known that, like many other bacteria, Bordetella species sense and respond to their 
surrounding environment using a two-component system (Gross, Arico and Rappuoli, 1989). In 
Bordetella, this system is the Bvg (Bordetella virulence gene) system, and it is almost identical in B. 
bronchiseptica, B. parapertussis, and B. pertussis (Mattoo and Cherry, 2005).   As shown in Figure 1.4, 
the BvgAS system comprises two proteins: a histidine sensor kinase, BvgS, which spans the inner 
membrane to sense environmental stimuli and activate a response regulator, BvgA, via a 
phosphorylation cascade (Cotter and Jones, 2003; Melvin et al., 2014).  
BvgAS is active at 37oC in the absence of chemical modulators; these conditions correspond to Lacey’s 
X mode, which is now known as the Bvg(+) phase. Bvg(+) conditions initiate the autophosphorylation 
of the BvgS histidine kinase (HK) domain, triggering a phosphorylation cascade which culminates in 
the phosphorylation and activation of BvgA. Activated BvgA promotes the expression of many genes 
in B. pertussis, including key virulence factors such as adhesins and toxins like filamentous 
hemagglutinin (FHA) and pertussis toxin (PT) (Moon et al., 2017). Together, the BvgA-activated genes 




Figure 1.4 The BvgAS two-component system of B. pertussis. Under Bvg(+) conditions, the venus flytrap (VFT) domains of 
BvgS undergo a conformational change, leading to autophosphorylation of the histidine kinase (HK) domain at a conserved 
histidine (H) residue. The phosphoryl group is then transferred in turn to the receiver (Rec) domain and histidine 
phosphotransferase (Hpt) domains of BvgS, and finally to conserved aspartate (D) residue in the BvgA Rec domain. The 
phosphorylated BvgA dimerises and acts as a transcription factor for the virulence-activated genes (vags), including the Bvg 
repressor protein, BvgR, which represses the virulence-repressed genes (vrgs). Under Bvg(-) conditions, no phosphorylation 
of BvgS or BvgA occurs, meaning expression of the vags is not promoted, and expression of the vrgs is not repressed. The 
expression of the vrgs can therefore be promoted by RisA. Bvg(i) exists as an intermediate between these two phases.  
                  
                            Figure inspired by Cotter and Jones (2003); Dupre et al. (2015); Hoffman (2017). 
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Bvg repressor protein, BvgR. Whilst the vags are activated by BvgA, the transcription of another set of 
genes is repressed by BvgR (Merkel and Stibitz, 1995; Merkel, Barros and Stibitz, 1998; Merkel et al., 
2003). These “virulence-repressed genes” (vrgs) include those involved in the outer membrane, those 
required for biofilm formation and motility, and those involved in a large number of metabolic 
pathways (Cotter and Jones, 2003; Hoffman, 2017; Chen, Q. and Stibitz, 2019; Hoffman et al., 2019). 
Bvg(+) is considered to be the default “on-state” for B. pertussis, and mutant bacteria which are unable 
to phosphorylate BvgA and therefore enter the Bvg(+) phase cannot colonise respiratory tracts in mice 
(Martinez de Tejada et al., 1998; Moon et al., 2017). 
Lacey’s C mode, now known as the Bvg(-) phase, is less well-characterised than Bvg(+). Bvg(-) can be 
induced in vitro by reduced temperature (lower than around 27oC) or the presence of chemical 
modulators such as ≥ 40 mM MgSO4 or ≥ 10 mM nicotinic acid, but in vivo triggers for the Bvg(-) in 
nature are as yet undetermined (Melton and Weiss, 1993; Chen, Q. and Stibitz, 2019). In the Bvg(-) 
phase, the expression of the vags, including the major B. pertussis virulence factors and BvgR, is not 
promoted, as BvgA does not become phosphorylated. Consequently, the expression of the vrgs is not 
repressed; in the Bvg(-) phase expression of the vrgs is promoted by RisA (Croinin, Grippe and Merkel, 
2005; Stenson et al., 2005). Expression of the vrgs has been shown to be detrimental to virulence in 
animal models; ΔbvgR knockout bacteria are unable to cause disease in mice. Instead, this class of 
genes is currently believed to play a role during transmission and survival outside of the optimal 
environment. Bvg(-) bacteria can survive in non-optimal conditions and locations for longer than 
Bvg(+) bacteria, as well as growing more quickly and not expressing the antigens commonly observed 
during infection (Akerley and Miller, 1993; Akerley, Cotter and Miller, 1995; Martinez de Tejada et al., 
1998; Merkel et al., 1998). 
Very little is known about the third Bordetella phase, Lacey’s I mode, which is now known as the Bvg-
intermediate, or Bvg(i) phase. Bvg(i) occurs during the transition between Bvg(+) and Bvg(-), or vice-
versa; the BvgAS system functions not simply as a biphasic switch, but as a gradient of expression and 
repression of vags and vrgs (Cotter and Miller, 1997; Deora et al., 2001; Stockbauer et al., 2001). Like 
Bvg(+) and Bvg(-), there is a set of genes which are characteristically expressed under Bvg(i) conditions, 
typically temperatures lower than 37oC but higher than 27oC, concentrations of MgSO4 lower than 40 
mM but higher than 15 mM, or 0.4 to 2 mM nicotinic acid in vitro (Mattoo and Cherry, 2005). Under 
these conditions, BvgS is less active, hence levels of phosphorylated BvgA are lower. Consequently, 
expression of the vags and repression of the vrgs is limited (Williams, C.L. et al., 2005).  In addition, a 
set of Bvg(i)-specific genes is thought to exist. The first of these to be described codes for an adhesin, 
Bvg-intermediate phase protein A, or BipA  (Stockbauer et al., 2001). The bipA promoter is activated 
by low levels of phosphorylated BvgA, but repressed by higher levels of BvgA. Thus, BipA is expressed 
maximally as bacteria transition between fully active and fully inactive BvgS, when it is involved in 
biofilm formation (Nishikawa et al., 2016). Bvg(i) is thought to play a role very early in infection, 
potentially during colonisation, but the majority of the genes involved, and their specific functions, 
remain largely undiscovered. 
Whooping cough has been resurgent since the late 1980s and early 1990s 
The World Health Organisation estimates that, globally, 90% of the target population receive at least 
one dose of pertussis-containing vaccine, and 85% receive the full three recommended doses; these 
levels of coverage have been stable since 2015 (WHO, 2018). Despite these relatively high levels of 
vaccination, the incidence of whooping cough has been increasing in many countries since the 1980s 
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(De Serres et al., 1995; Cherry, 1996; de Melker et al., 1997). Throughout this period, notable 
epidemics have occurred in the USA in 2005, 2010 and 2012, the UK in 2012,  Australia between 2008 
and 2012, Japan between 2008 and 2012, and, most recently, New Zealand between 2017 and 2019 
(Octavia et al., 2012; Winter et al., 2012; Miyaji et al., 2013; Bowden et al., 2014; Clark, 2014; Lam et 
al., 2014; Sealey et al., 2015; Stuff NZ, 2019). 
A key feature of the whooping cough resurgence is a slight shift in the epidemiological profile of the 
disease, as seen in Figure 1.5. Throughout the pre-vaccine era, whooping cough was a disease of 
childhood: around 95% of cases were seen in children younger than 10 years old. During the whole-
cell vaccine era, there was a slight shift towards the younger end of this range, with infants under one 
year old representing 53.5% of all cases diagnosed (Mattoo and Cherry, 2005). Since the late 1990s, 
however, a growing proportion of cases have been seen in older children and adolescents. In a 2004 
US epidemic, adolescents comprised 36% of cases, ultimately leading to the introduction of a Tdap 
booster for 11- or 12-year olds. Despite wide uptake of this booster, epidemics in 2010 and 2012 saw 
elevated infection rates in fully vaccinated children and adolescents aged 7-10 and 13-14 years old 
(Clark, 2014). 
To a certain extent, the increase in overall recorded incidence can be explained by a heightened 
awareness of the disease and the introduction of new, more sensitive, diagnosis methods such as PCR 
and serology. It is believed that when diagnoses were primarily made by culture, fewer than 20% of 
whooping cough infections were diagnosed, mainly because by the time diagnosis was attempted, the 
patient’s bacterial load was usually too small to detect via culture (Mattoo and Cherry, 2005). The 
ability of PCR and serology to detect smaller bacterial loads will therefore have resulted in an increase 
in the number of cases diagnosed, with notifications approaching the true number of infections for 
the first time. James D. Cherry, a paediatrician and researcher who has been a global expert in 
whooping cough for many decades, believes that the perceived “resurgence” of the disease is a myth: 
that, although more people are being diagnosed with the disease nowadays, the number of people 
Figure 1.5 Whooping cough incidence across age groups in the USA, 1990-2017. Incidence has increased in every age group 
and, although <1 year remains the group mostly highly affected, there has been a notable increase in the relative proportion 
of 1-19 year olds. 
 Data from Centers for Disease Control (2019b). 
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infected has not truly increased (Cherry, 2015). However, if this was correct, we might expect to have 
seen an initial increase in diagnoses when the new diagnosis techniques were introduced, followed by 
a plateau at whatever the true rate of incidence was. Instead, the measured incidence of the disease 
has continued to increase on an almost yearly basis, as seen in Figure 1.5. In addition, a 2014 survey of 
19 countries by the World Health Organisation indicated that at least five countries (Australia, Chile, 
Portugal, USA and the UK) demonstrated a clear resurgence of whooping cough, separate from any 
increase in notifications resulting from detection bias (World Health Organisation, 2014).Therefore, 
although some of the increased incidence is due to people now being diagnosed who previously would 
not have been, other factors must also be at play. 
One additional factor contributing to the recent resurgence of whooping cough is waning immunity. 
Even natural immunity to pertussis, gained through prior infection, is known to wane substantially in 
7-20 years. The immunity conveyed by the whole-cell vaccine was also thought to wane within a few 
years of vaccination; children vaccinated several years previously were commonly found to be infected 
with whooping cough, although their disease usually seemed to be less severe (Wendelboe et al., 
2005). The persistence of the three-to-five yearly epidemic cycle also suggests that the WCV was 
successful in preventing severe manifestations of whooping cough, but not in preventing its 
transmission (Clark, 2014). As indicated by the epidemiological shift in age groups infected, however, 
immunity conveyed by the acellular vaccine appears to wane faster than either naturally- or WCV-
conveyed immunity. Case-controlled studies from a 2010 California epidemic suggest that the 
protection conveyed by the ACV falls to 71% within five years of vaccination, and that the odds of 
pertussis infection increase 42% with every passing year (Klein et al., 2012; Misegades et al., 2012). It 
is nonetheless important to note that the whooping cough incidence has increased across all age 
groups even in countries which still use the WCV, like Brazil and China (World Health Organisation, 
2014; Guimarães, Carneiro and Carvalho-Costa, 2015). In addition, particularly severe whooping cough 
epidemics were observed over the decade prior to the switch from WCV to ACV, including the 
Netherlands, Australia, Canada and the US (Bass and Wittler, 1994; De Serres et al., 1995; Andrews, 
Herceg and Roberts, 1997; de Melker et al., 1997). Thus, like increased awareness and improved 
diagnosis techniques, the more rapidly waning immunity conveyed by the ACV compared to the WCV 
does not fully explain the resurgence of whooping cough. 
A final factor which may be contributing to the resurgence of whooping cough, and the focus of this 
thesis, is changes to B. pertussis at the genetic level, such that the strains used to prepare vaccines no 
longer fully represent the strains which are circulating. Such changes may have occurred by chance, 
as a result of natural genetic drift, or, more likely, they may have happened as a result of vaccination 
applying a selection pressure against the vaccine strains, thus selecting for strains which have 
diverged. Shifts in the circulating B. pertussis population were observed soon after the first whole-cell 
vaccines were introduced. The original WCVs contained cells with the fimbrial serotype 1,2 and, as 
early as the 1950s and 1960s, a rapid shift towards serotype 1,3 was noticed in vaccinated populations 
but not unvaccinated populations. This shift was thought to have contributed to a reduction in vaccine 
efficacy; the vaccine was subsequently changed to include both serotypes 1,2 and 1,3, which 
seemingly resulted in efficacy improvements (Preston, N.W., 1976). Thus, the concept of whooping 
cough vaccination causing circulating B. pertussis populations to shift, resulting in lowered efficacy, 
has been previously established at the protein level. Since the advent of whole genome sequencing 
(WGS) in the 1990s and 2000s, attention has turned to also observing such shifts at the genetic level, 
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investigating their influence on B. pertussis evolution, and understanding their potential contribution 
to reduced vaccine efficacy. 
B. pertussis evolved from Bordetella bronchiseptica by insertion sequence-mediated 
genomic streamlining 
Multilocus sequence typing (MLST) studies showed that the majority of B. bronchiseptica isolates can 
be assigned into one of two distinct complexes, Complex I and Complex IV (Diavatopoulos et al., 2005; 
Park et al., 2012). The higher resolution of WGS has allowed a deeper investigation of the relationships 
between B. bronchiseptica, B. parapertussis and B. pertussis. It appears that  B. pertussis and B. 
parapertussis are most closely related to different B. bronchiseptica complexes, B. pertussis to 
Complex IV and B. parapertussis to Complex I (Linz et al., 2016). Nonetheless, the two species cause 
very similar pathologies in humans and they both appear to have evolved from their B. bronchiseptica-
like ancestor primarily through insertion sequence (IS)-mediated genome reduction.  
The genome of B. bronchiseptica contains very few, if any, IS elements. The original reference strain 
to be whole genome sequenced by Parkhill et al. (2003) did not contain any IS elements, although 
some strains sequenced subsequently contain a handful of IS 481, IS 1001, IS 1002 or IS 1663, as seen 
in Table 1.4. The average B. parapertussis genome contains around 30 IS elements, mainly IS 1001 with 
a few copies of IS 1002, and no copies of IS 481 or IS 1663. The B. pertussis genome contains the most 
IS elements by far, with over 250 copies of IS 481 on average, fewer than 20 copies of both IS 1002 
and IS 1663, and no copies of IS 1001. The appearance and subsequent expansion of these IS elements 
via homologous recombination throughout the genomes of their B. bronchiseptica-like ancestors is 
thought to have led to the (independent) speciation of B. pertussis and B. parapertussis (Parkhill et al., 
2003; Preston, A., Parkhill and Maskell, 2004; Diavatopoulos et al., 2005).  
IS-mediated reductions in genome size and the number of functional genes was key in the speciation 
process of B. pertussis. As shown in Table 1.4, the genome size and number of genes in an average B. 
bronchiseptica are 5.21 Mbp and around 5,000, respectively. By contrast, the average genome size 
and number of genes in a B. pertussis isolate are only 4.11 Mbp and around 4,000, respectively. The 
B. pertussis genome has lost many genes present in B. bronchiseptica, including those involved in 
metabolism and membrane transport (Parkhill et al., 2003). The insertion of IS elements into genes 
has also produced over 350 pseudogenes in B. pertussis, compared to only around 20 in B. 
bronchiseptica. The extensive expansion and recombination between IS elements in B. pertussis has 
Table 1.4 Characteristics of all classical Bordetella closed genomes available in NCBI’s RefSeq database, 
March 2019 2 
Characteristic B. pertussis B. parapertussis B. bronchiseptica 
Number of closed genomes 421 18 19 
Genome size / Mb 1 4.11 (4.04 – 4.39) 4.78 (4.77 – 4.90) 5.21 (5.08 – 5.34) 
Number of predicted genes1 3,979 (3,856 – 4,239) 4,501 (4,490 – 4,574) 4,911 (4,774 – 5,090) 
Number of proteins 1 3,615 (3,425 – 3,866) 4,166 (4,157 – 4,184) 4,804 (4,663 – 4,993) 
G+C% 1 67.7 (67.7 – 67.8) 68.1 (67.8 – 68.1) 68.2 (68.1-68.4) 
IS 481 1 256 (234 - 273) - 1 (0-3) 
IS 1001 1 - 22 (22-28) 1 (0-1) 
IS 1002 1 8 (5 – 10) 9 (0-9) 0 (0-5) 
IS 1663 1 17 (16 – 24) - 2 (0-14) 
1 Figures shown are mean and (range) 
2 Table adapted from Ring et al. (2019) 
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sculpted a streamlined and specialised bacterium, and likely explains why the pathogen is entirely 
niche-restricted to the human nasopharynx. 
At the base level, B. pertussis strains exhibit limited inter-strain variation, although certain 
genes have been evolving more rapidly since the introduction of vaccination 
Prior to the wide availability of WGS (the “pre-genomics” era), a variety of alternative molecular 
techniques were used to investigate diversity in B. pertussis genomes. These techniques included 
multilocus enzyme electrophoresis (MLEE), multiple-locus variable number tandem repeat analysis 
(MVLA), restriction fragment length polymorphism (RFLP) analysis, ribotyping, randomly amplified 
polymorphic DNA (RAPD) typing and pulsed field gel electrophoresis (PFGE) (Musser et al., 1986; 
Moissenet et al., 1996; van der Zee, Vernooij, et al., 1996; van der Zee et al., 1997; Vandamme et al., 
1997; Mooi et al., 2000; Kurniawan et al., 2010). Using these pre-genomics techniques to investigate 
strains isolated in the pre-vaccine and WCV eras, a picture began to emerge of a B. pertussis 
population which had continued to shift since the introduction of vaccination but which, on the whole, 
exhibited very little inter-strain variation compared to other bacteria (van der Zee, Vernooij, et al., 
1996; Mooi et al., 1998; van Loo et al., 1999; Kurniawan et al., 2010)). However, pre-genomics 
molecular techniques provided limited resolution, relying on small numbers of already well 
characterised genomic features (e.g. MLVA, ribotyping, serotyping) or on visualisation of restriction 
enzyme reactions which could have been influenced by mutations within enzyme recognition sites 
(e.g. MLEE, RFLP, PFGE). 
The higher resolution of WGS means that many investigations into diversity within bacterial 
populations are now centred around the identification of single nucleotide polymorphisms (SNPs) 
between strains. SNPs can be used to estimate relatively accurately the relationships between strains, 
the time since certain lineages diverged from others, and how quickly genomes are mutating and 
evolving. Investigations of SNPs in B. pertussis, however, are limited by the same limited variation 
which was observed using pre-genomics techniques. For example, by comparing six Dutch strains, Bart 
et al. (2010) estimated B. pertussis to have a SNP rate between strains of 1 per 8,675 bases, in contrast 
to 1 per 3,000 bases in Mycobacterium tuberculosis or 1 per 6,700 bases in E. coli (Fleischmann et al., 
2002; Gutacker et al., 2002; Zhang, W. et al., 2006).  
Another benefit of WGS has been the ability to conduct higher throughput strain screens.  Bart, Harris, 
et al. (2014) used WGS to screen 343 strains which had been isolated from 19 different countries 
across a 90-year period (1920-2010). This landmark longitudinal study, the first to consider genetic 
information from across the entire genome of so many strains, had two key findings. Firstly, 
phylogenetic analysis of the 343 strains revealed two deep lineages, one of which (branch I) contained 
only 1.7% of the strains screened, and which has ostensibly disappeared since the year 2000. Branch 
I and branch II seemingly diverged around 2,000 years ago, which the authors speculate may represent 
two independent introductions of B. pertussis into humans. Most recent B. pertussis isolates clustered 
to a sub-branch of branch II (IIb), and there was seemingly no geographical structure in the 
phylogenetic tree, reflecting the limited inter-strain diversity previously observed. Secondly, allele 
typing showed that the genes coding for the antigens included in the ACV have undergone a number 
of allelic profile shifts, away from the alleles represented by the vaccine strains (Figure 1.6). This finding 
was supported by Sealey et al. (2015) and, more recently, Etskovitz et al. (2019), who showed that the 
antigens included in the ACV have begun to evolve more rapidly since the switch from WCV to ACV.  
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One of the most striking allelic shifts observed in longitudinal studies like Bart, Harris, et al. (2014) is 
the appearance and rapid spread of a new pertussis toxin promoter allele, ptxP3, since the late 1980s. 
ptxP3 is characterised by a single base pair (bp) G-to-A mutation in the recognition sequence to which 
BvgA, ptx’s transcriptional regulator, binds. This SNP appears to increase binding affinity in BvgA, 
increasing the transcription and, thus, production of pertussis toxin in ptxP3-carrying strains. The 
increased expression of this important virulence factor is accompanied by altered expression of 
proteins involved in complement resistance and, together, these changes result in the transmissibility 
and severity of whooping cough infections caused by ptxP3 strains (Mooi et al., 2009; Bart et al., 2010; 
King et al., 2013; de Gouw et al., 2014).  
The rapid selective sweep of ptxP3 may have been related to the use of the ACV. Advani et al. (2011) 
found a higher and earlier prevalence of ptxP3-carrying strains in Gothenburg compared to the rest of  
Figure 1.6 Allelic changes in the genes which code for the ACV antigens since the introduction of whooping cough 
vaccination, away from the alleles represented in the vaccine strains. Notable selective sweeps have been seen in ptxP (from 
ptxP1 towards ptxP3), prn (from prn1 to prn2), ptxA (from ptxA2 to ptxA1) and fim3 (from fim3-1 towards fim3-2). Most 
recent strains now have the allelic profile ptxA1-ptxP3, prnA2, fim3-2, fim2-1.            
                                                                                                                                                          Figure from Bart, Harris, et al. (2014). 
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Sweden. Gothenburg used first a single-component PT-only ACV, followed by a two-component 
PT+FHA ACV, whilst the rest of Sweden was using a three-component PT+FHA+PRN ACV. Advani et al. 
suggest that the accelerated appearance of ptxP3 could have been because of the greater pressure 
against PT conveyed by PT-only or PT+FHA vaccines; although the one- and  two- component vaccines 
did not cause the SNP which produces ptxP3, they caused the allele to spread more rapidly because 
of the pressure they apply against the vaccine allele, ptxP1. However, the appearance and rapid spread 
of strains carrying ptxP3 may have occurred even if no whooping cough vaccines were in use; a lone 
SNP can arise by chance, and the fitness benefit conveyed by the enhanced virulence of strains 
carrying this mutation means that the allele would have spread rapidly with or without vaccine 
pressure. 
A similar selective sweep, which was almost definitely due to pressure applied by the ACV, is the 
appearance and proliferation of strains which are deficient in one or more of the ACV antigens. In the 
1990s, prior to the introduction of the ACV, only a handful of strains were isolated which had 
mutations resulting in their non-ability to express PRN, in a variety of countries around the world 
(Mastrantonio et al., 1999; Miyaji et al., 2013; Weigand et al., 2018). Bart et al.’s longitudinal study, 
which included 323 strains isolated prior to 2007, did not find any PRN-deficient strains, although one 
has since been resequenced and found to be deficient after all (Bart, Harris, et al., 2014; Zomer et al., 
2018). From the mid-2000s onwards, however, an increasing number of PRN-deficient strains have 
been isolated. For example, in Australia the percentage of strains found to be PRN-deficient increased 
from 5% to 78% in the four year period between 2008 and 2012, whilst 640 of 753 strains isolated in 
the United States between 2011 and 2013 were PRN-deficient (Lam et al., 2014; Martin et al., 2015). 
Strong evidence suggests that PRN-deficiency has increased so rapidly in response to the introduction 
of the ACV. Martin et al.’s study of 753 US strains found a significant association between ACV status 
and likelihood of being infected by PRN-deficient B. pertussis instead of PRN-positive B. pertussis 
(Martin et al., 2015). In addition, Barkoff et al. studied PRN-deficiency in European B. pertussis strains 
isolated between 1998 and 2015, and found that the longer a country had been using the ACV, the 
higher the chance that strains from the country would be PRN-deficient, as shown in Figure 1.7 (Barkoff 
et al., 2019). A variety of different PRN deficiency-causing mechanisms have been observed, including 
insertion of IS 481 into the gene, large deletions and deleterious SNPs. No single mechanism appears 
to be predominant (Hegerle et al., 2012; Queenan, Cassiday and Evangelista, 2013; Barkoff et al., 
2019).  
A slightly different PRN deficiency trend has been seen in Japan, however. Japan introduced the ACV 
in 1981, many years before most countries. The number of PRN-deficient strains appears to have 
increased initially, reaching 41% of all strains isolated between 2005 and 2007. At every time point 
since then, the proportion of PRN-deficient strains appears to have decreased: to 35% between 2008 
and 2010, and to 25% between 2011 and 2013. Furthermore, PRN was removed from Japan’s ACV in 
2012; a significant further decrease was observed between 2014 and 2016, with only 8% of strains 
now found to be PRN-deficient (Hiramatsu et al., 2017). Limited recent data from Ontario suggests the 
same trend may also now be occurring in Canada. The first PRN-deficient strains were isolated in 2011, 
when 16.7% were deficient.  The proportion of deficient strains increased rapidly, reaching 70.8% in 
2016. As seen in Japan, after reaching a peak, the number of PRN-deficient strains now appears to be  
decreasing: a sharp fall was seen from 2016 to 2017, when only 46.2% of strains were deficient (Tsang 
et al., 2019). No more recent data is available as yet to confirm whether this trend of decreasing 
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deficiency has continued. Nonetheless, the observations in these two countries indicate that there 
may yet be further twists in the ACV-mediated PRN deficiency story.       
A smaller number of strains have also been isolated since the late 2000s which are deficient in other 
ACV antigens. A few strains have been found which were unable to produce PT. Interestingly, these 
strains were always also PRN-deficient (Bouchez et al., 2009; Williams, M.M. et al., 2016; Weigand et 
al., 2018). Additionally, and slightly more frequently, FHA-deficient strains have been isolated in recent 
years. Like PT deficiency, FHA deficiency often appears to occur in tandem with PRN deficiency (Bart 
et al., 2015; Weigand et al., 2018). Like PRN deficiency, PT and FHA deficiency can be caused by the 
insertion of IS481 into the gene, deletions, or deleterious SNPs in the protein coding genes themselves 
or in related regulatory genes.  
Pertactin is thought to play an important role in the ACV: a clinical study showed that a three-
component ACV containing PT, FHA and PRN was substantially more effective than a two-component 
ACV containing only PT and FHA, for example (Hewlett, 1997). Thus, PRN-deficient strains may have a 
selective advantage over PRN-producing strains in countries where a PRN-containing ACV is in use. 
Additionally, as Δprn deletion strains do not seem to have a negative effect on virulence in vivo or in 
vitro, the benefits of PRN deficiency likely outweigh any costs to the deficient bacteria (Lipscombe et 
al., 1991; Roberts et al., 1991; Cherry et al., 1998; Storsaeter et al., 1998). Both PT and FHA, however, 
are thought to play more vital roles than PRN during B. pertussis infection, hence being deficient in 
either may result in a less virulent strain. Therefore, despite the selective pressure applied by their 
Figure 1.7 Barkoff et al. (2019) found a significant correlation between the year of  introduction of the ACV and the 
proportion of B. pertussis isolates found to be Prn-deficient.  
Figure reproduced with permission from Barkoff et al (2019) and Ring et al. (2019). 
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inclusion in the ACV, we may not see a rapid proliferation in strains which are deficient in these 
antigens; although deficiency-causing mutations may be occurring more frequently, the deficient 
strains are less likely to cause infection, therefore they will not be isolated and observed in vitro. 
However, as the FHA gene is long (10 kbp) and contains repetitive regions, it has often not been 
included in screens such as Bart, Harris, et al. (2014). 
B. pertussis has a highly repetitive genome 
Whilst the wide availability of WGS since the early 2000s has allowed numerous high-throughput 
studies of B. pertussis, these studies have been limited by the apparent monomorphic nature of the 
bacterium: very few inter-strain differences are detectable at the base level, aside from the changing 
allelic profile and increasing deficiency in a few key genes. On the other hand, the presence of so many 
IS elements in the B. pertussis genome, and the tendency of such regions to move within the genome, 
means that genome-level differences between strains may exist (Bentley et al., 2008; Siguier et al., 
2014). In other species, for example Pseudomonas aeruginosa and E. coli, genome-level variations 
such as rearrangements have been shown to result in altered gene expression and phenotypic 
diversity (Sousa, de Lorenzo and Cebolla, 1997; Darch et al., 2014). However, detailed investigation of 
genome-level variations would require the assembly of closed genome sequences, which was not 
possible with any of the early-2000s WGS technologies. These technologies, such as Illumina’s 
fluorophore-based sequencing, Roche 454’s pyrosequencing and Ion Torrent’s pH-based sequencing, 
produce sequencing reads of lengths in the order of hundreds of base pairs. B. pertussis’s repetitive IS 
elements are over a thousand base pairs long, hence have confounded attempts to assemble closed 
genomes using short sequencing reads. The B. pertussis genomes sequenced throughout the 2000s 
and 2010s using short-read sequencing have therefore tended to consist of at least several hundred 
pieces (contigs), ostensibly one contig per IS copy in the genome. 
During the speciation of B. pertussis from its B. bronchiseptica-like ancestor, extensive genome 
arrangements occurred, largely due to IS-mediated recombination. It is likely that IS-mediated 
rearrangements are an ongoing phenomenon in the B. pertussis genome, as it has been demonstrated 
that reductions in genome size, which occur via the same mechanism, are also ongoing (King et al., 
2010). IS-mediated rearrangements could result in phenotypic variation between strains, either 
through altering the distance of genes from the origin of replication, or through the recently 
discovered inward- and outward-facing promoters within the IS 481 sequence itself, either of which 
could cause changes in gene expression or regulation (Amman et al., 2018). Supporting this, Brinig et 
al. (2006) used microarrays to reveal altered gene expression in isolates with different genomic 
arrangements. Furthermore, PFGE studies have tended to suggest that each B. pertussis isolate can 
be assigned a “pulsed-field type”, representing different genome arrangements in isolates which are 
otherwise similar, for example in terms of SNPs (Bisgard et al., 2001; Advani, Donnelly and Hallander, 
2004; Advani et al., 2013; van Gent et al., 2015).  
There has therefore long existed strong evidence that the assembly of closed B. pertussis genome 
sequences could reveal previously unresolved genome-level inter-strain variations, almost certainly 
including genome rearrangements and deletions, and potentially other additional IS-mediated 
changes, such as duplications. Thus, the arrival of long-read sequencing technologies on the scene in 




1.2 The evolution of genome sequencing 
First generation sequencing facilitated the Human Genome Project 
Genome sequencing has undergone several periods of rapid progress. The first full protein-coding 
gene to be fully sequenced, in the early 1970s, coded for the 129 amino acid (387 bp) coat protein of 
the RNA bacteriophage MS2. This first gene was sequenced by Min Jou et al. (1972), using a very 
lengthy, manual, ribonuclease and gel electrophoresis method. The entire bacteriophage MS2 RNA 
genome contains only three genes, and it was not long before the entire 3,569 bp genome had been 
sequenced: the first genome, RNA or DNA, ever fully sequenced (Fiers et al., 1976). However, larger 
whole genomes were thought to be too large and difficult to sequence in full using these manual 
methods and, for the next decade, sequencing projects continued to focus on a few select genes or 
the smaller phage genomes, such as the 5,375 bacteriophage φX174 (PhiX), which was the first full 
DNA genome ever sequenced, in the late 1970s (Sanger et al., 1977; Sanger et al., 1978; Green, Watson 
and Collins, 2015; Wetterstrand, 2016). 
The Human Genome Project (HGP), begun in 1990, was a game changer for genome sequencing, 
requiring the collaboration of hundreds of researchers around the world, costing over $500 million, 
and taking over a decade to complete. This enormous undertaking paved the way for the sequencing 
of whole genomes of all kinds of organisms, from every kingdom of life. The sequencing of whole 
genomes was facilitated by a sequencing technique developed by Sanger, Nicklen and Coulson (1977). 
Originally known as the “chain termination method”, this sequencing technique is still considered to 
be the most reliable, albeit most expensive and manual, sequencing method in existence. In the years 
since its inception, the chain termination method has come to be known, simply, as “Sanger 
sequencing”. 
Sanger sequencing makes use of dideoxynucleotides (ddNTPs) which, when incorporated in a DNA 
strand, terminate chain elongation by DNA polymerase. The DNA fragment to be sequenced is 
amplified, a short primer sequence is ligated to the template strand, and DNA polymerase is used to 
synthesise new complimentary strands. Synthesis requires the addition of nucleotides, A, C, G and T. 
In nature, deoxynucleotides (dNTPs) are incorporated into the new strand; in Sanger sequencing, both 
dNTPs and ddNTPs are present in the reaction mix. ddNTPs lack a hydroxyl group which is present in 
dNTPs and which is necessary for DNA polymerase to extend a DNA fragment. Numerous new copies 
of the original DNA fragment are synthesised by the DNA polymerase adding dNTPs one-by-one, until 
a ddNTP is incorporated instead and the synthesis halts. Because the ddNTPs are incorporated at 
random, if enough copies of the original fragment have been synthesised, fragments of all possible 
lengths, from 1 bp up to the total length of the original, will be present in the reaction mix. The original 
chain termination method utilised radiolabelled nucleotides to characterise the identity of each base 
in the sequence. In modern Sanger sequencing, however, the ddNTPs are tagged with fluorophores. 
Using capillary electrophoresis, which can resolve fragments to as little as 1 bp length difference, 
combined with laser excitation and detection, the identity of each base in the sequence can be 
deduced according to its fluorescence, as shown in Figure 1.8 (Sanger and Coulson, 1975; Sanger, 
Nicklen and Coulson, 1977; Branton and Deamer, 2018). 
Due to the single-base resolution of capillary electrophoresis, Sanger sequencing is highly accurate 
(Karger and Guttman, 2009). Technological developments during the 1980s allowed automation of 
the process, greatly increasing the speed at which DNA could be sequenced. This, in turn, made the 
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prospect of sequencing the full 3 billion base pairs of the human genome far more realistic. However, 
the length of reads produced by Sanger sequencing is limited by the ability of the capillary 
electrophoresis process to resolve fragments to single base pairs; typically, reads produced by Sanger 
sequencing have a maximum length of 500-800 bases (Heather and Chain, 2016; Branton and Deamer, 
2018). In addition, despite automation, the process is relatively slow, as evidenced by the length of 
time taken to sequence the original human genome during the HGP. In order to speed up the HGP, 
many hundreds of researchers, in many different research centres around the world, were involved in 
the sequencing which, in turn, significantly increased the cost of the project. Nonetheless, the HGP 
proved that sequencing whole genomes was feasible, essentially giving rise to the field of genomics. 
However, faster and cheaper technologies would be required to conduct more high-throughput whole 
genome sequencing. 
Technological advances enabled massively parallel Next Generation Sequencing 
The early 2000s saw the rapid development of several new competing sequencing technologies, 
collectively known as the Next Generation Sequencing (NGS) technologies. The main aim of each of 
these was to decrease the time and cost involved in sequencing genomes. This aim was achieved 
through the development of massively parallel sequencing; a high number of short DNA fragments 
Figure 1.8 The “chain termination” technique, now known as Sanger sequencing. DNA fragments of all possible lengths are 
produced when labelled ddNTPs are incorporated at random during DNA polymerase elongation, as the ddNTP prevents 
further DNA polymerase activity. The fragments are separated according to size using capillary electrophoresis, which can 
resolve fragments to as little as 1 bp length difference. As the fragments pass through the capillary in size order, a laser 
excites the ddNTP’s fluorophore label, and the identity of the fluorophore is detected and recorded. Thus, original sequence 
of the DNA can be deduced.   
                              Image from ABM Knowledge Base (2017). 
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being sequenced at the same time. Genomes could now be sequenced in days or weeks instead of 
years, and the average cost of sequencing a genome decreased to thousands of dollars instead of 
millions by the early 2010s (Wetterstrand, 2016).  
One of the first NGS methods to be developed was pyrosequencing, which was pioneered by Pål Nyrén 
and his colleagues in the late 1990s, and released commercially in the 2000s by 454 Life Sciences, 
which was later taken over by Roche (Nyren, 1987; Ronaghi et al., 1996; Ronaghi, Uhlen and Nyren, 
1998). The pyrosequencing method makes use of pyrophosphate ions, which are released during DNA 
synthesis when a complementary base is incorporated into the growing strand, to fuel a chain reaction 
which culminates in the release of light, as illustrated in Figure 1.9. ATP sulfurylase catalyses the 
synthesis of ATP from pyrophosphate and adenosine pyrosulfate (APS). Luciferase can then use the 
ATP produced from the pyrophosphate to catalyse the conversion of luciferin to oxyluciferin, 
producing light as a by-product. In pyrosequencing, the template strand of interest is bathed in DNA 
polymerase, APS, ATP sulfurylase, luciferin and luciferase. dNTPs are introduced to this mixture in 
turn; when the next complementary dNTP is introduced, DNA polymerase will incorporate a base into 
the growing complementary strand, releasing a pyrophosphate ion which subsequently results in the 
release of light. The light can be detected, hence the identity of each base in the DNA can be deduced 
according to which dNTP was present in the mix when the light was released. The amount of light 
released corresponds to the number of bases which have been incorporated; if the next several bases 
in the template strand are all the same (a homopolymeric tract), more light will be detected. However, 
homopolymeric tracts are a source of error in pyrosequencing, because the amount of light detected 
can be misinterpreted, and resolution between single base pair differences is difficult (Balzer, Malde 
and Jonassen, 2011). Because dATP would catalyse the luciferase reaction without the need for 
Figure 1.9 The pyrosequencing method developed by Pål Nyrén and colleagues and commercialised by 454 Life Sciences 
and Roche. 
                        Figure adapted from atdbio (2019). 
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pyrophosphate release, dATPαS is used instead. dATPαS can be incorporated into the complementary 
strand by DNA polymerase, but cannot be used by luciferase. 
Massively parallel pyrosequencing was achieved through the use of microbeads. The DNA of interest 
is sheared into fragments less than a thousand base pairs long, and denatured to form single-stranded 
DNA (ssDNA). The ssDNA fragments are adhered to individual microbeads, and PCR is used to amplify 
the DNA on the beads, so that each microbead is coated with millions of copies of the same fragment. 
The microbeads are placed into microwells on a single plate, each of which can contain hundreds of 
thousands of microwells; thus, by detecting the output of each microwell individually, hundreds of 
thousands of DNA fragments can be sequenced at the same time (Margulies et al., 2005; Heather and 
Chain, 2016). This ability to sequence large numbers of DNA fragments at the same time, facilitated 
by technological advances - in microfabrication to produce the microbeads and in high-resolution 
imaging to detect signals produced during the sequencing process - is the defining feature of NGS, and 
is key in many other DNA sequencing methods developed during the 2000s (Shendure and Ji, 2008; 
Heather and Chain, 2016). 
Another such NGS technique which employs a massively parallel, microbead-based, method is Ion 
Torrent (Rothberg et al., 2011). The Ion Torrent was the first sequencer to use a non-imaging method; 
instead, the Ion Torrent method deduces the sequence of DNA strands by monitoring fluctuations in 
pH as a strand complementary to the fragment of interest is synthesised. The binding of a nucleotide 
to a growing DNA strand releases protons, hence the incorporation of a nucleotide can be detected 
as a pH change. During Ion Torrent sequencing, as with pyrosequencing, dNTPs are delivered in an 
iterative fashion to the reaction mix, and a pH change is only detected when the dNTP matching the 
next base in the DNA sequence is delivered. Despite the elegant theory behind this method, Ion 
Torrent sequencing shares one of pyrosequencing’s major flaws: it is prone to errors when sequencing 
homopolymeric sequences, because more than one dNTP may be incorporated at the same time, and 
the extra signal can be missed or difficult to interpret accurately. 
Most NGS technologies are similar to Sanger sequencing, in that they use DNA polymerase-based 
methods which are collectively known as “sequencing-by-synthesis” (SBS). SBS methods work by using 
DNA polymerases to synthesise new DNA strands complementary to the template strand of interest, 
whilst monitoring the order in which bases are added to the new strand. Each SBS technology uses a 
slightly different method to monitor which bases are being added, each with its own accompanying 
strengths and weaknesses. Not all NGS sequencers use SBS methods, however. Applied Biosystems’ 
“sequencing by oligonucleotide ligation and detection” (SOLiD) sequencing system uses, for example, 
a sequencing-by-ligation (SBL) method (McKernan et al., 2009). The SOLiD method is complicated and 
requires several sequencing cycles per strand, but the basic principle involves the use of DNA ligase, 
instead of DNA polymerase, to hybridize short fragments instead of individual bases to the template 
strand of interest, releasing differently coloured fluorophores to help identify each base along the 
way. Unlike Ion Torrent and pyrosequencing, the SOLiD method is not prone to homopolymer errors. 
Conversely, it has been reported to have a high error rate when sequencing palindromic sequences 
(Huang et al., 2012). 
The most commonly-used NGS method also monitors the release of fluorophores to decipher DNA 
sequences. Originally called Solexa, Illumina sequencing is an SBS technology which has become the 
gold standard for WGS since its inception in the mid-2000s (Bennett, 2004; Bentley et al., 2008; 
Greenleaf and Sidow, 2014). As shown in Figure 1.10, the Illumina method binds short fragments of 
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ssDNA to the surface of a flow cell, where they are amplified by PCR to produce clonal clusters. 
Sequencing then commences using cycles of DNA polymerase and DNA-blocking enzymes to 
sequentially add single fluorescently-tagged dNTPs, building a new strand complementary to that 
being sequenced. As each dNTP is incorporated into the nascent strand, its fluorophore is released 
and can be detected by the sequencer. Each of the nucleotides (dATP, dTTP, dGTP, dCTP) is tagged 
with a differently-coloured fluorescent molecule, thus the sequence of the template strand can be 
deduced according to the colour of the fluorescence released. The use of clonal clusters ensures that 
this fluorophore signal is strong enough to be distinguished from background noise, as the release of 
a single fluorophore would not be. The accuracy of Illumina sequencing is generally high, with error 
rates 0.1% or below (Fox et al., 2014; Pfeiffer et al., 2018). However, the inclusion of a PCR 
amplification step can introduce bias, mainly in genomes with a particularly high or low GC content 
(Kanagawa, 2003; Benjamini and Speed, 2012; Chen, Y.C. et al., 2013). This kind of bias results in the 
over- or under-representation in certain DNA fragments in sequencing libraries. GC-bias is a problem 
which has affected every sequencing method discussed thus far, even those which do not use PCR, 
like Sanger sequencing (Aird et al., 2011).   
Most NGS sequencers are large and expensive. Illumina, for example, produce a wide range of 
sequencing machines, with outputs ranging from 0.14 Gb of data in a 9.5-hour run using the Illumina 
iSeq, to the ultra-high-throughput Illumina NovaSeq which has an output of 3 Tb of data in a 44-hour 
run. Even the iSeq requires a bench-top and weighs 16 kg  (Illumina, 2019a, b). The running cost per 
sample for Illumina sequencers is relatively low, but the start-up cost of Illumina sequencing remains 
a barrier for many laboratories, with the iSeq costing around $20,000, the NovaSeq costing almost $1 
Figure 1.10 Illumina has been the gold-standard sequencing method during the 2010s. The strand of interest is 
bound to one of the thousands of adaptor sequence tethered to the flow cell. Numerous cycles of PCR produce a 
clonal cluster, in which all strands are identical to the template strand. Sequencing then progresses in a cyclic fashion: 
DNA polymerase is attached to the template strand, and sequentially adds fluorophore-tagged dNTPs to build the 
complementary strand. After the addition of each dNTP, synthesis is temporarily blocked enzymatically, and the 
fluorophore is released. The fluorophore is laser-detected, sequencing is unblocked, and the next dNTP can be 
incorporated. Each type of dNTP is tagged with a different colour, thus the identity of each base in the strand can be 
deduced according to the colour sequence detected from each clonal cluster. 
                Figure from Illumina (2017). 
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million, and the other Illumina sequencers costing anywhere in between (Herper, 2017; Proffitt, 2018). 
Nonetheless, the establishment of large sequencing service centres, like MicrobesNG at the University 
of Birmingham, means that WGS has become increasingly widely available throughout the late 2000s 
and 2010s (MicrobesNG, 2019).  
In 1995, the 1.83 Mb genome sequence of Haemophilus influenzae Rd was published, the first bacterial 
whole genome ever to be sequenced, and a major leap forward in the genomics field (Fleischmann et 
al., 1995). This was duly followed by the first draft human genome sequence in 2001, and a slightly 
more complete draft in 2004 (Lander et al., 2001; International Human Genome Sequencing 
Consortium, 2004). So rapid has been the development and widespread uptake of whole genome 
sequencing since then that the number of curated genome assemblies across all kingdoms of life 
available from the NCBI database is now (as of September 2019) over 270,000, representing almost 
50,000 different organisms and including 213 different human genome assemblies. The vast majority 
of the genomes sequenced thus far have been prokaryotic: over 210,000 of the genome assemblies 
stored in the NCBI database are prokaryotic, and over 206,000 of those are bacterial (almost 18,000 
of these assemblies belong to the model gram-negative bacterium, E. coli) (NCBI, 2019). Our 
understanding of bacterial genomics has increased at an unprecedented rate, to the extent that we 
now know enough to be able to design new bacterial species, like the synthetic bacterial genome of 
Caulobacter ethensis-2.0 published in April 2019 (Venetz et al., 2019). However, most of the genome 
assemblies available from the NCBI database are not closed; they consist of multiple fragments, known 
as contigs. Until 2011, for example, only one closed genome sequence for B. pertussis existed: that of 
the reference strain, Tohama I, which was sequenced in 2003 (Parkhill et al., 2003). The reason for the 
lack of closed genomes is the length of sequencing read produced by the NGS technologies used to 
sequence most of the available genome assemblies. 
As mentioned at the end of section 1.1, sequencing read length is limited in NGS technologies. In 
Illumina sequencing, reads are limited to the length of the tethered strands in the clonal clusters, 
usually 150-300 bp. The sequencing of the identical strands in clonal clusters, whilst initially ensuring 
higher accuracy, is prone to phasing issues. The base within the strand being called at any given 
moment tends to get out of sync between the different strands within each cluster; the longer the 
sequencing continues, the more out of sync the sequencing will be, rapidly deviating beyond the level 
of phasing which can be corrected informatically. This means sequencing longer strands would result 
in lower accuracy (Nakamura et al., 2011; Loman, 2013). In addition, the read lengths for all 
sequencing methods which use PCR to produce clonal clusters or fragment-covered microbeads will 
be limited by the efficiency and accuracy of PCR reactions, which decreases with increasing fragment 
length (Knierim et al., 2011; Jia et al., 2014). 
As shown in Figure 1.11, repetitive regions of DNA sequence are difficult or impossible to assemble into 
single fragments using short reads. Instead, reads which are longer than the longest repetitive region 
in a genome are required to produce a closed sequence for that genome. It has been suggested that 
the “golden threshold” of read lengths for the assembly of microbial genomes is 7 kbp, because 7 kbp 
should span even the longest repetitive region in any microbial genome (Koren and Phillippy, 2015). 
During the 2010s, therefore, the focus of the newest DNA sequencers has been the production of read 




Long-read sequencing of B. pertussis with Pacific Biosciences instruments succeeded in 
producing closed genome sequences 
The first long-read sequencing technology to be commercially released was Pacific Biosciences 
(PacBio) sequencing. Theoretically to be acquired by Illumina by the end of 2019 for $1.2 billion, PacBio 
sequencing represents another step-change in genomics, facilitating widespread assembly of closed 
microbial genome sequences for the first time (Eisenstein, 2019). The PacBio sequencing method is a 
variation of classic SBS, sharing much in common with Illumina sequencing. In Illumina sequencing, 
the DNA to be sequenced is bound to the flow cell, and DNA polymerase and fluorescently tagged 
dNTPs are in solution. By contrast, in PacBio sequencing, the DNA polymerase is bound to wells in the 
flow cell, and the DNA to be sequenced is in solution with the dNTPs. As shown in Figure 1.12, DNA 
strands are captured by the DNA polymerase and the complementary strand is synthesised, releasing 
fluorescence each time a base in incorporated (Eid et al., 2009). The location of each DNA polymerase 
well is monitored precisely, meaning the fluorescence from single DNA strands can be distinguished 
from background noise. This means that PCR is not required, thus some of the bias intrinsic to NGS 
techniques is avoided (Kanagawa, 2003). The PacBio method is able to produce read lengths much 
longer than NGS technologies; the average read produced by the PacBio RSII or Sequel sequencers is 
10-16 kbp, and reads of up to 60 kbp have been regularly reported (Rhoads and Au, 2015; Weirather 
et al., 2017; Ardui et al., 2018). PacBio sequencing read length does have an upper limit, however, as 
the lifespan of the DNA polymerases is limited. 
Figure 1.11 Repetitive regions of sequence can be resolved by reads longer than the repetitive region 
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Sequencing individual DNA strands instead of clonal clusters or clonal microbeads results in a slightly 
lower raw accuracy. Consequently, PacBio sequencing includes an internal consensus step: template 
strands are circularised and processed multiple times by the same DNA polymerase, giving multiple 
calls for each base in the strand, which can be averaged. Early PacBio sequenced had a raw error rate 
of up to 18% (Nagarajan and Pop, 2013). However, developments to the sequencing chemistry and 
data analysis tools have led to rapid raw accuracy improvements. In addition, unlike most NGS 
technologies which make systematic errors (such as Ion Torrent’s homopolymer issues, or SOLiD’s 
palindromic sequence issues), PacBio sequencing has a random error profile. This means that errors 
can be corrected informatically, with high enough sequence coverage. Together, these factors have 
led to reported PacBio accuracies of over 99.9% (Eisenstein, 2019). 
The first study to take advantage of PacBio for B. pertussis was Bart, Zeddeman, et al. (2014). Using 
PacBio’s long reads, Bart et al. were able to produce closed, fully annotated, genomes for two B. 
pertussis strains: B1917 and B1920. These were the first closed B. pertussis genomes to be produced 
since the original sequencing of the Tohama I reference strain using Sanger sequencing (Parkhill et al., 
2003). The arrangement of the B1917 and B1920 genomes differed significantly, with three large 
Figure 1.12 PacBio’s SMRT sequencing method. DNA polymerases are attached to the bottom of wells across the flow cell. 
DNA strands to be sequenced are introduced in solution, and can be captured by the polymerases. Sequencing then 
progresses in a manner largely similar to the Illumina SBS method: DNA polymerase catalyses the synthesis of the 
complementary strand, using fluorescently tagged dNTPs which are also supplied in solution. The location of each 
polymerase-containing well is monitored precisely for fluorescence, thus the sequence of the strand is deduced. 
             Figure adapted from Eid et al. (2009) 
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inversions and a variety of deletion and/or insertion events between the pair (Figure 1.13). Having 
proven the ability of PacBio to produce closed B. pertussis genomes, Bart et al. (2015) next sequenced 
11 B. pertussis strains which represented the pandemic ptxP3 lineage, again using PacBio sequencing 
to produce 10 kbp-long reads. These additional strains were predictably similar in terms of SNPs and 
indels, but again showed extensive differences in the arrangement of their genomes. 
Since its commercial rollout in the early 2010s, the cost of PacBio sequencing has continued to rapidly 
decrease. Thus, high-throughput strain screens are becoming increasingly feasible. Figure 1.14 shows 
the dramatic increase in closed genome sequences for the classical Bordetella species available from 
the NCBI’s RefSeq database since 2014. In 2011, only one closed sequence was available each for B. 
bronchiseptica, B. parapertussis and B. pertussis. As of September 2019, 20 B. bronchiseptica, 21 B. 
parapertussis and 550 B. pertussis closed genomes were available (not including those produced in 
this thesis). A large number of the closed B. pertussis genomes have been generated by the USA’s 
Centers for Disease Control (CDC), mostly using PacBio long reads in hybrid with Illumina short reads. 
The hybrid assembly approach improves the accuracy of assemblies produced using long-read 
sequencing, as long-read sequencing still has an intrinsically higher error rate than short-read 
sequencing (Au et al., 2012; Koren et al., 2012). 
Bowden et al. (2016) at the CDC conducted the first whooping cough outbreak screen to use long and 
short reads in hybrid, sequencing 31 strains isolated in the USA during 2010 and 2012 whooping cough 
outbreaks. 21 different arrangement profiles were seen in the 31 genomes, most consisting of 
inversions around the origin of replication, as appears to be common in bacterial genomic 
rearrangement (Boccard, Esnault and Valens, 2005). They also validated the arrangements using 
whole genome optical mapping. This showed that, as predicted, the boundaries between rearranged 
sections were composed of a repeated element: an insertion sequence, or the rRNA operon. 89% of 
the boundaries consisted of the most abundant insertion sequence, IS 481. 
The most thorough investigations of B. pertussis genomic rearrangement thus far were also conducted 
by the CDC, and used a hybrid assembly strategy. Weigand et al. (2017) combined PacBio long reads 
with Illumina short reads to close the genomes of 257 strains, dating from 1939 to 2014. When 
clustered based on their arrangement profiles, most isolates clustered according to allelic profile. This 
suggests that most structures are relatively stable, as supported by a clinical isolate which showed the 
Figure 1.13 Different arrangements of the B. pertussis genome seen in BP1917 and BP1920. Three large sections of the 
genome (1, 2, and 3) are inverted in BP1920, as shown by their appearance on the complementary strand when the two 
whole genome sequences are aligned using progressiveMauve (Darling, Mau and Perna, 2010). The Genbank accession 
numbers for the genome sequences produced by Bart, Zeddeman, et al. (2014) for BP1917 and BP1920 are CP009751 and 
CP009752, respectively.   




same structure before and after 11 serial passages. Furthermore, these findings suggest that lineages 
are conserved not just in terms of SNPs, but also in genomic arrangement. Interestingly, Weigand et 
al. note that, on average, only half of their predicted IS 481 target sites are occupied in any given 
genome, suggesting a potential for further IS-mediated structural changes in future generations, 
assuming these sites are not non-permissive. This study was followed by Weigand et al. (2019), in 
which closed genome sequences were produced for 469 B. pertussis isolates and 167 isolates from 
other Bordetella species with multiple IS elements. This showed that, across the genus, 
rearrangements tended to take the form of large, symmetrical inversions. In addition, whilst the scope 
for different genome arrangements is very large, only a small subset of arrangements tends to be 
observed, suggesting that certain gene orders are more favourable than others. 
Like NGS technologies, PacBio sequencers are large and expensive: the most recent sequencer, the 
Sequel II, is reported to have a basic price of almost $500,000 (Genome Web, 2019). This means that 
only larger sequencing centres, like the CDC, can afford to run on-site PacBio sequencing, although a 
number of sequencing service providers have started to add PacBio sequencing as an option. In 2014, 
however, a competing long-read sequencer was released to early access users, one which promised 
to reduce start-up costs to less than $1,000, and to make DNA sequencing portable: Oxford Nanopore 
Technology (ONT)’s MinION nanopore sequencer. 
Nanopore sequencing has developed over three decades 
Nanopore sequencing is the brainchild of David Deamer and Daniel Branton, who began developing 
the concept in 1989 (Deamer, Akeson and Branton, 2016). The theory behind nanopore sequencing is 
simple: single strands of DNA can be drawn through nano-scale pores in a membrane by 
electrophoresis, disrupting the flow of current across the membrane in a manner distinctive of which 
bases are translocating at any given moment. However, the journey from conception to 






























B. pertussis B. bronchiseptica B. parapertussis
Figure 1.14 The numbers of closed classical Bordetella genomes available on RefSeq has increased rapidly since long-read 
sequencing technologies became widely available.                                                                                                            . 
                                              Figure from Ring et al. (2019). 
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proteins. From conception to the release of the prototype nanopore sequencers to a group of “early 
access” users in 2014 took 25 years, and even since its release, the technology has continued to 
develop rapidly. 
The earliest research into nanopore sequencing all focussed on the Staphylococcus aureus 
transmembrane protein, α-hemolysin. Work in the 1980s and early 1990s showed that the 1.5 nm 
pore formed by α-hemolysin was big enough to accommodate ssDNA (~1.2 nm diameter), but not 
double-stranded DNA (dsDNA, >2 nm diameter) (Menestrina, 1986; Song et al., 1996). John 
Kasianowicz worked extensively with α-hemolysin throughout the 1990s, establishing the conditions 
under which polynucleotides could be drawn through the pore by inserting the protein into a lipid 
bilayer between two compartments filled with KCl (Kasianowicz et al., 1996). By applying a positive 
voltage difference of greater than 80 mV across the membrane, RNA homopolymers were seen to 
move from the “cis” compartment into the “trans” compartment. The flow of current was disrupted 
as the RNA moved, for lengths of time proportional to the length of the strand. Having shown that 
translocation of RNA was possible, the next trials included homopolymeric double-stranded and 
single-stranded DNA. qPCR was used to quantify the strands in the trans compartment, showing that 
only ssDNA had been able to translocate and  thus proving that the width of the α-hemolysin pore did 
limit translocation to single strands alone (Kasianowicz et al., 1996). 
The next important developments, from the late-1990s to late-2000s, focussed on proving whether 
the S. aureus α-hemolysin pore could discriminate between different nucleotide bases according to 
their level of current disruption. Along the way, Akeson et al. (1999) used synthesized RNA strands 
consisting of 70 Cs followed by 30 As to show that two distinct levels of current disruption could be 
recorded, although it was found that these different levels were due to the different secondary 
structures formed by the polyC segment compared to the polyA, rather than differences between 
individual bases. Soon afterwards, Meller et al. (2000) showed that ssDNA polynucleotides of identical 
length but different base sequences produced different current blockage signals. Five years later, 
Ashkenasy et al. (2005) synthesised a variety of polyC strands which each had a single adenosine 
substitution at a different position. Each type of strand produced a different flow of current through 
the α-hemolysin pore, which could be used to distinguish at which base the adenosine had been 
substituted, essentially proving that it was possible to resolve sequences at the level of single bases. 
This was followed by several years of work by David Stoddart, showing that individual bases could be 
resolved even in non-homopolymeric sequences, and further characterising how the structure of the 
α-hemolysin pore interacted with the ssDNA strands to disrupt the flow of current (Stoddart et al., 
2009; Stoddart, Heron, et al., 2010; Stoddart, Maglia, et al., 2010).  
By 2010, therefore, it had been well established that the idea of using nanopores to sequence DNA or 
RNA with single base resolution was feasible. However, the studies to that point had almost all used 
terminal hairpin complexes to suspend the strand of interest within the pore, which greatly improved 
the signal-to-noise ratio, but would not be suitable for a high-throughput sequencing method 
(Deamer, Akeson and Branton, 2016). For high-throughput sequencing, strands would need to flow 
freely from the cis chamber to the trans chamber, leaving the pore unblocked for subsequent strands. 
Therefore, a mechanism for slowing down the translocation of strands through the pore was needed; 
unhindered, the voltage bias required to drive strands through a pore would result in a translocation 
speed of less than 10 µs per nucleotide. To ensure that current fluctuations lasted long enough to be 
detected, a  processive enzyme would be required, to ratchet strands through the pore at a detectable 
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rate, calculated to be at least 100 µs per nucleotide (Deamer, Akeson and Branton, 2016; Byrd and 
Raney, 2018). 
Previous work had already demonstrated the utility of processive enzymes in slowing the rate of DNA 
translocation through a protein pore (Church et al., 1998; Benner et al., 2007; Hornblower et al., 2007). 
Cockroft et al. (2008) then successfully showed than an A family DNA polymerase could allow single-
nucleotide resolution. This method included the attachment of a hairpin structure to the end of the 
DNA strand of interest. The DNA strand could translocate through the pore, driven by the positive 
voltage difference, up to the hairpin structure. The DNA polymerase could then theoretically ratchet 
the DNA strand back through the pore one nucleotide at a time. However, this type of polymerase 
required a voltage alternating between -30 and 30 mV applied to the membrane, to force the DNA 
polymerase to bind to and then dissociate from the DNA strand being sequenced. The voltage 
difference needed to drive the DNA strand through the pore initially would therefore force the A 
family DNA polymerase to remain dissociated from the DNA, hence at most only two nucleotide 
additions could be observed in sequence using this type of polymerase. It was soon discovered that 
phi29 DNA polymerase was more resistant to the necessary voltage, staying tightly associated with 
the DNA long enough to sequence strands up to tens of nucleotides long, using the α-hemolysin pore 
(Lieberman et al., 2010; Cherf et al., 2012; Byrd and Raney, 2018). The mechanism is illustrated in 
Figure 1.15. 
Early prototype nanopore sequencers were therefore produced in 2011 and 2012, which used phi29 
DNA polymerase to ratchet DNA strands through a pore, this time an engineered MspA porin protein. 
Although single base resolution was possible using α-hemolysin, it had become apparent that the 
physical characteristics of the pore were sub-optimal. Chiefly, its length (~5nm) allowed 12 nucleotides 
to traverse the membrane at the same time, meaning that the current signal was dependent on 12-
mers. This made the processing of the current trace into single bases very computationally intensive 
and difficult (Meller, Nivon and Branton, 2001; Deamer, Akeson and Branton, 2016). Consequently, a 
pore protein with a much shorter aperture, but same diameter, was trialled and developed: the MspA 
porin from Mycobacterium smegmatis (Niederweis et al., 1999; Faller, Niederweis and Schulz, 2004). 
The aperture of the MspA pore was almost ten times shorter (~0.6 nm) than that of α-hemolysin and, 
with some targeted mutations, was engineered to produce a protein which enabled far easier 
discrimination between single nucleotides than the original nanopores tested (Butler et al., 2008; 
Derrington et al., 2010). The trials of the phi29 DNA polymerase-MspA prototype sequencers were 
successful, and spurred on the development of more widely available commercial nanopore 
sequencing (Cherf et al., 2012; Manrao et al., 2012). 
The first commercially available nanopore sequencer, the MinION, was announced by Oxford 
Nanopore Technologies in 2012, before being released to early access users two years later. The early 
MinION used the same MspA pore as the prototypes, but now used a helicase enzyme to ratchet the 
DNA through the pore one nucleotide at a time, as shown in Figure 1.15. Like α-hemolysin before it, 
phi29 DNA polymerase turned out to be sub-optimal for large scale nanopore sequencing due to a 
number of inhibitive errors, such as periodically skipping forward or backwards by multiple bases 
(Heron, 2018). Thus, a helicase enzyme, Dda, from bacteriophage T4 was engineered instead (Byrd 
and Raney, 2018). Because no shearing of DNA is required by the helicase-nanopore method, DNA 







Figure 1.15 DNA polymerase (1) vs DNA helicase (2) as a DNA processing enzyme.  
1) DNA polymerase is bound to a short hairpin polymer, which is then ligated to the 3’ end of the ssDNA fragment of 
interest. The voltage difference across the membrane draws the DNA strand through the nanopore to the trans 
chamber. The DNA polymerase cannot pass through the pore, and is activated when the two come into contact. 
The activated polymerase then ratchets the DNA back through to the cis chamber, one nucleotide at a time, 
resynthesising the complementary strand in the process. 
2) A synthetic polymer strand is ligated to the 5’ end of a dsDNA fragment to be sequenced, both of which are captured 
through a helicase enzyme. The anionic polymer is drawn through the nanopore by the voltage difference across 
the membrane. The helicase cannot pass through the pore, and is activated when the two make contact. The 
activated helicase then steps along the dsDNA strand, unzipping it and feeding nucleotides through the pore to the 
trans chamber one at a time. The complementary strand is released into the cis chamber.  






The MinION uses a “two-electrode self-referencing” electrochemistry system, which allows for a 
steady flow of ionic current from the cis chamber to the trans. This system uses platinum electrodes 
in both chambers, and a bright yellow potassium ferricyanide/ferrocyanide solution to donate and 





A synthetic membrane separates the cis and trans chambers. The cis chamber is a single compartment, 
with a single electrode, whereas the trans compartment consists of 2,048 wells, each of which 
contains its own electrode. Each well can contain a single nanopore, meaning a MinION flow cell can 
contain up to 2,048 individual pores (although a variety of factors during production and shipping 
mean the actual number of pores on any flow cell is usually significantly lower than this). An 
application-specific integrated circuit (ASIC) chip sits below the pore wells, and can detect current 
from 512 of them at any given moment. Each ASIC channel is therefore responsible for sensing current 
from four wells; the MinION software, MinKNOW, periodically scans all the pores and determines 
which set of 512 (if 512 are still functional) should be sensed by the ASIC chip (Clarke, 2018). This 
system is reminiscent of the massively parallel sequencing strategies of NGS and, indeed, early users 
were optimistic that the MinION could achieve comparable sequencing yields. 
A pilot study using early nanopore sequencing to sequence B. pertussis was unsuccessful 
When the first MinIONs were made available in 2014, preliminary gDNA sequencing was carried out 
by the Bagby group for two B. pertussis strains, UK48 and UK76. Like PacBio sequencing before it, the 
long reads that the MinION was capable of generating should have been well able to produce fully 
resolved, closed B. pertussis genome sequences. The preliminary sequencing used the Mk1 MinION, 
the first publicly available sequencing chemistry, R7.3, and cloud-based basecalling with Metrichor. 
gDNA was extracted from UK48 and UK76 by Tom Belcher at the University of Bath and shipped to the 
Nanopore Group at the University of California, Santa Cruz. Two 48-hour sequencing runs were 
completed for UK76, and one was completed for UK48. These runs demonstrated the long-read 
capabilities of MinION-based nanopore sequencing, with mean read lengths of 5.2 kbp for UK48 and 
6.5 kbp for UK76. However, the throughput of the R7.3 flow cells was poor: the single 48-hour run for 
UK48 produced only 7.1x coverage of the B. pertussis genome, and even the two more successful 48-
hour UK76 runs only produced a total of 47.8x coverage. Such low yields were characteristic of early 
MinION flow cells; one 2015 study from Nature Methods reports a total yield of only 133.6 Mb from 
four sequencing runs (Loman, Quick and Simpson, 2015). In addition, the variation in performance 
observed between the UK48 and UK76 runs is also reflected in word-of-mouth reports from around 
the same period (Robison, 2017; Stack Exchange, 2017; van der Helm, 2017).  
Attempts to de novo assemble the UK76 genome using the 47.8x coverage generated in the two R7.3 
runs were unsuccessful. Five different assembly tools were tested: ABruijn, Miniasm, Canu, 
SMARTdenovo and SPAdes (Bankevich et al., 2012; Ruan, 2015; Li, 2016; Lin et al., 2016; Koren et al., 
2017). ABruijn (now called Flye), Miniasm and Canu are still three of the most popular de novo 
assembly tools within the nanopore community and, as of 2019, are known to produce highly 

























however, all three, plus SPAdes and SMARTdenovo, were unable to produce a single closed genome 
sequence, as shown in Figure 1.16. This inability to produce a closed sequence despite relatively high 
coverage in reads longer than the repetitive B. pertussis IS481 sequence was likely due to R7.3’s high 
raw error rate, which was reportedly  as high as 34% (Jain et al., 2015). 
Ultimately, the 2015 pilot study showed that nanopore sequencing using the R7.3 flow cell chemistry 
was not suitable for the assembly of closed B. pertussis genome sequences: the low yield, 
unpredictability of flow cell performance and high raw error meant that multiple flow cells would be 
required to produce high enough coverage for accurate consensus assembly, which would be cost-
prohibitive for most labs, particularly those running low-throughput sequencing. 
A test of new nanopore sequencing chemistry and Mk 1b MinION proved de novo 
assembly of B. pertussis genomes was possible 
In 2016, however, a new type of sequencing chemistry was released by ONT. R9.4 flow cells contain a 
new pore protein (the E. coli lipoprotein, CsgG), which was engineered to provide improved accuracy, 
thanks to an even shorter, more specific base-sensing region. In addition, improvements to the 
helicase enzyme allowed for higher sequencing speeds (up to 450 bases per second, compared to 70 
bases per second for R7), thus greater yield per run (Oxford Nanopore Technologies, 2016; Clarke, 
2018). The Mk1 MinION was retired and the Mk1b, which is adapted for R9.4 flow cells, was 
introduced. A new basecalling algorithm was also released, which used neural networks instead of 
Hidden Markov Models (HMM) and was reported to further improve the raw accuracy of reads 
produced by R9.4 flow cells.  
In December 2016, another sample of UK76 gDNA was sent to the Nanopore Group at the University 
of California Santa Cruz, where it was sequenced using an R9.4 flow cell and Mk1b MinION. In 48 
Figure 1.16 Attempts to assemble UK76 reads generated by R7.3 MinION flow cells were unsuccessful. Assembling Illumina 
short reads usually produces around 300, unresolved, contigs (A). Five assembly tools which had a long-read-only setting 
were tested with nanopore-generated UK76 long reads. ABruijn (B), Miniasm (C), SMARTdenovo (D), Canu (E) and SPAdes 
(F) all failed to assemble the nanopore long reads into single contigs. Additionally, each of the assemblers arranged the 
contigs in a different layout when aligned with progressiveMauve (Darling, Mau and Perna, 2010). Long-read-only assembly 
of R7.3 reads was therefore unsuited to investigation of B. pertussis genome arrangement.  
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hours, around 9.3 Gb of data was produced, equating to almost 2,500x coverage of the B. pertussis 
genome: nearly 50 times higher than the two R7.3 UK76 runs. Tests with Miniasm (the quickest de 
novo assembly tool) showed that this large R9.4 data set could be assembled into a single-contig, 
closed genome assembly. However, Miniasm produces low accuracy assemblies, because it does not 
incorporate any correction or polishing steps. Attempts to assemble the 9.3 Gb of UK76 data using 
Canu, which includes a thorough read correction step, indicated that assembly of such a large data set 
would take an impractical length of time, even on a high-performance computing (HPC) cluster. 
Alternatively, a subset of only one twentieth of the reads could also be assembled into a single contig, 
suggesting that each R9.4 flow cell produced enough data, of high enough accuracy, to sequence 
multiple strains together in the same sequencing run.  
ONT produce several library preparation kits which allow for multiple samples to be sequenced 
together, using read barcoding. Each barcode is a short (tens of base pairs) sequence, which is ligated 
onto every DNA fragment in a DNA library. As shown in Figure 1.17, during sequence barcoding, also 
known as multiplexing, different barcodes are added to different samples, which can then be pooled 
and sequenced together, followed by computational demultiplexing (Smith et al., 2010). As of 2017, 
an increasing number of groups  had shown the utility of barcoded nanopore sequencing to achieve 
closed bacterial genome sequences, usually in hybrid with short reads generated by Illumina 
sequencing (for example: Bayliss et al., 2017; Wick et al., 2017a). Thus, one of the first aims of this 
project was to test ONT’s barcoding protocols with B. pertussis, and establish a workflow which 






Figure 1.17 Barcodes can be added to DNA strands of interest in order to sequence multiple samples using 
the same flow cell 
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1.3 Aims of this project 
The B. pertussis genome requires long-read sequencing for full resolution and assembly of single-
contig, closed genome assemblies. Closed genome sequences can reveal differences, such as 
rearrangements, between strains which otherwise appear to have highly similar genomes. Thus, 
closed genomes may help in the development of a deeper understanding of B. pertussis evolution 
which, in turn, could play a role in understanding the ongoing resurgence of whooping cough. 
Nanopore sequencing offers the opportunity to produce closed genomes in a high-throughput 
manner, at a cost which is affordable for smaller labs, who are not sequencing specialists. The 
overarching aim of this project was therefore to explore how nanopore sequencing, and long-read 
sequencing more generally, can be used to study B. pertussis genomes and begin to investigate some 
of the genomic phenomena which may only become apparent through the comparison of closed 
genome sequences. 
The work in this thesis can be split into two separate, but related, project areas: 
Chapters 2 and 3 detail the development and use of a workflow for whole genome sequencing and de 
novo genome assembly of B. pertussis isolates using multiplexed nanopore sequencing. The workflow 
is developed and optimised using a subset of five previously characterised isolates in Chapter 2 (Ring 
et al., 2018), then in Chapter 3 the workflow is adapted and used to investigate a set of 66 
uncharacterised samples isolated in New Zealand between 1982 and 2018. 
Chapters 4 and 5 explore the potential offered by long-read sequencing to identify and investigate 
genome-level inter-strain variations. In Chapter 4, an ultra-long genome duplication identified during 
workflow development (Chapter 2) is explored in more depth, including additional sequencing and 
investigation of potential phenotypes arising in affected strains (Abrahams et al., In review). In Chapter 
5, all currently available B. pertussis genomes which have been closed using long-read sequencing are 
mined to examine any ongoing changes in a gene which codes for one of the antigens used in the 
acellular whooping cough vaccination but which has previously been excluded from allele typing due 





Chapter 2:  Resolving the complex 
Bordetella pertussis genome using 
barcoded nanopore sequencing 
 
 
The work presented in this chapter is published as a peer-reviewed publication: 
“Resolving the complex Bordetella pertussis genome using barcoded nanopore sequencing”. 
Natalie Ring, Jonathan S. Abrahams, Miten Jain, Hugh Olsen, Andrew Preston and Stefan Bagby. 
Microbial Genomics, 4, doi: 10.1099/mgen.0.000234 
November 2018 













“Well, the thing about a black hole, its main distinguishing feature is it’s black. And the thing about 
space - the colour of space, your basic space colour - is it’s black. So how are you supposed to see 
them?” 




2.1 Commentary text – preliminary tests and chapter summary 
The work in this chapter establishes a current optimal workflow for the use of barcoded nanopore 
sequencing to whole genome sequence B. pertussis strains. Prior to the main bulk of the chapter (the 
paper itself), several preliminary tests were conducted.  
PCR barcoding vs native barcoding 
Two methods exist for attaching barcode sequences to DNA fragments during nanopore sequencing 
library preparation. The first, “barcoding-by-PCR”, uses specific PCR primers for each barcode, 
followed by several rounds of PCR. This method has the benefit of amplifying the starting mass of 
DNA, meaning a low yield during extraction can be overcome. Nonetheless, the use of PCR also comes 
with disadvantages; for example, certain sequence structures are less likely to be successfully 
amplified (e.g. highly repetitive or palindromic sequences), which introduces bias into the eventual 
sequencing library (Kanagawa, 2003). The second barcoding method, “native barcoding”, 
enzymatically ligates barcode sequences onto the gDNA fragments in the same way sequencing 
adapters are ligated, without the need to introduce PCR bias. However, the obvious disadvantage of 
not using PCR is the need for a higher starting mass of DNA. 
The “low input PCR barcoding” library preparation was trialled with five strains in June 2017 (those 
sequenced in the main body of the chapter, UK36, UK38, UK39, UK48 and UK76), using the standard 
protocol as per ONT’s instructions (SQK-LWB001) and a starting mass of 50 ng per strain. Solid phase 
reversible immobilization (SPRI) beads are used several times throughout the library preparation. A 
common side-effect of SPRI clean-ups is gDNA loss and, during the 2015 pilot study, B. pertussis gDNA 
appeared to be particularly susceptible (Personal Communication, Stefan Bagby, 2017). The same 
issue was encountered during the PCR barcoding library preparation: after starting with 50 ng gDNA 
per strain, each strain retained at most 13.3 ng after the first SPRI clean-up step. The PCR amplification 
step of the preparation could have negated this loss; indeed, after the PCR step, yields of 70 ng and 
above were achieved for three of the five strains. However, the yields for the remaining two strains 
were much lower, at ~45 ng and ~15 ng each, meaning that these strains were underrepresented in 
the final sequencing library. After 48 hours of sequencing on an R9.4 MinION flow cell, the sequencing 
yield and mean read length were also low: 1.11 Gb in total, with a mean read length of 1,210 bp. In 
addition, 44% of all reads had no recognisable barcode attached. This meant that the highest coverage 
yielded for any strain was only 50x which, given nanopore sequencing’s high raw error rate, was 
unlikely to be sufficient for de novo assembly of closed genome sequences, as seen in the 2015 pilot 
study. The native barcoding library preparation, which requires a starting mass of 1.5 µg gDNA, was 
therefore used for this study instead of PCR barcoding. Although the native barcoding protocol also 
requires SPRI clean-ups, the much higher starting mass of DNA means that more should be retained 
in the final sequencing library. 
FFPE repair test 
The native barcoding library preparation protocol (SQK-LSK108 with EXP-NBD103) includes an optional 
FFPE end-repair step. FFPE repair can improve sequencing yields, by repairing damaged fragments 
which would otherwise be unsuitable for adapter ligation. FFPE repair is recommended for samples 
which have been repeatedly freeze-thawed, or which are very old. The B. pertussis gDNA sequenced 
here was freshly extracted and had not been freeze-thawed; nonetheless, half of each strain’s gDNA 
40 
 
sample was repaired with NEBNext FFPE reagents (NEB) to test whether sequencing yield or raw 
accuracy could be improved by including this optional step prior to library preparation. However, 
predictably, neither the yield (n=5, paired t-test p=0.39) nor the raw accuracy (n=5, paired t-test 
p=0.937) was significantly improved for the five strains tested. For full statistics, see Supplementary 
table S2.1. The “FFPE-repaired” and “non-FFPE-repaired” reads for each strain were therefore pooled 
for all subsequent analysis detailed in the main body of this chapter.  
Basecaller comparison 
The natively barcoded sequencing run was originally basecalled using the basecalling tool built into 
the sequencing software, MinKNOW (vJune2017). The de novo assembly process was therefore first 
optimised using the MinKNOW-basecalled data. However, in mid-2017, a new standalone basecalling 
tool, Albacore, was made publicly available by ONT. Word-of-mouth feedback suggested that this new 
basecalling tool was significantly more accurate than the algorithm included in the MinKNOW software 
in June 2017. Therefore, the raw sequencing data files (fast5s) were re-basecalled with Albacore, and 
the MinKNOW and Albacore reads for each of the five sequenced strains were compared to an 
Illumina-only assembly for each strain, to compare raw accuracy.  The mean identity for the MinKNOW 
reads was 2.46% lower than that of the Albacore reads, meaning Albacore produced significantly more 
accurate basecalls than MinKNOW for our five strains (n=5, paired t-test p<0.001). For full statistics, 
see Supplementary table S2.1. Consequently, the pipeline optimisation process was repeated using the 
Albacore-basecalled reads, as thoroughly detailed in the main body of this chapter.  
Commentary text – chapter summary and context 
Five B. pertussis strains from the 2012 UK whooping cough outbreak were sequenced using ONT’s 
native barcoding library preparation and a single R9.4 MinION flow cell, and a wide variety of data 
analysis tools for basecalling, demultiplexing, pre-assembly read correction, de novo assembly and 
post-assembly polishing were trialled, in all possible combinations. Long-read-only strategies were 
also compared with hybrid (long nanopore reads plus short Illumina reads). The optimal long-read-
only workflow available at the time of these trials (although newer and better tools are now available 
for almost every step) utilised Albacore basecalling, Porechop demultiplexing, pre-assembly read 
correction with Canu, de novo assembly with Flye and post-assembly polishing with Nanopolish. The 
optimal hybrid workflow replaced the de novo assembly and polishing steps: for hybrid assembly, 
these steps were both carried out using Unicycler. Four of the five strains sequenced were resolved 
into closed genomes; we discovered that the genome which remained unclosed contained a 





The genome of Bordetella pertussis is complex, with high G+C content and many repeats, each longer 
than 1000 bp. Long-read sequencing offers the opportunity to produce single-contig B. 
pertussis assemblies using sequencing reads which are longer than the repetitive sections, with the 
potential to reveal genomic features which were previously unobservable in multi-contig assemblies 
produced by short-read sequencing alone. We used an R9.4 MinION flow cell and barcoding to 
sequence five B. pertussis strains in a single sequencing run. We then trialled combinations of the 
many nanopore user community-built long-read analysis tools to establish the current optimal 
assembly pipeline for B. pertussis genome sequences. This pipeline produced closed genome 
sequences for four strains, allowing visualization of inter-strain genomic rearrangement. Read 
mapping to the Tohama I reference genome suggests that the remaining strain contains an ultra-long 
duplicated region (almost 200 kbp), which was not resolved by our pipeline; further investigation also 
revealed that a second strain that was seemingly resolved by our pipeline may contain an even longer 
duplication, albeit in a small subset of cells. We have therefore demonstrated the ability to resolve 
the structure of several B. pertussis strains per single barcoded nanopore flow cell, but the genomes 
with highest complexity (e.g. very large duplicated regions) remain only partially resolved using the 
standard library preparation and will require an alternative library preparation method. For full strain 
characterization, we recommend hybrid assembly of long and short reads together; for comparison of 
genome arrangement, assembly using long reads alone is sufficient. 
 
2.3 Data Summary 
1. Final sequence read files (fastq) for all five strains have been deposited in the Sequence Read 
Archive, BioProject PRJNA478201, accession numbers SAMN09500966, SAMN09500967, 
SAMN09500968, SAMN09500969, SAMN09500970. 
2. A full list of accession numbers for Illumina sequence reads is available in Supplementary table S2.1 
(https://figshare.com/s/003465e08ba1e8fc8780). 
3. Assembly tests, basecalled read sets and reference materials are available from figshare: 
https://figshare.com/projects/Resolving_the_complex_Bordetella_pertussis_genome_using_barcod
ed_nanopore_sequencing/31313 . 
4. Genome sequences for B. pertussis strains UK36, UK38, UK39, UK48 and UK76 have been 
deposited in GenBank, accession numbers: CP031289, CP031112, CP031113, QRAX00000000, 
CP031114. 
5. Source code and full commands used are available from Github: 
https://github.com/nataliering/Resolving-the-complex-Bordetella-pertussis-genome-using-
barcoded-nanopore-sequencing  . 
 
2.4 Impact Statement 
Over the past two decades, whole genome sequencing has allowed us to understand microbial 
pathogenicity and evolution to an unprecedented degree. However, repetitive regions, like those 
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found throughout the Bordetella pertussis genome, have confounded our ability to resolve complex 
genomes using short-read sequencing technologies alone. We have used nanopore sequencing, which 
can generate reads longer than these problematic repetitive regions, to resolve multiple B. pertussis 
genomes with a single flow cell. The resolved genomes can be used to visualize previously predicted 
genome rearrangements and, in addition, the inability of our long reads to resolve some of our 
genomes has allowed us to infer the presence of previously unidentified ultra-long duplications in two 
of our five strains. Thus, our findings point towards unanticipated genome-level genetic variation in 
strains which appear otherwise monomorphic at the nucleotide level. This work expands the recently 
emergent theme that even the most complex genomes can be resolved with sufficiently long 
sequencing reads. Our optimization process, moreover, shows that the analysis tools currently 
favoured by the sequencing community do not necessarily produce the most accurate assemblies for 




Bordetella pertussis is the pathogenic bacterium which causes most cases of whooping cough 
(pertussis). Pertussis was a major medical burden prior to the international introduction of vaccination 
in the 1940s and 1950s. Widespread vaccine uptake greatly reduced incidence of the disease in 
developed countries. Original whole-cell vaccines were replaced by new acellular vaccines throughout 
the 1990s and early 2000s. The acellular vaccines contain one to five of the B. pertussis protein 
antigens pertactin (PRN), pertussis toxin (PT), filamentous haemagglutinin (FHA), and the fimbrial 
proteins Fim2 and Fim3. Despite continued high levels of pertussis vaccination coverage, since the 
early 1990s the number of cases of whooping cough has increased in many countries (Burns, Meade 
and Messionnier, 2014; Jakinovich and Sood, 2014). 
Suggested causes for this resurgence include improved diagnostic tests and awareness, waning 
immunity as a result of the switch to acellular vaccination, and genetic divergence of circulating B. 
pertussis from the vaccine strains due to vaccination-induced selection pressure (Ausiello and 
Cassone, 2014; Clark, 2014; Sealey, 2015). A global survey of strains from the pre-vaccine, whole-cell 
vaccine and acellular vaccine eras showed that the genome of B. pertussis, widely regarded as a 
monomorphic and slowly evolving organism, has been evolving since the introduction of the whole-
cell vaccine (Bart, Harris, et al., 2014). Analysis of strains from several recent epidemics showed the 
rate of evolution of the genes encoding vaccine antigens has increased since the switch to the acellular 
vaccine (Octavia et al., 2012; Bowden et al., 2014; Lam et al., 2014; Sealey et al., 2015). 
The B. pertussis genome contains up to 300 copies of a 1053 bp insertion sequence (IS), IS 481. A 
smaller number of copies of IS 1002 (1040 bp) and IS 1663 (1014 bp) contribute further complexity to 
the genome. These regions of repetition mean that assembly of closed, single-contig B. pertussis 
genomes using short-read sequencing, which produces reads shorter than the IS repeats, has been 
particularly difficult: most genome sequences available on NCBI comprise several hundred contigs, or 
at least one contig per IS copy. Over the last decade, many studies have shown that reads longer than 
the longest repeat are required to resolve regions of high complexity (Chin et al., 2013; Conlan et al., 
2014; Koren and Phillippy, 2015; Loman, Quick and Simpson, 2015; Wick et al., 2017a; Jain, Koren, et 
al., 2018; Jain, Olsen, et al., 2018; Schmid et al., 2018). Assembly of closed genomes may reveal 
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genomic features which were previously unobservable in multi-contig assemblies; this is particularly 
true for genomes which contain a high number of IS copies, as insertion sequences are known to 
impact genomic structure via rearrangement, deletion and, more rarely, duplication (Bentley et al., 
2008; Siguier et al., 2014). 
In 2016, Bowden et al. (2016) were the first to use long reads, together with Illumina short reads, to 
conduct a survey of B. pertussis strains which had circulated during two whooping cough epidemics, 
in the USA, in 2010 and 2012. Assembling closed genomes for these epidemic isolates revealed 
extensive genomic arrangement differences between isolates which appeared to be otherwise closely 
related. Bowden et al. concluded that further comprehensive whole genome studies are required to 
fully understand the international resurgence of whooping cough. More recently, Weigand et al. 
showed that the B. pertussis genome continues to undergo structural rearrangement on a frequent 
basis, usually mediated by IS 481 (Weigand et al., 2017). As well as causing structural rearrangement, 
IS elements have also repeatedly been shown to be responsible for the ongoing reduction of the B. 
pertussis genome via gene deletion (Parkhill et al., 2003; Preston, A., Parkhill and Maskell, 2004; Caro 
et al., 2006; Heikkinen et al., 2007). 
Bowden et al. and Weigand et al. both used Pacific Biosciences (PacBio) long read sequencing, which 
has high start-up costs, and lacks the portability needed for on-the-ground epidemic surveillance. In 
contrast, Oxford Nanopore Technology (ONT)’s MinION nanopore sequencer has relatively low start-
up costs. Recent improvements to flow cell yield and the introduction of barcoded library preparation 
make per-sample MinION costs comparable to those of PacBio or Illumina (Bayliss et al., 2017; Ton et 
al., 2017; Wick et al., 2017a). In addition, the pocket-sized MinION sequencer is portable, enabling in-
the-field sequencing (Edwards et al., 2016; Quick et al., 2016; Pomerantz et al., 2017). 
Here we test the ability of barcoded nanopore sequencing, together with a variety of available data 
analysis tools, to resolve the genomes of five B. pertussis strains from a UK epidemic, which were 
previously unclosed and comprised many contigs assembled using short reads sequenced with 
Illumina’s MiSeq (Sealey et al., 2015). We then briefly investigate the resulting genomes to identify 
any previously unobserved features, with a particular focus on the genome of one strain which 
remained unresolved by our hybrid assembly strategy. 
 
2.6 Methods 
Full method and bioinformatics procedures are described at:    
https://github.com/nataliering/Resolving-the-complex-Bordetella-pertussis-genome-using-
barcoded-nanopore-sequencing. 
All data analysis was carried out using the Medical Research Council’s Cloud Infrastructure for 
Microbial Bioinformatics (CLIMB) (Connor et al., 2016). 
Strain isolation and Illumina sequencing 
Five strains originally isolated during the UK 2012 whooping cough epidemic were obtained from the 
National Reference Laboratory, Respiratory and Vaccine Preventable Bacteria Reference Unit, at 
Public Health England. Short-read sequencing data were generated previously, using genomic DNA 
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(gDNA) extracted using a DNeasy Blood and Tissue kit (Qiagen), multiplex library preparation and 
Illumina sequencing (Sealey et al., 2015). Full details, including accession numbers, are included in 
Supplementary table S2.1. 
DNA extraction 
Strains were stored at −80°C in PBS/20 % glycerol at the University of Bath. They were grown on 
charcoal agar plates (Oxoid) for 72 h at 37°C. All cells were harvested from each plate and resuspended 
in 3 ml PBS. The optical density of each cell suspension was measured at 600 nm, and volumes of 
suspension equating to an OD of 1.0 (~2×109 B. pertussis cells) in 180 µl were pelleted in a 
microcentrifuge for 2 min at 12 000 g. gDNA was extracted from each pellet using a GenElute bacterial 
genomic DNA kit (Sigma Aldrich) according to the manufacturer’s instructions, including the optional 
RNAase A step and a two-step elution into 200 µl elution buffer (10 mM Tris-HCl, 0.5 mM EDTA, pH 
9.0). QuBit fluorometry (dsDNA HS kit; Invitrogen) was used to measure gDNA concentration, and 
Nanodrop spectrometry (ThermoFisher Scientific) was used to assess gDNA purity. 
Nanopore library preparation and MinION sequencing 
In total, 1.5 µg of gDNA per strain was concentrated using a 2.5× SPRI clean-up (AMPure XP beads; 
Beckman Coulter), eluting into 50 µl of nuclease-free (NF) water (Ambion). Then, 48 µl of this was 
sheared to 20 kbp using g-tubes (Covaris), according to the manufacturer’s instructions. 
Sequencing libraries were prepared for all samples using ONT's 1D ligation sequencing kit (SQK-
LSK108) with native barcoding (EXP-NBD103), according to the manufacturer’s instructions. Ten 
barcodes were used, two per strain (see Supplementary table S2.2 for full details). After library 
preparation, different volumes of samples were combined to produce an equi-mass pool for eight 
samples; two samples had much lower concentration after library preparation so were pooled in full. 
A total mass of 712.5 ng was pooled in 208.9 µl NF water, which was concentrated to 50 µl by 2.5× 
SPRI clean-up. Full details of mass pooled per sample are given in Supplementary table S2.2. This pooled 
library (712.5 ng in 50 µl) was used for sequencing adapter ligation. 
The final sequencing library was loaded onto an R9.4 flow cell and sequenced for 48 h using a 
MinION MK1b device with MinKNOW sequencing software (protocol  
NC_48h_Sequencing_Run_FLOMIN106_SQK-LSK108). 
Additional basecalling and demultiplexing 
The fast5 files were basecalled using ONT’s Albacore (v2.1.3) program, with barcode binning. As 
suggested by Wick et al. (2017a), Porechop was then used to demultiplex the Albacore reads, keeping 
only those for which Albacore and Porechop agreed on the bin. The Albacore+Porechop fastq files 
were deposited in the Sequence Read Archive (SRA) with accession codes SAMN09500966 to 
SAMN0900970. Full details of all read sets (including reads output by MinKNOW’s concurrent 
basecalling algorithm) are given in Supplementary table S2.1. 
Assembly of short-read-only drafts 
Assuming the available Illumina data to have typically low error, short-read-only genome sequences 
were assembled for each strain using ABySS (v2.0.3) (Simpson et al., 2009). Prior to assembly, reads 
were prepared using Trimmomatic (v0.34) (Bolger, Lohse and Usadel, 2014), which trimmed the first 
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10 bases of each read, and discarded any reads whose four-base sliding-window q-score fell below 32. 
These assemblies had low contiguity, but theoretically high accuracy. 
Comparison of raw reads 
A shell script, ‘summary_stats’, was used to give the total number of reads, mass sequenced and 
minimum, maximum, mean and median read lengths for each set of raw reads. Summary_stats uses 
seq_length.py (Gummy-Bear, 2014) and all_stats. All are available from 
https://github.com/nataliering/Resolving-the-complex-Bordetella-pertussis-genome-using-
barcoded-nanopore-sequencing. 
Raw percentage identity was estimated by comparing each read set to the B. pertussis reference 
genome (Tohama I, NC_002929.2). As the UK 2012 strains were not expected to be identical to the 
Tohama I sequence, read error was also estimated by comparison with the respective Illumina-only 
assemblies. The comparison was conducted using BWA MEM (Li, 2013) and SAMtools stats (Li et al., 
2009), which produces a long output file including ‘error rate’ [% identity was calculated from this: 
100 − (error rate*100)]. Raw_error (https://github.com/nataliering/Resolving-the-complex-
Bordetella-pertussis-genome-using-barcoded-nanopore-sequencing/blob/master/raw_error) 
produces a stats file using this method, given a read set and reference genome. Using the same BWA 
MEM output, raw read coverage of the Tohama I reference genome was checked using SAMtools 
depth and visualization with a rolling window in R. 
Finally, raw G+C content was calculated using GC_calculator, which outputs the percentage G+C 
content of a given fasta file (https://github.com/nataliering/Resolving-the-complex-Bordetella-
pertussis-genome-using-barcoded-nanopore-sequencing/blob/master/GC_calculator). 
Assembly tool testing – nanopore only 
The Albacore+Porechop reads for one strain, UK36, were used to test a variety of de novo assembly 
strategies. Four community-built assembly tools were trialled: ABruijn (now called Flye, v1.0 and 
v2.3.2 respectively), Canu (v1.5), Miniasm with Minimap/Minimap2 (v0.2-r128, v0.2-r123 and v2.0-
r299-dirty, respectively) and Unicycler (v0.4.4) (Li, 2016; Lin et al., 2016; Koren et al., 2017; Wick et 
al., 2017b; Li, 2018). 
Canu has a standalone option to conduct pre-assembly read correction. This was used to correct the 
359× coverage UK36 read set to 40× coverage of more accurate reads. Each assembly tool was then 
trialled with and without pre-assembly read correction. As Canu’s read correction step is relatively 
time-consuming as regards CPU, an alternative was also trialled. Filtlong 
(https://github.com/rrwick/Filtlong) does not correct reads, but produces read sets comprising the 
longest and most accurate reads, up to a given level of coverage; 40× and 100× coverage were trialled 
here. 
Finally, Racon (v.1.2.0) was tested to determine whether the draft assemblies could be improved by 
post-assembly polishing (Vaser et al., 2017). After each Racon polish, the accuracy of the assembly 
produced was estimated. If an improvement was observed, another round of polishing was 
conducted, up to a total of five rounds. Once two successive rounds of polishing showed no further 
improvement, no further Racon polishes were conducted. For Unicycler, no manual Racon polishes 
were conducted, because Racon polishing is part of the Unicycler assembly process. After Racon 
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polishing, each assembly was further polished with a single round of Nanopolish (v0.9.0) (Loman, 
Quick and Simpson, 2015). 
Testing exhaustive combinations of each of these steps produced 28 draft assemblies for each of the 
four assembly tools tested (ABruijn/Flye, Canu, Miniasm and Unicycler), a total of 112 draft UK36 
assemblies (see Supplementary table S2.3 for all combinations). 
Assembly tool testing – hybrid 
As Illumina reads were already available for the strains sequenced here, a variety of hybrid de novo 
assembly strategies were also tested. Using Pilon (v1.22), the best nanopore-only assembly for each 
of the assembly tools was polished with the Illumina reads, up to a total of five rounds (Walker et al., 
2014). In addition, a hybrid assembly was produced using Unicycler’s hybrid mode, which both 
combines read sets for assembly, and conducts several rounds of Racon and Pilon polishes 
automatically. Finally, the hybrid assembly mode of SPAdes (v3.12.0) was tested. These hybrid tests 
produced another 22 draft assemblies (Supplementary table S2.4) (Bankevich et al., 2012). 
Assessing assembly accuracy 
Summary_stats was used to determine the number of contigs, and contig length for each draft 
assembly. The percentage identity of each draft compared to the Illumina-only draft was estimated 
using a method developed by Wick et al. (2018a). Their chop_up_assembly.py and 
read_length_identity.py scripts were used to generate percentage identity values for 10 kbp sections 
along the entirety of each assembly, and a custom shell script, assembly_identity 
(https://github.com/nataliering/Resolving-the-complex-Bordetella-pertussis-genome-using-
barcoded-nanopore-sequencing/blob/master/assembly_identity), was used to calculate the mean 
percentage identity of the whole. 
Quality metrics for each assembly were produced using Quast (v4.5) and BUSCO (v1.22) (Gurevich et 
al., 2013; Simão et al., 2015). In addition, a method developed by Watson, Ideel 
(https://github.com/mw55309/ideel), was used to assess the effect of any erroneous indels in the 
final UK36 hybrid assembly (Watson, 2018). 
Comparing genome arrangement 
After the best nanopore-only and hybrid assembly pipelines were identified for UK36, the pipelines 
were used to produce draft assemblies for the remaining four strains. The hybrid assembly for each 
strain was annotated with Prokka (v1.12) using the proteins from Tohama I as a reference (Seemann, 
2014b). The genomes were also submitted to GenBank (accession numbers CP031289, CP031112, 
CP031113, QRAX00000000 and CP031114). 
The arrangement of each nanopore-only assembly was compared to that of each hybrid using 
progressiveMauve (v20150226 build 10) (Darling, Mau and Perna, 2010). Finally, the nanopore-only 
assemblies for each strain were compared to each other, also using progressiveMauve. Prior to these 
alignments, each draft was manually rearranged so that the first gene after the B. pertussis origin of 
replication, gidA, was at the beginning of the sequence. gidA_blast 
(https://github.com/nataliering/Resolving-the-complex-Bordetella-pertussis-genome-using-
barcoded-nanopore-sequencing/blob/master/gidA_blast) locates the gidA sequence in the draft to 
enable manual rearrangement. Later, this same process was used to identify IS element copies in the 
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assembled genomes. If a tool assembled the complementary strand instead of the template (as 






During the 48 h MinION sequencing run, 1 803 648 reads were generated, equating to 9.73 Gbp of 
sequence. In total, 28.78 % of these reads (574 053 reads, 2.8  Gbp) were not assigned to the correct 
barcode bin during demultiplexing, leaving 6.93 Gbp (1 229 595 reads) of useable sequencing data 
(Figure 2.1). Normalized yield per barcode (taking into account nanograms of gDNA included in the 
pooled sequencing library) was particularly high for one barcode (NB11, 15.28 Mbp ng−1) but 
otherwise relatively consistent, ranging from 7.38 to 10.28 Mbp ng−1 with a mean yield of 9.06 Mbp 
ng−1 (se=0.37). Mean read length for the full read set was 5689 bp. Read lengths ranged from 4 to 
201 977 bp. 
The Albacore-demultiplexed reads were re-demultiplexed using Porechop, which keeps only the reads 
for which both tools agree on the barcode identified. This additional step resulted in a small but 
Figure 2.1 The Albacore+Porechop reads were used to assess barcode distribution. This showed that a large 
portion of the raw reads was placed into the ‘no barcode’ bin, meaning Albacore and Porechop either did not 




significant improvement in identity compared to Illumina-only assembly: 82.43 to 82.52 % (n=5, paired 
t-test P<0.001). Consequently, the reads used for data pipeline testing were those that had been 
basecalled and demultiplexed by Albacore, followed by Porechop re-demultiplexing. 
For full results, including which barcode was assigned to each sample, see Supplementary table S2.1. 
Assembly tool testing – nanopore-only 
Table 2.1 shows the quality measurements for the best nanopore-only assembly per tool trialled. All 
tools tested were able to resolve the nanopore long reads for UK36 into a complete, closed contig, 
using default assembly options with no manual intervention. In total, 112 different tool combinations 
were trialled. Alignment of drafts from different tools using progressiveMauve revealed that each tool 
also assembled the genome into the same arrangement. However, the length of the draft assemblies 
showed some variation: 3.984 to 4.134 Mbp, with a mean length of 4.108 Mbp. 
Comparing like-for-like assemblies before and after polishing shows that Nanopolish improves identity 
by 0.216 % on average (n=16, paired t-test P<0.001). Polishing with Racon produced inconsistent 
results: identity decreased after Racon polishing of ABruijn and Flye drafts, increased by 2.01 % after 
the optimal number of polishing rounds for pre-corrected non-ABruijn/Flye drafts (n=3), and increased 
by 15.15 % after optimal rounds for non-ABruijn/Flye drafts with no pre-correction (n=4). The mean 
number of Racon polishes required to reach optimal percentage identity (after which it began to 
decrease) was 4.75 (n=7). 
The assembly with greatest percentage identity compared to the Illumina-only draft (99.59 %) 
combined pre-assembly read correction with Canu, assembly with ABruijn and post-assembly 
polishing with Nanopolish. The assemblies were also assessed using BUSCO, which searches draft 
assemblies for copies of benchmarking universal single-copy orthologues (BUSCOs). BUSCOs are sets 
of core genes which are likely to appear universally in related organisms. A set of 40 such core genes 
from the Escherichia coli genome are used as the gram-negative bacterial BUSCOs; if a genome has 
been assembled accurately, the tool BUSCO is more likely to be able to identify these 40 genes within 
its sequence. Of the drafts assessed here, the ABruijn assembly contained the highest number of 
identifiable BUSCOs (37 full and two partial, of the full set of 40; see Table 2.1 for full results). 
Assembly tool testing – hybrid 
A number of hybrid assembly strategies were trialled, including polishing a long-read assembly with 
short reads, scaffolding short-read contigs with long reads, and using both short and long reads 
together during assembly (Table 2.2 shows the best draft produced by each tool). Scaffolding short-
read contigs with long reads using SPAdes produced one of the highest accuracy assemblies (99.68 %), 
but did not fully resolve the genome, as six contigs remained. No further polishing was attempted with 
this SPAdes assembly, as polishing would not close the remaining gaps between the contigs. 
The best hybrid assemblies per tool were significantly more accurate than the best nanopore-only 
assemblies per tool, with a mean identity improvement of 0.11 % (hybrid n=6, nanopore-only n=5, 
paired t-test P<0.001). In addition, all hybrids contained all 40 identifiable BUSCOs, and all except the 
SPAdes hybrid were single closed contigs and showed the same arrangement when aligned using 
progressiveMauve. The best single-contig hybrid assembly, with 99.68 % identity, was produced using 
Unicycler’s hybrid option, which uses SPAdes, Minimap, Miniasm, Racon and Pilon. Supplementary 


































missing (of 40) 
ABruijn Yes No No 0 Yes 3 1 4.109 99.67 40/0/0 
Canu Yes No No 4 Yes 3 1 4.130 99.66 40/0/0 
Flye Yes No No 0 Yes 3 1 4.108 99.67 40/0/0 
Miniasm + Minimap No No No 5 Yes 4 1 4.107 99.66 40/0/0 
SPAdes Yes No Yes n/a n/a n/a 6 4.105 99.68 40/0/0 
Unicycler Yes No Yes 4* No 8* 1 4.107 99.68 40/0/0 
*The rounds of Racon and Pilon listed for Unicycler were carried out as part of the Unicycler protocol; no manual rounds of polishing were conducted for this assembly 
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missing (of 40) 
ABruijn Yes No 0 Yes 1 4.105 99.59 37/2/1 
Canu Yes No 4 Yes 1 4.133 99.54 36/1/3 
Flye Yes No 0 Yes 1 4.108 99.56 35/3/2 
Miniasm + Minimap Yes No 5 Yes 1 4.111 99.55 37/0/3 
Unicycler Yes No 8* Yes 1 4.107 99.55 35/2/3 




Assembly and annotation of all strains 
Using the nanopore-only and hybrid pipelines defined through the tests described here (Figure 2.2), 
draft genomes were assembled for all five UK strains sequenced during our barcoded run. The 
assemblies were assessed for percentage identity compared to each strain’s Illumina-only assembly, 
G+C content, genome length and number of key IS element features; they were also annotated using 
Prokka. The full results of this analysis are shown in Tables 2.3, S2.6 and S2.7. 
The hybrid assembly for one strain, UK76, had slightly lower percentage identity (99.54 %) than the 
other strains, each compared to their respective Illumina-only ABySS assembly. Discounting UK76, the 
assemblies had a mean identity of 99.69 % (n=4). The G+C content of the strains varied little: the 
content for all strains was 67.70 % when rounded to two decimal places. The number of genes 
predicted by Prokka was also relatively consistent, varying from 3757 to 3804. 
The UK36 proteins predicted by Prokka were assessed by Ideel, which searched the Trembl database 
for similar proteins (Bairoch and Apweiler, 2000). The length of the Prokka-predicted proteins was 
divided by those of the identified similar Trembl proteins; a perfect match would equal 1.0. This 
method, therefore, indicates whether indels in a draft sequence cause frameshifts which subsequently 
lead to truncated (or over-long) protein prediction. After manual curation to remove results which 
represented genes known to be fully present in other Bordetella species but truncated in B. pertussis, 
over 98 % of Prokka-predicted genes had a Prokka:Trembl length ratio of greater than 0.9. This 
suggests that the residual error in the hybrid assemblies does not cause substantial annotation 
problems, so the hybrid assemblies for all five strains were submitted to GenBank (accession numbers 
CP031289, CP031112, CP031113, QRAX00000000 and CP031114). 
Comparison of genomic structure of all strains 
All strains were assembled into single contigs using the nanopore-only pipeline. These assemblies 
were aligned using progressiveMauve (Figure 2.3), displaying genomic rearrangement between strains; 
three, UK36, UK38 and UK39, shared exactly the same arrangement, whilst UK48 and UK76 were 
rearranged.  
Of the hybrid assemblies, two strains, UK48 and UK76, had longer genomes than the others (4.112 
and 4.113 Mbp, respectively, compared to 4.108 Mbp), which corresponds with them also having 
more copies of the most abundant IS element, IS 481. All strains but one were assembled into single 
contigs. The remaining strain, UK48, was assembled into five contigs (N50=3.934 Mbp). Of these, three 
were shorter than 500 bp, and were subsequently discarded. The remaining two contigs were 
3 934 355 and 178 023 bp. Mapping the raw UK48 reads to the Tohama I reference sequence revealed 
a section of almost 200 kbp, located between 1.35 and 1.53 Mbp, which had double the read depth of 
the rest of the reference; the doubled read depth suggests that this section of the genome is 
duplicated in UK48. No other strain had a similarly duplicated section, although the coverage of UK76 
was enriched by around 25 % at the same locus (Figure 2.4), potentially indicating a heterogeneous 
UK76 population, of which a subset (i.e. 25 %) of cells carries a duplication. These abnormalities are 
also present in the Illumina reads, which were obtained approximately 5 years before our nanopore 






Are residual unresolved ultra-long repeats present in some strains? 
Our primary aim in this study was to determine whether long reads produced by nanopore sequencing 
using ONT’s MinION can be used to produce closed B. pertussis genome sequences, which will enable 
visualization of large-scale inter-strain genomic differences, and may further reveal previously hidden 
genomic features. Our nanopore-only assembly pipeline produced closed-contig assemblies for all five 
strains sequenced here, allowing visualization and validation of previously predicted IS-mediated 
genomic rearrangements. In addition, the inability of our long reads to produce a closed hybrid 
assembly for UK48 has revealed a separate, unpredicted, genomic feature in our UK strains. 
The region of enriched coverage between 1.35 and 1.53 Mbp in the Tohama I reference genome 
observed in the UK48 reads (Figure 2.4) is likely to indicate a large (almost 200 kbp) duplication of that 
region which is present in UK48 but not in the reference. A less obvious duplication may also be 
present in the genome of UK76: a 300 kbp region from 1.38 to 1.68 Mbp shows 125 % coverage. The 
presence of the same abnormalities in other read sets for both strains suggests that they have not 
been caused by contamination (Figure 2.4). Similar duplicated regions have been observed previously 
in a very small number of French and Finnish strains (fewer than five) through microarray-based 
studies in 2006 and 2007 (Caro et al., 2006; Heikkinen et al., 2007). More recently, Weigand et al. 
(2016; 2018) noted complex duplications in two US strains and two Indian vaccine-reference strains; 
these genomes were long-read sequenced with PacBio, but resolution of the duplications was only 
possible with optical mapping. The locus found to be duplicated in these previous studies was the 
same as that we predict is duplicated in UK48 and UK76; however, at 180 and 300 kbp, our predicted 
duplications are longer than any of those observed previously. The identification of two additional 
strains carrying a duplication of the same region suggests that IS-mediated duplication is occurring  
Table 2.3 Assembly statistics for five UK B. pertussis strains, assembled using our hybrid pipeline 































UK36 1 4.108 67.69 99.47 4698 258 8 17 
UK38 1 4.108 67.69 99.49 4741 258 8 17 
UK39 1 4.109 67.70 99.48 4588 258 8 17 
UK48 1 4.114 67.70 99.47 4610 262 8 17 







UK36 1 4.107 67.70 99.68 3757 258 8 17 
UK38 1 4.108 67.70 99.69 3757 258 8 17 
UK39 1 4.108 67.70 99.69 3804 258 8 17 
UK48 2 4.112 67.70 99.68 3763 262 8 17 




Figure 2.2 Our nanopore-only and hybrid sequencing pipelines, developed through extensive testing of available tools. 
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more frequently in B. pertussis than previously believed. Furthermore, the apparent heterogeneity of 
our UK76 culture suggests that only a portion of UK76 cells may carry the duplication, a phenomenon 
previously unobserved in any duplication-carrying B. pertussis isolate. Finally, the locus of the 
duplication itself, which contains many motility-related genes, may have interesting implications for 
an organism traditionally described as non-motile. 
Neither our nanopore-only pipeline using Flye nor our hybrid pipeline using Unicycler was able to 
resolve the duplication correctly, however. The nanopore-only pipeline produced closed contigs for 
all five strains, seemingly missing the duplication completely, whilst the hybrid pipeline produced a 
multi-contig assembly for UK48 and the same closed contig as the nanopore-only pipeline for UK76. 
Our UK48 reads ranged from 73 to 108 575 bp with a mean length of 6243 bp, whilst the UK76 reads 
ranged from 4 to 70 486 bp with a mean length of 5480 bp; if the key to resolving long repeats is to 
use reads longer than the longest repeat, we will need high coverage of ultra-long reads in the order 
of hundreds of thousands of bases to resolve these putative duplications via sequencing (Jain, Koren, 
et al., 2018; Schmid et al., 2018). Nanopore sequencing is currently the only sequencing method 
theoretically capable of producing such long reads; methods to obtain ultra-long reads are under 
development by the nanopore community, with reports of reads in the order of millions of bases 
(Payne et al., 2018a). 
Accuracy of long-read sequencing is improving but error estimation is challenging 
In addition to our primary aim, we also compared a variety of de novo assembly strategies to 
determine the current optimal pipeline for producing the most accurate genome sequences for B. 
pertussis. 
Without a recent, closely related reference sequence, error estimation in B. pertussis assemblies is 
inexact. Comparison with the Tohama I reference sequence will identify basecalling errors which are 
false positives, having arisen due to natural variation between different strains (that is, true SNPs will 
be identified as errors). Moreover, the validity of Tohama I as a representative of all B. pertussis strains 
is questionable (Caro, Bouchez and Guiso, 2008). The Illumina reads available for four of our 
sequenced strains (UK36, 38, 39 and 48) showed 98.44 % identity with the Tohama I sequence, 
suggesting natural genetic variation between Tohama I and these UK strains of around 1.5 %. The false 
positive rate is thus around 1.5 % when using Tohama I to assess assembly accuracy. On the other 
hand, comparison with Illumina-only assemblies requires short read data to be available, and assumes 
the Illumina reads to be close to 100 % accurate, which could be a flawed assumption. The Illumina 
reads for UK76, for example, had raw identity of only 87.32 % compared to Tohama I. With no 
distinctive features noted for UK76 in our assembly or in the original comparison of UK epidemic 
strains, it is unlikely that the UK76 genome is truly 11 % less like Tohama I than the other strains 
sequenced here (Sealey et al., 2015). It seems more likely that the Illumina reads are inaccurate; if this 
is the case, our assessments of the accuracy of our UK76 assemblies were skewed. This could explain 
why our UK76 hybrid assembly had a slightly lower estimated accuracy than the other strains. 
Compared to Tohama I, our hybrid UK76 assembly showed 98.49 % identity, similar to the identity of 
our other hybrid assemblies (n=5, mean=98.57 %), suggesting that the inaccuracies of the raw Illumina 
reads do not translate into inaccuracies in the final assembly; only our estimation of accuracy by 
comparison to the Illumina-only draft is affected. Overall, neither comparison to the Tohama I 




Figure 2.3 Alignment of our five sequenced strains, showing genomic rearrangement. Our five UK B. pertussis strains (UK36, UK38, UK39, UK48 and UK76) were assembled using our nanopore-only pipeline, 






Figure 2.4 Alignment of nanopore reads to the Tohama I reference sequence compared to alignment of Illumina reads to the Tohama I 
reference sequence. Raw reads from each sequencer were aligned to the reference using BWA MEM, followed by coverage calculation 
with SAMtools depth. Plots were constructed by calculating a rolling average of coverage, with a window size of 5000 bp. The coverage of 
three strains (UK36, UK38 and UK39) was consistent across the whole reference genome, whereas UK48 and UK76 coverage was enriched 
in certain locations. In UK48, a large section from 1.35 to 1.53 Mbp into the reference appears to have exactly twice as much coverage as 
the rest of the genome. In UK76, a section from 1.38 to 1.68 Mbp is enriched by 25%. The coverage abnormalities seen in UK48 and UK76 
are present in both sets of reads, suggesting they are not the result of a quirk in sequencing method, or contamination. 
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novel strains, and neither strategy gives us a completely accurate estimate, but using a combination 
of both comparisons allows a good estimate of assembly error. 
Having estimated our hybrid assemblies to be, on average, 99.69% accurate, we can conclude that 
roughly 13 000 bases in each 4.1 Mbp draft genome are incorrect. Whilst these incorrectly called bases 
will not influence comparisons of genome arrangement, residual base errors in draft genome 
sequences assembled using long reads remain a concern, with the potential to falsely identify SNPs or 
prevent accurate protein prediction (Watson and Warr, 2019). Incorrect sequencing of homopolymers 
is a known weakness of many sequencing methods, including nanopore sequencing, and our 
assemblies are no exception (Jain, Koren, et al., 2018). Indeed, a base-level manual comparison of one 
of our hybrid assemblies with a more accurate Illumina-only draft using progressiveMauve revealed 
that every difference occurred in a homopolymeric tract, with the hybrid sequence having inserted or 
deleted bases. Two options for correct SNP identification, therefore, are manual correction of known 
homopolymeric indels, and simply ignoring SNPs which appear to occur in homopolymeric regions. 
The manual correction option would be time-consuming, whilst the second option could result in false 
negatives. Nevertheless, until improved pore chemistry or basecalling tools are available which do not 
produce homopolymeric indels, the use of either option means that SNP identification is still possible, 
even in assemblies which are less than 100% accurate. 
Correct prediction of proteins appears to be of less concern than SNP identification in our hybrid 
assemblies: all 40 potential bacterial BUSCOs were present in full for all of our strains, and both Quast 
and Prokka were able to identify the majority of the Tohama I reference proteins in the same 
assemblies. In addition, assessment of our UK36 hybrid using Watson’s Ideel pipeline suggested that, 
although we know some errors remain, they do not substantially inhibit the correct prediction of full-
length proteins during annotation (Watson, 2018). It is here, however, that we can see clearly the 
benefit of the hybrid assemblies over the nanopore-only assemblies: although the mean accuracy of 
the nanopore-only assemblies (99.48%) was only 0.2% lower than that of the hybrids, none of the 
nanopore-only assemblies contained full copies of all 40 BUSCOs. 
Does the de Bruijn graph method assemble highly repetitive prokaryotic genomes more 
accurately than other commonly used methods? 
The opinion of the sequencing community has long been that de Bruijn graph assembly is not as 
effective for error-prone long reads as other de novo assembly methods (Pop, 2009; Lu, Giordano and 
Ning, 2016). This is likely because the de Bruijn graph method requires the reads to be cut into much 
shorter kmer-length fragments, meaning the benefit of longer reads could be lost. The tool which 
consistently produced the most accurate nanopore-only B. pertussis assemblies was therefore 
unexpected: the percentage identity and indel rates of our assemblies produced by ABruijn, which is 
a de Bruijn graph assembler, were better by far than those of the Canu, Miniasm or Unicycler 
assemblies. The recent version change of ABruijn to Flye seems to have negatively affected these 
metrics in some of our strains; however, whilst the ABruijn assemblies were better than the Flye 
assemblies, the Flye assemblies were still better than those produced by other tools. Another recent 
study, which assembled highly complex and repetitive Pseudomonas koreensis genomes using ultra-
long nanopore reads, also found Flye to produce the most accurate assemblies (Schmid et al., 2018). 
This suggests that the de Bruijn method, and particularly ABruijn/Flye, might be optimal for 
prokaryotic genomes which contain a high number of repeats. 
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Two possible pipelines for B. pertussis genome sequence resolution 
We have shown here that resolution of five B. pertussis genomes per MinION flow cell is possible, 
whether using long reads alone or in combination with short reads. Sequencing five strains using one 
flow cell produced a mean yield of over 300× B. pertussis genome coverage per strain, which probably 
exceeds that required to achieve comparable results. A draft produced from using roughly half of our 
reads (175× coverage) for UK36, pre-corrected and assembled with Flye, had an identity of 99.467%, 
whilst the same assembly produced by the full (360× coverage) read set had an identity of 99.474%. 
This suggests that twice as many strains could be de novo assembled per flow cell without a notable 
drop in accuracy. Thus, resolution of ten B. pertussis genomes per MinION flow cell should be possible. 
If short reads are also available, we have shown that hybrid assembly, using pre-correction with Canu 
followed by Unicycler, remains the most accurate method. Indeed, for now, for full strain 
characterization (including comparison of genome arrangement, SNP identification and allele-typing), 
hybrid assemblies are required. For comparison of genome structure and arrangement only (e.g. Figure 
2.3), however, our nanopore-only pipeline, which uses Canu pre-correction, Flye assembly and post-
assembly polishing with Nanopolish, can produce single contig assemblies of adequate accuracy for 
all but the most unusual B. pertussis genomes. 
Continued improvement of long-read data processing tools 
Although the pipelines we have defined here produce the most accurate B. pertussis genome 
sequences currently possible, the tools available for the analysis of nanopore sequencing data are 
continually improving. A recent update to Racon added the ability to polish assemblies with Illumina 
reads; a brief comparison of this with Pilon, however, showed little improvement to our data, so we 
did not add short-read Racon polishing to our suite of tests. Alternative basecallers such as Chiron or 
the currently in-development Guppy, which use entirely new basecalling algorithms, may also offer 
further accuracy improvements and could be trialled with existing and future B. pertussis data sets, 
particularly if Illumina short reads are not available for hybrid assembly (Teng et al., 2018). 
We tested the most commonly used de novo assembly tools suitable for long reads and, at the time 
of writing, are not aware of any newly released tools. However, minor (or sometimes major, in the 
case of ABruijn to Flye) updates are common. New polishing tools are also being developed: ONT’s 
own Medaka, for example, is claimed to rival Nanopolish in terms of speed and assembly improvement 
capabilities (Oxford Nanopore Technologies, 2018a). In addition, MaSuRCA was not trialled here due 
to the low Illumina coverage (the manual suggests 50×+ for hybrid assemblies, whereas we had only 
37.5× coverage for UK36) (Zimin et al., 2017). Ultimately, for the foreseeable future, no data pipeline 
including nanopore reads should be set in stone; we will continue to trial new tools and to update our 
pipeline where appropriate, and would suggest that similar pipeline optimization may be required for 
each organism to be sequenced.  
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2.9 Commentary text – conclusions 
The work presented in this paper established a workflow which can be used to rapidly sequence and 
de novo assemble closed genomes for larger numbers of B. pertussis isolates. The key findings (below) 
from this body of work lead directly to the research questions addressed in Chapter 4, which 
investigates the duplications discovered here, and to the development of sequencing methodology 
for Chapter 3, which screens a larger number of isolates from New Zealand. 
Key findings: 
 The most recent long-read basecalling, assembly, and other data processing tools tended to 
produce the most accurate data, likely because they are developing as ONT’s sequencing 
technology does. As the technology develops, the Nanopore Community will be a valuable 
resource to keep track of which library preparation, flow cells and tools are currently 
favoured. Periodic re-optimisation (to a lesser extent) of the workflow may also be prudent 
 For analyses which include variant calling, hybrid assembly will produce more accurate results 
than assembly of long reads alone 
 A significant portion of sequencing data is lost during the demultiplexing process. This limits 
the number of strains which could be sequenced on the same flow cell; a yield of, for example, 
10 Gb should not be assumed to contain 10 Gb of usable data. The loss of data can be 
explained in two ways. Firstly, some DNA strands may survive through the library preparation 
process without having had a barcode ligated, thus will produce reads with no known barcode 
during demultiplexing. Secondly, the high raw error raw of MinION sequencing may mean that 
even some reads which do have barcodes may be added to the “unknown barcode” bin during 
demultiplexing, because the barcode has been misread 
 Large duplications, of unknown phenotypic consequence, may be present in the genomes of 
some B. pertussis strains, which would not be noticed during de novo assembly with short 
reads, and would only be apparent during de novo assembly with long reads because they 
mean that the genome cannot be resolved into a single contig. All sequenced strains should 
therefore be investigated using the coverage analysis method demonstrated here, as this 
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“It's a dangerous business, Frodo, going out of your door. You step into the road, and if you don't keep 
your feet, there's no knowing where you might be swept off to.” 




Whooping cough, the respiratory disease caused by Bordetella pertussis, has seen a wide-spread 
resurgence over the last several decades. Predicted causes for this resurgence include changes to the 
bacterium at the genomic level, potentially in response to the introduction of an acellular whooping 
cough vaccine in the late 1990s. Previously, we developed a pipeline to assemble the repetitive B. 
pertussis genome into closed sequences using hybrid nanopore and Illumina sequencing. Here, this 
sequencing pipeline was used to conduct a more high-throughput, longitudinal screen of 66 strains 
isolated between 1982 and 2018 in New Zealand. New Zealand suffers from a higher incidence of 
whooping cough than almost any other vaccine-using country, usually at least twice as many cases per 
100,000 people than the USA and UK and often even higher, despite similar rates of vaccine uptake. 
We believe these strains represent the first New Zealand B. pertussis isolates ever sequenced, and the 
screen is the first to use nanopore sequencing. The analyses here show that, on the whole, genomic 
trends in New Zealand B. pertussis isolates, such as changing allelic profile in vaccine-related genes 
and increasing pertactin deficiency, have paralleled those seen elsewhere in the world. At the same 
time, phylogenetic comparisons of the New Zealand isolates with global isolates suggest that a number 
of strains are circulating in New Zealand which are closely related to each other, and which cluster 
separately from other global strains. Whilst in apparent continuous circulation, these strains appear 
to be more highly represented during outbreak periods. The results of this study add to a growing 
body of knowledge regarding recent changes to the B. pertussis genome, and are the first genetic 
investigation into New Zealand’s high incidence of whooping cough. 
 
3.2 Data Summary 
1. Nanopore and Illumina fastq sequence files for all strains have been deposited in the NCBI’s 
Sequence Read Archive, BioProject PRJNA556977. A full list of accession numbers for all 
sequence read files is provided in Supplementary table S3.1. 
2. Genome sequences for all strains have been deposited in the NCBI’s GenBank, accession 
numbers shown in Supplementary table S3.1. 
 
3.3 Introduction 
A (brief) history of whooping cough vaccination in New Zealand 
The whooping cough vaccine has been available in New Zealand since 1945, and part of the 
immunisation schedule since 1960. The original schedule included three doses of the whole cell 
pertussis vaccine with diphtheria and tetanus (DTwP), at 3, 4 and 5 months old. In 1980, the schedule 
for DTwP vaccination included two doses, at 3 and 5 months of age. A third, earlier, dose was added 
at 6 weeks in 1984. The fourth dose was added in 1996, at 2 years, and the fifth was added in 2002, at 
4 years (Reid, 2006, 2012).  
New Zealand switched from the whole cell vaccine to a three-antigen (PT-FHA-PRN) acellular pertussis 
vaccine (DTaP) in 2000. After the switch to the acellular vaccine, the timings of some of the doses were 
changed; the current New Zealand pertussis vaccination schedule consists of doses at 6 weeks, 3 
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months, 5 months, 4 years and 11-12 years (Reid, 2006, 2012). Table 3.1 shows the major changes to 
the vaccine schedule from 1960 onwards. 
Historically immunisation coverage in New Zealand has been low 
Prior to 2008, vaccination coverage in New Zealand was only surveyed sporadically. The last surveys 
before regular records were kept were in 1991/2 and 2005. In 1991/2, fewer than 60% of two-year-
olds were fully immunised; by 2005, this had increased to 77.4% (NZ Ministry of Health, 2005). In 
1993/4, national immunisation coverage targets were created to initiate an effort to increase coverage 
closer to the levels required for effective herd immunity (often cited at 90-95%) (NZ Ministry of Health, 
2005). 
Since 2008, comparatively robust immunisation data has been kept by each of New Zealand’s District 
Health Boards, on behalf of the Ministry of Health, and published on a three-monthly cycle (New 
Zealand Ministry of Health, 2019). These figures show a marked improvement in immunisation 
coverage over the last decade, and certainly since the 1991/92 coverage survey (Figure 3.1). 
Immunisation coverage in New Zealand at all age points up to 5 years is now comparable to mean 
coverage in the United Kingdom, although coverage in the UK also varies significantly according to 
area (approaching 100% in some areas) (NHS, 2017).  
Rates of whooping cough in New Zealand are high 
Since the whooping cough vaccination was introduced globally, New Zealand has noted a high rate of 
infections and hospitalisations compared with other developed countries; some sources indicate 
disease rates 5 to 10 times higher in New Zealand than the UK or USA. For instance, during the 1980s, 
hospitalisation for whooping cough was required for 0.37 per 100,000 people in the USA, compared 
with 3.75 per 100,000 in New Zealand (Reid et al., 1994). In addition, epidemic periods have often 
been more severe in New Zealand than other countries. In a 1993 epidemic, disease notifications in 
the USA were seven times lower than in a New Zealand 1996 epidemic (Somerville et al., 2007). During 
concurrent epidemics in the UK and New Zealand in 2012, 122.3 cases were seen per 100,000 people 
in New Zealand, compared to 20 per 100,000 in the UK (ESR, 2012; Sealey et al., 2015). 
Table 3.1 Changes to the pertussis vaccination schedule in New Zealand 
 Year  
1960 1980 1984 1996 2000 2002 2008 
6 weeks 
  
DTwP DTwPH DTaP DTaP-IPV DTaP-IPV-Hep/Hib 
3 months DTwP DTwP DTwP DTwPH DTaP DTaP-IPV DTaP-IPV-Hep/Hib 
4 months DTwP 
      
5 months DTwP DTwP DTwP DTwPH DTaP DTaP-IPV DTaP-IPV-Hep/Hib 
15 months 
   
DTwPH DTaP-Hib DTaP-Hib 
 
4 years 
     
DTaP-IPV DTaP-IPV 
11 years 
      
Tdap 
DTwP: Diptheria, Tetanus, whole cell Pertussis 
DTwPH: Diptheria, Tetanus and whole cell Pertussis and Haemophilus influenzae type b 
DTaP: Diptheria, Tetanus and acellular Pertussis (under 7s) 
DTaP: Diptheria, Tetanus, acellular Pertussis and Polio 
DTaP-IPV: Diptheria, Tetanus and acellular Pertussis and Haemophilus influenzae type b 
DTaP-IPV-Hep/Hib: Diptheria, Tetanus, acellular Pertussis, Polio, Hepatitis B and Haemophilus influenzae B 
Tdap: Diptheria, Tetanus and acellular Pertussis (booster for over 10s, including adults) 
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The latest outbreak of whooping cough in New Zealand was announced in December 2017 (New 
Zealand Ministry of Health, 2017) and, between the identified beginning of the outbreak (16 October 
2017) and 4 May 2018, 2,411 cases were reported, representing an infection rate of 50.8 per 100,000 
(ESR, 2018). By May 2019, notifications of whooping cough cases had returned to the “expected” level, 
after a total of 4,697 cases in the 19-month outbreak period (ESR, 2019). The most recent previous 
outbreak lasted for 16 months, between August 2011 to December 2013, totalling 11,000 cases (247.6 
cases per 100,000 across the whole epidemic period) (New Zealand Ministry of Health, 2017).  
The higher rates of whooping cough in New Zealand have often been explained by the lower rates of 
vaccine uptake in the country, particularly in the youngest age categories (Somerville et al., 2007). 
However, despite an increase in immunisation coverage across all age groups over the last decade, 
non-epidemic cases of whooping cough in New Zealand have remained at least two times, and often 
between three and four times higher than in England and Wales or the USA (Figure 3.2). Theoretically, 
this residual higher incidence could be explained by differences in population density, with spread of 
disease being more likely in more densely populated areas. The portions of the population living in 
urban settings in New Zealand, the USA and UK are comparable, however, at 87%, 83% and 83% 
respectively (Worldometer, 2020). Furthermore, during the latest outbreak, the highest rates of 
incidence were seen outside of the most populated areas, with the West Coast, Nelson Marlborough 
and Wairarapa district health boards reporting the highest rates, as opposed to those which contain 
the three largest cities (Auckland, Christchurch and Wellington) (ESR, 2019).  
Whooping cough only became a notifiable disease in New Zealand in 1996, hence age incidence data 
from prior to this is patchy or unavailable. Figure 3.3a shows the incidence in each age group in the late 
1999s, just before the acellular vaccine was introduced. This incidence agrees with that seen 
elsewhere in the world during the whole cell vaccine era, with infants representing a majority of cases, 
and incidence steadily decreasing with age (Mattoo and Cherry, 2005). In 1999-2000, a slight increase 
in incidence is seen in the 5-9 years age group compared to the 1-4 years age group. In 2002 a vaccine 
booster dose was added to the schedule at age 4 years old. This booster dose appears to have been 
successful, as no similar increase is seen in the 5-9 years age group in the 2008-2009 or 2018-2019 
data. It is also notable that, in almost every age group, incidence was higher in 1999-2000 than in 
Figure 3.1 Rates of vaccination uptake in New Zealand between 2009 and 2017, across the five main immunisation time 
points. Supplementary Table S3.2 shows the raw data from which this figure was constructed. The data shown here 
represents the whole country; some areas have much lower or higher rates of immunisation coverage. Data was not available 
for the 2009 5 years time point. 
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either 2008-2009 or 2018-2019, both of which include outbreak periods. This lower incidence in the 
more recent years is likely a result of the increasing vaccine coverage in New Zealand since the 1990s. 
Incidence remained the highest in infants in 2008-2009 and 2018-2019, although a shift towards a 
slightly higher incidence in adolescents compared with 1999-2000 can be seen; this pattern also 
matches that seen elsewhere in the world since the introduction of the acellular vaccine (Mattoo and 
Cherry, 2005).   Figure 3.3b shows the age distribution and vaccination status for cases notified 
between 1st January 2017 and 31st May 2018, where vaccination status was known. This period 
includes six months of the latest outbreak period. At every age group, the number of cases in 
vaccinated patients was higher than those in unvaccinated patients, suggesting that waning immunity 
or vaccine inefficacy may have played a part in this outbreak.  
Why screen strains from New Zealand using hybrid sequencing? 
No B. pertussis sequencing reads or submitted genomes on the NCBI database are currently tagged as 
being from New Zealand (although this does not preclude the possibility of New Zealand genomes 
being available but lacking location metadata). B. pertussis isolates are, however, stored “pending new 
method development” at the Institute of Environmental Science and Research Ltd (ESR)’s Invasive 
Pathogen Laboratory (ESR Invasive Pathogen Laboratory, 2019). This unusual lack of genome 
screening in a developed country therefore makes New Zealand’s bank of B. pertussis isolates 
potentially very informative. 
Extensive screens of circulating strains during epidemics in the UK, Australia and USA (multiple), have 
been conducted in recent years (Octavia et al., 2012; Bowden et al., 2014; Lam et al., 2014; Sealey et 
al., 2015; Bowden et al., 2016) , each contributing to our understanding of how B. pertussis is evolving 
under selection pressure from the whooping cough vaccine, and supporting Mooi, Zeddeman and van 
Gent’s 2015 contention that strain characterization is vital, alongside classical epidemiology, to 
address the problem of resurging Pertussis (Mooi, Zeddeman and van Gent, 2015). Interestingly, 
although the strains involved in the USA and UK epidemics were polyclonal and relatively disparate, 
the strains identified in the prolonged Australian epidemic from 2008 to 2011 (156 cases per 100,000) 
Figure 3.2 Whooping cough cases per 100,000 between 2000 and 2017 in New Zealand, the USA and England & Wales. 
Supplementary Table S3.3 shows the raw data used to construct this figure.  
*denotes years within a New Zealand epidemic period. 
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showed higher levels of similarity, with 86% represented by just three “closely-related SNP profiles” 
(Octavia et al., 2012). This suggests that, especially during epidemics, certain strains may circulate 
more commonly than others, although this has not been observed in every country. 
A landmark screen of global strains by Bart et al. in 2014 showed that the genome of B. pertussis has 
been evolving since the introduction of first the whole cell vaccine, and more rapidly since the switch 
to acellular vaccination (Bart, Harris, et al., 2014). Changes which have occurred include a swift, near 
global, adoption of a new, more virulent, allele of the pertussis toxin promoter (ptxP3) since its first 
appearance in the 1980s, and the appearance of strains which do not express pertactin; PT and PRN 
Figure 3.3 Age stratification of whooping cough cases in New Zealand, 1996-2019. 
a) Incidence per 100,000 in different age categories in 1999-2000, 2008-2009 and 2018-2019. 1999-2000 incidence from 
Grant (2004), 2008-2009 incidence from ESR (2009), 2018-2019 incidence from (ESR, 2019).  
b) Age distribution and vaccination status of whooping cough cases in New Zealand, 1st January 2017 to 31st May 2018. Not 
all cases are shown, as for many the vaccination status was unknown. Supplementary Table S3.4 shows the raw data from 
which this figure was constructed. 
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are both antigenic proteins included in the acellular vaccine, therefore it is likely that these changes 
are related to the introduction of vaccination, and to the switch from WCV to ACV. However, a 2015 
comparison of strains from Finland, Sweden and China by Xu et al. suggested that in countries where 
vaccine uptake has traditionally been lower or delayed (such as China or, indeed, New Zealand), the 
rate of allelic change has also been delayed (Xu, Y. et al., 2015).  
Bowden et al.’s 2016 comparison of epidemic strains from Vermont and California was the first of its 
kind to use long-read sequencing for genome surveillance, and resulted in the identification of a 
variety of structural differences between the strains which would have otherwise gone unvalidated 
using only short reads, Pulsed Field Gel Electrophoresis or genome mapping (Bowden et al., 2016). 
However, access to Pacific Biosciences sequencing is restricted by the cost of the sequencers 
themselves. The availability of previously unsequenced isolates in New Zealand therefore presents an 
opportunity to demonstrate the utility of an alternative long read sequencer, Oxford Nanopore 
Technology’s MinION, to conduct an outbreak strain screen, based on the hybrid workflow developed 
in Chapter 2 (Ring et al., 2018).  
 
3.4 Research questions 
Research question 1: Were the strains circulating during the recent New Zealand outbreak closely 
related, as in the Australian 2008-2011 outbreak, or polyclonal, as in the UK and USA 2012 outbreaks? 
Research question 2: Has New Zealand’s historic lower immunisation coverage caused allele 
frequencies in New Zealand to change more slowly than observed in Bart et al.’s 2014 global survey 
(and other recent relevant surveys)? 
Research question 3: Are rates of whooping cough infection unusually high in New Zealand due to the 




66 strains, collected between 1982 and late 2018, were provided from the New Zealand Institute of 
Environmental Science and Research (ESR)’s Invasive Pathogens, Special Bacteriology and Culture 
Collection by Audrey Tiong and Angela Brounts. Figure 3.4 shows the locations and years in which, and 
the age of the patient from whom, strains were isolated. Strains were grown and heat-killed at the 
ESR Kenepuru Science Centre, Porirua, New Zealand, and shipped on ice to the University of Bath, 
United Kingdom. On arrival, the heat-killed cells were stored at -20°C. Where serotyping data was 
available (46/66 strains), these results were provided with the strains by the ESR. Full details, including 
accession numbers, are included in Supplementary Table S3.9. 
DNA extraction and Illumina sequencing 
Heat-killed cells were resuspended in 1 ml PBS and OD600 was measured. Volumes of suspension 
equating to an OD of 2.0 (~4x109 B. pertussis cells) were pelleted in a microcentrifuge for 2 min at 





Figure 3.4 (a) Location, (b) patient age and (c) isolation year of the 66 B. pertussis samples received from the New Zealand Institute of Environmental Science and Research (ESR)’s Invasive 
Pathogens, Special Bacteriology and Culture Collection. The sizes of the location markers in a) are proportional to the number of isolates received from that location. Map and timeline were 





the manufacturer’s instructions, including a single-step elution into 200 µl of elution buffer (buffer 
AE). 
At least 2.5 µg gDNA from each strain, suspended in 50 µl elution buffer, were sent for Illumina MiSeq 
sequencing at the Milner Centre, University of Bath in May 2019. In March 2020, 29 strains were sent 
to Novogene for resequencing with NovaSeq (see Supplementary table S3.9 for full details).  
Nanopore library preparation and sequencing 
Sequencing libraries were prepared for all samples using ONT’s Rapid Barcoding Kit (SQK-RBK004), 
according to manufacturer’s instructions, including the optional 1x SPRI concentration and clean-up 
step (using Promega ProNex size selection beads) after library pooling and before addition of RAP 
adaptors. Between 10 and 12 barcodes were used per MinION flow cell (see Supplementary Table S3.10 
for full details).  
Each pooled sequencing library was loaded onto an R9.4 MinION flow cell and sequenced for 48 h 
using a MinION Mk1b device with MinKNOW sequencing software, including concurrent Guppy fast 
Flip-flop basecalling to allow monitoring of translocation speed and q-score. If translocation speed 
dropped below 300 bases per second during the 48-h sequencing run, the flow cell was refuelled, as 
per manufacturer’s instructions for SQK-RBK004. If the translocation speed falls below 300 bases per 
second, the overall yield of the run can be negatively affected. In addition, the MinKNOW algorithms 
which monitor the current across the flow cell membrane and produce the raw fast5 “squiggle” plots 
have been optimised for speeds between 300 and 425 bases per second. Consequently, if the 
translocation speed slows, the quality scores of the subsequent reads can also begin to decrease. 
Translocation speeds fall when ATP levels in the running buffer fall beneath optimal levels, which can 
occur when high masses of DNA are loaded. ATP is used by the adaptor proteins which feed DNA 
strands through the pore proteins. Hence, lowered ATP can result in reduced protein function and 
slower DNA translocation. Adding more flow cell running/flush buffer (FLB, ONT), which contains ATP, 
during the run can recover decreased translocation speeds, as shown in Figure 3.5. Using the mid-run 
refuelling method, high masses of DNA can be loaded to maximise pore throughput without negatively 
affecting translocation speed and quality scores, thus increasing the overall yield and mean quality 
score of the run. 
Basecalling, demultiplexing and adaptor-trimming 
Deepbinner (v0.2.0) (Wick, Judd and Holt, 2018b) was used to demultiplex the raw fast5 files, using 
the “realtime” setting with “rapid” option. This placed all fast5 files into separate bins, one for each 
barcode. ONT’s Guppy fast Flip-flop basecaller (v3.1.5+781ed57) was then run on each of these 
barcode bins, with its own rapid barcode demultiplexing option enabled. This placed each of the fastq 
files basecalled from the fast5s in the Deepbinner barcode bins into further barcode bins, resulting in 
twelve Deepbinner barcode bin fast5 directories (plus one “unclassified” bin, containing reads with 
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unclassifiable barcodes), each containing up to twelve further barcode bin fastq directories (plus 
“unclassified”). Theoretically, most of the reads from any specific Deepbinner bin should have been 
placed in a bin corresponding to the same barcode by Guppy, but in some cases the two tools may 
disagree over the barcode identity; for example, most of the reads in the “barcode01” Deepbinner bin 
should have also been placed in the “barcode01” bin by Guppy after basecalling, but some may have 
been placed in other bins. Only reads which were identified as having the same barcode by both tools 
were retained for further processing - see Figure 3.6 for schematic. Finally, Porechop (v0.2.4) (Wick, 
2017) was used to trim the barcodes and other adaptor sequences from the demultiplexed reads. 
Occasionally (usually 0-2% of reads), two individual reads can be read as a single read by the 
sequencing software; Porechop corrects chimeric reads by detecting sequencing adaptors in the 
middle of single reads and splitting them into multiple reads instead. 
Hybrid genome assembly 
Illumina MiSeq data was provided pre-trimmed by the Milner Genomics Centre. Illumina NovaSeq data 
provided by Novogene was trimmed using Trimmomatic (v0.36, Bolger, Lohse and Usadel, 2014) with 
the options PE, HEADCROP:10, SLIDINGWINDOW:4:25 and MINLEN:100. Genome assembly was 
attempted for all strains using the hybrid pipeline presented in Chapter 2 (Figure 2.2). Nanopore reads 
were pre-corrected using Canu (v1.8, Koren et al., 2017), followed by hybrid assembly with nanopore 
and Illumina reads using Unicycler (v0.4.7, Wick et al., 2017b). However, some of the available Illumina 
data was of poor quality (reads <70 bp, non-uniform length) or low coverage (<40x). Unicycler uses an 
Illumina-centric hybrid assembly method, using SPAdes to first assemble the Illumina data into contigs, 
then the nanopore reads to attempt to bridge the contigs. The low quality of some of the Illumina data 
therefore prevented Unicycler from assembling closed genomes for these strains. After confirming 
that the nanopore long reads alone were sufficient for the assembly of closed genomes for these 
strains, the best long-read-centric hybrid assembly strategy identified in Chapter 2 was used to 
assemble genomes for the strains with low quality Illumina data (full details of which strategy was 
used for each strain are shown in Supplementary Table S3.9).  
Figure 3.5 Refuelling with FLB during a sequencing run can recover falling translocation speeds and thus increase overall 
flow cell yield and mean read quality score. Here, the translocation speed of DNA strands through the pore proteins fell 
below 300 bases per second around 11 hours into the sequencing run. The flow cell was refuelled with 250 µl extra FLB at 
around 16 hours (see grey arrow), recovering the translocation speed to around 350 bases per second. 
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The best long-read-centric hybrid assembly strategy in Chapter 2 used Flye to assemble Canu-
corrected nanopore reads, followed by polishing with Nanopolish once, and polishing with Pilon three 
times using the Illumina short reads. As shown in Table 2.2, the estimated accuracy of this strategy was 
only 0.01% lower than that of Unicycler. Since the work in Chapter 2 was conducted, however, 
Nanopolish has been succeeded by Medaka as the favoured tool for nanopore-based polishing. 
Medaka is optimised to polish assemblies which have already been polished four times with Racon. 
The following assembly strategy was therefore used to assemble the strains which Unicycler was 
unable to assemble: Canu-corrected nanopore reads were assembled with Flye (v2.7b-b1526) and 
polished four times with Racon (v1.4.11), then polished with Medaka (v0.11.3, 
https://github.com/nanoporetech/medaka), both using the nanopore reads alone. Finally, the 
assembly was polished three times using Pilon (v1.22) with the short Illumina reads.   
Illumina reads were not available for three strains (NZ1, NZ5 and NZ29). Genome assemblies were 
produced for these strains using nanopore reads alone, using the Flye-Racon-Medaka strategy above, 
without the Pilon polishing steps. These strains were not included in SNP analysis, phylogenies or allele 
typing, but they were included in analysis of genome arrangement and numbers of IS elements.  
Assessing assembly completeness and quality 
Closed sequences were checked for misassemblies using BUSCO (v4.0.2, Seppey, Manni and Zdobnov, 
2019). Version 4.0.2 of BUSCO is very different to v1.22, used in Chapter 2. Instead of 40 gram-negative 
representative genes, 124 generic bacterial BUSCO genes were used here (using the command line 
option “-l bacteria_odb10”).  
Figure 3.6 Demultiplexing and basecalling by Deepbinner and Guppy. Deepbinner demultiplexes the raw fast5 files, placing 
them in barcode bins (one for each barcode, plus one for “unclassified” reads). Guppy then basecalls and demultiplexes the 
fast5s within each of the Deepbinner bins, placing the resulting fastqs in barcode bins (one for each barcode, plus one for 
“unclassified”). Theoretically, most reads should be placed in corresponding barcode bins by both tools (i.e. a read from the 
Deepbinner barcode01 bin should be placed in the Guppy barcode01 bin after basecalling). Only reads for which both tools 
agreed a barcode were retained. 
70 
 
In addition, Illumina reads were assembled with ABySS (v2.0.2, Simpson et al., 2009; Jackman et al., 
2017), and the resulting contigs were used to estimate the accuracy of the hybrid assemblies, as 
described in Chapter 2. 
Quantifying IS elements 
After assembly, the numbers of four IS elements (IS 481, IS 1001, IS 1002, IS 1663) in each closed 
genome were counted by searching for their sequences using blastn (IS element accession numbers 
shown in Table 3.2). IS 1001 was included to screen for any B. parapertussis isolates mislabelled as B. 
pertussis. The blastn option “qcov_hsp_perc” was set to 50, to ensure all counted hits represented at 
least half a copy of the relevant IS element present in the genome. 
Comparing genome arrangement 
Nanopore-only assemblies were produced for all strains, using the Flye-Racon-Medaka strategy 
detailed above. These assemblies were used for genome arrangement comparisons, to ensure that 
assembly strategy did not contribute to any observed arrangement differences. Closed genome 
sequences were aligned against each other using progressiveMauve (v20150226 build 10, Darling, 
Mau and Perna, 2010). The results were manually inspected and grouped into types (within each type, 
no arrangement differences were visible). A representative of each New Zealand arrangement type 
was aligned against 29 global strains (Supplementary Table S3.12), representing each of the CDC 
arrangement types defined in Weigand et al. (2017)’s landmark B. pertussis genomic arrangement 
study, in order to place the New Zealand arrangements in a wider global context.  
Allelic profile typing 
Allele type was assigned to the genes coding for the ACV proteins and the promoter for pertussis toxin 
(ptxA-E, prn, fim2, fim3, fhaB, and ptxP) using a custom-made MLST scheme with Seemann’s MLST 
tool (v2.16.2, Seemann, 2019), using the hybrid assembled genomes. The commands and custom 
scheme are available from https://github.com/nataliering/FHA_screening. Instructions for using a 
custom scheme are available from https://github.com/tseemann/mlst. To make the ACV-gene MLST 
scheme, all known alleles were downloaded for each gene from PubMLST (Jolley, Bray and Maiden, 
2018) and processed using tfa_prepper (https://github.com/nataliering/FHA_screening). The 
exceptions were prn and fim3, for which the alleles defined in Bart, Harris, et al. (2014) (supplemental 
text sd6) were used for consistency, as the nomenclature for both on PubMLST appears to be different. 
Prediction of duplications 
As in Chapter 2, strains were screened for potential large copy number variants by using BWA MEM 
(v0.7.15-r1140, Li, 2013) to map raw Illumina reads to the Tohama I reference sequence 
(NC_002929.2) and assessing the read coverage at every position in the genome using SAMtools depth 
(v1.8-25-g2c7cd7c, Li et al., 2009). 
 
Table 3.2 IS elements counted in NZ genomes  
IS element NCBI accession 
IS 481 M22031.1 
IS 1001 X66858.1 
IS 1002 NP_881859.1 
IS 1663 NP_881791.1 
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Prediction of pertactin, pertussis toxin and filamentous haemagglutinin deficiency 
The final closed genome sequence for each strain was annotated using Prokka (v1.14.6, Seemann, 
2014a), with the Tohama I reference proteins for NC_002929.2 from GenBank as a guide. The resulting 
annotations for prn, ptxA-E and fhaB were screened for presence/absence, and for insertion of IS 481, 
IS 1002, or IS 1663. Additionally, the assembled prn sequences were screened for the presence of 
other mutations previously identified in pertactin-deficient strains (Pawloski et al., 2014). 
Phylogenies 
To place the New Zealand strains in a global context, 73 global strains representing different 
continents, time periods and allelic profiles were included in the analysis. A further 125 global strains 
were included in more detailed trees for each of New Zealand’s four whooping cough outbreaks since 
2004. Illumina reads were downloaded from the NCBI’s SRA using fasterq-dump (v2.10.5) and trimmed 
using Trimmomatic (v0.36) using the options HEADCROP:10, SLIDINGWINDOW:4:20 and MINLEN:30 
(see Supplementary Table S3.11 for full details including accession numbers).  
Several different trees were constructed: one containing only the New Zealand strains, one containing 
the New Zealand strains along with the 73 global strains, and one for each of the four New Zealand 
whooping cough outbreaks since 2004. Snippy (v4.6.0, Seemann, 2014b) and SNP-sites (v2.1.3, Page 
et al., 2016) were used to perform variant calling and define the core genome, using the paired-end 
Illumina fastq files for all test strains, with the Tohama I genome as a reference. A maximum-likelihood 
phylogeny was inferred using IQ-Tree 2 (v2.0.4, Minh et al., 2020). IQ-Tree’s built-in ModelFinder 
(Kalyaanamoorthy et al., 2017) module was used to select the best model for each dataset (the New 
Zealand and global trees used K3Pu+F+ASC, the 2004-2006 and 2008-2011 outbreak trees used 
K3P+ASC, the 2012 outbreak tree used TVMe+ASC, and the 2017-2018 outbreak tree used K2P+ASC). 
Up to 2,000 bootstrapping steps were conducted, using the built-in Ultrafast bootstrap module (Hoang 
et al., 2018). The best maximum likelihood tree for each dataset was output in Newick format, which 
was then visualised using Microreact (Argimon et al., 2016) or iTOL (Letunic and Bork, 2019).  
 
3.6 Results 
12 isolates can be sequenced per R9.4 RevD flow cell using the rapid library preparation 
Although 12 barcodes were available, only 10 barcoded strains were included in the first rapid 
barcoding (SQK-RBK004) run here. Our previous trials (Chapter 2, Ring et al. 2018) had shown that the 
yield of a single R9.4 flow cell provided enough coverage of 10 strains, but we had not tried to 
sequence using more than 10 barcodes. In addition, the previous benchmarking was conducted using 
the 1D ligation library preparation with native barcoding; the rapid barcoding library preparation used 
during the sequencing of the New Zealand isolates in this chapter does not include the multiple DNA 
end-repair and clean-up steps, hence was likely to produce a significantly lower yield. However, the 
raw yield of this first run using the SQK-RBK004 kit with an R9.4 RevD flow cell was over 20 Gb, which 
provided over 180X coverage for each of the 10 strains, even after some of the data was lost during 
demultiplexing. Therefore, during subsequent SQK-RBK004 MinION runs, 12 strains were barcoded 
and sequenced on each flow cell.  
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In total, 6 MinION R9.4 RevD flow cells were used to sequence the 66 New Zealand isolates. The 
amount of usable data, after demultiplexing, varied from 3.94 to 12.76 Gb. This corresponded to 
coverage between 42X and 484X per isolate, with a mean coverage of 207X. The yield of each run 
tended to correlate with the number of pores available at the beginning of the sequencing, which 
reflects the quality of the flow cell. The overall mean read length across all sequencing runs was 6,282 
bp. The individual run mean read lengths ranged from 4,908 to 7,917 bp. The coverage and read 
lengths were sufficient to assemble closed genome sequences for all isolates (see next section). 
Using nanopore and Illumina reads, closed genomes were produced for all 66 isolates, but 
some assemblies were not complete 
After basecalling and demultiplexing, the reads for each strain were corrected using Canu. 63 strains 
were then assembled in hybrid with paired Illumina data; 34 strains were assembled using Flye, and 
29 were assembled using Unicycler. The closed genome sequences produced by Flye were polished to 
improve their accuracy. First, the assemblies were polished using the long reads; 4 successive Racon 
polishes were conducted, followed by a single long-read polish with Medaka. Finally, the assemblies 
were polished with Illumina short reads, using 3 successive rounds of Pilon. The Unicycler assembly 
pipeline already includes Racon and Pilon polishing steps. Illumina data was not available for 3 strains 
(NZ1, NZ5 and NZ29), hence these were assembled with the Flye-Racon-Medaka strategy, without the 
Pilon polishes. Between the Flye and Unicycler strategies, closed genome sequences were produced 
for all strains.  
The accuracy of the hybrid assemblies was estimated after each step, by comparison with highly-
fragmented ABySS assemblies produced using each strain’s Illumina data. The mean identity after Flye 
long-read-only assembly was 99.60% (n=37), increasing to 99.63% after the Racon and Medaka long-
read polishing steps (n=37). Polishing with short reads further increased the mean identity to 99.70% 
(n=37), which is 0.01% higher than the mean identity of the UK genomes assembled in Chapter 2. The 
individual identities of each hybrid Flye strain compared to their own Illumina data ranged from 99.68 
to 99.72%: the maximum percent identity was therefore higher than the maximum of the UK genomes 
(99.69%).  In total, 17 New Zealand genomes assembled with Flye had a percent identity higher than 
99.69%.  
The mean identity after Unicycler hybrid assembly was 99.65% (n=26). However, the identity of one 
strain, NZ60, was noticeably lower than every other strain, at 98.11%. Excluding this strain, the mean 
identity after Unicycler hybrid assembly was 99.71% (n=25), which is 0.01% higher than the mean Flye 
identity. The individual identities for each strain assembled with Unicycler ranged from 98.11% to 
99.73%, 0.01% higher than the maximum hybrid Flye identity. 24 Unicycler hybrid assemblies had 
identities higher than the best identity achieved in Chapter 2 (99.69%).  
The final closed genome sequences were checked for misassemblies using BUSCO. A newer version of 
BUSCO was used here than in Chapter 2; instead of checking for 40 universal bacterial orthologues, 
the newer version of BUSCO checked for 124. For reference, the UK genome sequences from Chapter 
2 were also checked with the newer version of BUSCO. The 5 hybrid-assembled UK genome sequences 
contained 40 complete BUSCOs using the older version of the tool, and all 5 also contained 124 
complete BUSCOs using the newer version. They were therefore considered to be 100% complete and 
largely error-free. However, not all of the hybrid-assembled New Zealand genome sequences 
contained 124 complete BUSCOs. Every sequence assembled using Unicycler (n=26) was 100% 
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complete according to BUSCO. The sequences assembled with Flye had a mean completeness of 
98.03% (n=37); however, the Flye assemblies polished with NovaSeq data (n=3) were all 100% 
complete, compared to none of the assemblies polished with the MiSeq data (n=34). This suggests 
that the higher coverage and/or more consistent read lengths of the NovaSeq data enabled Pilon to 
polish the incomplete Flye assemblies more effectively. As noted by Watson and Warr (2019), residual 
uncorrected errors in the incomplete genomes likely resulted in some BUSCOs being fragmented or 
truncated, meaning they could not be predicted by the Prodigal protein prediction algorithm used by 
BUSCO.  
No strains have any ultra-long copy number variations, although two strains share the 
same 14 kbp duplication  
Trimmed nanopore and Illumina reads were aligned with the Tohama I reference genome 
(NC_002929.2) and processed as described in Chapter 2 to produce coverage plots, to screen for 
potential copy number variants (CNVs). The resulting plots can be seen in full in Supplementary Figures 
S3.1-S3.7. 
Certain previously observed regions of deletion were observed in all strains. A ~29 kbp region from 
BP0911 to BP0937 (RD3, Supplementary Table S3.5), flanked by copies of IS 481 was previously 
identified as deleted in all French strains since 1980 and all Finnish clinical strains since 1977 in  Caro 
et al. (2006) and Heikkinen et al. (2007), respectively. The RD3 region was deleted in all New Zealand 
isolates since 1982 studied here. Likewise, the ~7 kbp region from BP1135 to BP1141 (RD2, 
Supplementary Table S3.6) identified as absent in most French strains and every Finnish strain since 
1953 in Caro et al. (2006) and Heikkinen et al. (2007) respectively was also absent in all New Zealand 
strains here. 
One region which fluctuated noticeably between different strains was the region from BP1948 to 
BP1966 (see Supplementary Table S3.7 for full details), which was deleted in some strains but not 
others. This 22.7 kbp region was originally noted by Caro et al. (2006), who named it region of 
difference 4, “RD4”. Caro et al. saw RD4 in only a small number of isolates belonging to their PFGE 
subgroup IV-β, however Bouchez et al. (2008) later found the deletion to be present in a wider 
selection of isolates, including every isolate they studied between 1999 and 2007. A similar pattern 
was seen here, with only 35.7% (5/14) of strains isolated in the 1980s and 1990s lacking the region, 
increasing to 90.4% (47/52) of strains isolated in the 2000s and 2010s. Interestingly, four of the five 
strains lacking the deletion in this second time period were all isolated during the same whooping 
cough outbreak, between 2004 and 2006. Full details of which genomes contained the RD4 deletion 
are given in Supplementary Table S3.9. Figure 3.7 shows one strain from the 2004-2006 outbreak, NZ32, 
which does not show the RD4 deletion, compared with another strain from the strain outbreak, NZ30, 
which does show the deletion.  
The other notable CNV seen in this New Zealand strain cohort became apparent in the same way as 
the ultra-long duplication in the UK48 genome in Chapter 2: Unicycler was unable to assemble the 
genomes of NZ35 and NZ36 into single contigs. Instead, a nearly-complete contig of around 4.1 Mb 
was assembled, which Unicycler labelled as “incomplete”, along with a much smaller contig of around 
14 kb, which Unicycler labelled as both “complete” and “circular”. The “circular” label suggested that 
this 14 kb segment contained the same sequence at the beginning and end, most likely an IS element. 
The coverage analysis (Figure 3.8) for both strains revealed the duplication of a 13.2 kbp region flanked  
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by IS 481 (14.3 kbp long in total, including the flanking IS 481), around 1.8 Mb into the reference 
genome sequence. This region contains 11 open reading frames (ORFs), including two copies of cphA 
(cyanophycin synthetase), one pseudogene, and a variety of hypothetical exported or membrane 
proteins. Full details of the region are shown in Supplementary Table S3.8. This CNV was previously 
identified in extremely high copy numbers in UK54, and explored more thoroughly in Abrahams et al. 
(In review). 
Flye was able to assemble the genomes of both strains into single contigs, due to its long-read-centric 
rather than short-read-centric assembly strategy, so the Flye-Racon-Medaka-Pilon pipeline detailed in 
the Methods section was used for these two strains instead of Unicycler. NZ35 and NZ36 were isolated 
in the 2004-2006 outbreak, around a month apart, and in the same health region in New Zealand 
(Midcentral). 
 
Figure 3.7 Coverage plots for two strains isolated during the 2004-2006 whooping cough outbreak in New Zealand. The RD4 
deletion can be seen in the genome of NZ30 (the red box), but not in the genome of NZ32. Plots were constructed by 
calculating a rolling average of coverage, with a window size of 2000 bp. 
Figure 3.8 Coverage plots from three strains isolated during the New Zealand 2004-2006 whooping cough outbreak. The 
genomes of NZ35 and NZ36 contain a duplication of a 14.3 kbp region around 1.8 Mb into the reference sequence (indicated 
with red box). For comparison, the plot for NZ37, which does not contain the duplication, is also shown. Plots were 




Two clear groups of genome sizes were observed , but no trends in IS numbers were seen 
from the 1980s to 2018 
Assembling closed genomes allowed genome size and exact numbers of each IS element in the 66 
strains to be compared (Figure 3.9). Genome length varied from 4.101 Mb (NZ33) to 4.134 Mb (NZ27), 
with a mean length of 4.111 Mb. Two length groups appear to exist; most genomes (n=54) were 
between 4.101 and 4.114 Mb, but a second group (n=12) were between 4.125 and 4.134 Mb, with no 
genome lengths falling in between the two groups. Overall, the more recent genomes tended to be 
found in the “smaller genome” group.  Phylogenetic analysis did not show any clear trends between 
phylogenetic relationships and genome size group (Figure 3.12). On the whole, more “larger” genomes 
were seen at one end of the tree, which correlates with ptxP1 genomes from earlier years; however, 
the “larger” genome group were not all found on the same branch of the phylogeny. 
IS element copies were counted using blastn, with options which ensured that only copies of IS 
elements where more than 50% of the sequence was present were counted. The number of IS 481 
copies in the 66 closed genomes ranged from 245 to 258, with a mean copy number of 251.6. The 
copy numbers of IS 1002 and IS 1663 were less variable, ranging from 5 to 7 and 16 to 17, with mean 
copy numbers of 6.0 and 16.2 respectively. No obvious trend in numbers of IS elements was observed 
over the time period studied.  
In addition, the closed genomes were searched for the presence of IS 1001, which is specific to B. 
parapertussis and can thus indicate a misidentification of the causative bacterium in whooping cough 
cases (Parkhill et al., 2003). No copies of IS 1001 were seen in any of the 66 strains studied here, 
suggesting that all the patients from whom the strains were isolated were indeed infected with B. 
pertussis rather than the rarer B. parapertussis.  
Figure 3.9 Trends observed in a) genome size or b) IS copy number over the time period studied. Genome length ranged 
from 4.101 Mb to 4.134 Mb, with a mean length of 4.111 Mb, and has appeared to trend downwards overall, with two clear 
groups of genome sizes (between 4.0 and 4.15 Mb, and between 4.25 and 4.35 Mb). No trends were seen in numbers of IS 
elements. IS 481 copy number ranged from 245 to 258, with a mean of 251.5, IS 1002 copy number ranged from 5 to 7 with 
a mean of 6.0, and IS 1663 copy  number ranged from 16 to 17, with a mean of 16.2. The gradients of the linear trendlines 
(not displayed on this figure) were 0.05, -0.002 and -0.02 for IS 481, IS 1002 and IS 1663 respectively; these essentially 
horizontal trendlines suggest there has been no ongoing increase or decrease in  copy number of these abundant IS elements 
over the 36-year period  studied (1982 to 2018). 
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19 different genome arrangements were seen in the 66 New Zealand isolates 
Closed genome sequences were produced for all 66 New Zealand isolates using the nanopore-only 
Flye-based assembly pipeline. The genome arrangement of these closed sequences was investigated 
using progressiveMauve. The isolates were then grouped based on shared arrangement, resulting in 
19 different arrangement groups (listed in Supplementary Table S3.13. Ten isolates displayed 
“singleton” arrangements which were not shared with any other isolate; the remaining 56 isolates 
shared nine arrangements between them (shown in Figure 3.10a). As seen in Weigand et al. (2019), 
the rearrangements generally displayed a pattern of symmetrical inversions around the origin of 
replication. 
One representative of each of the arrangement groups, including all of the singletons, were aligned 
using progressiveMauve against representatives of each of the arrangement types defined in Weigand 
et al. 2017 and Weigand et al. 2019 (the representatives are listed in Supplementary Table S3.11). This 
revealed that six of the New Zealand arrangements were congruent with Weigand arrangement types, 
including one of the New Zealand singletons, which was congruent with the CDC046 arrangement 
type. 30 New Zealand isolates shared the same arrangement type, CDC010. The remaining isolates 
were spread more evenly in smaller groups across the other eight arrangement types, as shown in 
Figure 3.10b. Full details of the grouped arrangement types are given in Supplementary Table S3.13. 
CDC010 was the fifth most commonly seen arrangement type in Weigand et al. (2017), after CDC237, 
CDC002, singletons and CDC013; CDC237, CDC002 and CDC013 were also observed here. 
Allelic profile shifts in New Zealand isolates have paralleled those seen elsewhere in the 
world 
MLST was used to identify which alleles of ptxP, ptxA, prn, fim2 and fim3 were present in the closed 
genome sequences for the 63 New Zealand isolates for which Illumina data was available, using allele 
definitions from PubMLST or as defined in Bart, Harris, et al. (2014). The results are shown in Figure 
3.11. The most common allelic profile in New Zealand in the WCV era, particularly before the 1990s, 
was ptxP1-ptxA1-prn1-fim2-1-fim3-1 (75% of 1980s strains, n=8). This then shifted gradually to ptxP3-
ptxA1-prn2-fim2-1-fim3-1 (90.3% of 2010s strains, n=31) throughout the 1990s, 2000s and 2010s. A 
brief increase in the circulating proportion of fim3-2 was seen, although this decreased again by the 
2010s. 
During the 1990s and 2000s, a number of strains carrying the prn3 allele circulated, partly related to 
the 2004-2006 outbreak (60%, n=5). However, by the 2010s, only prn2 was circulating. Additionally, 
44.4% (n=9) of strains circulating during the 2004-2006 outbreak carried the ptxP1 allele, which had 
largely been replaced by ptxP3 throughout the 1990s. Interestingly, three of the four ptxP1 strains 
isolated during the 2004-2006 outbreak also carried prn3, and shared the same genomic arrangement 
(arrangement type NZ002). Two of these strains were isolated within a month of each other in the 
same region (NZ35 and NZ36, Midcentral), so may have been directly related. However, the third 
strain (NZ37) was isolated nearly a year later, in a different region (Capital and Coast). This suggests 
that ptxP1-prn3 may have been a common allelic profile during that outbreak. No other similar 






Figure 3.10 Genome structures of New Zealand isolates.  
a) 56 of the 66 isolates could be grouped into nine shared genome arrangements. The differences between the arrangement types tended to be inversions (often large) around the central 
region of the chromosome. Five of the nine arrangement types were found to be congruent with CDC structures defined in Weigand et al. (2017).  
b) 30 New Zealand isolates shared the same arrangement type (Type 1/CDC010). Ten isolates had “singleton” arrangements shared with no other isolate (although one of these arrangements 







Figure 3.11 The changing allelelic profile of New Zealand 
strains from 1982 to 2018. Some of the genes involved in the 
ACV have undergone noticeable shifts globally since the 
switch from WCV to ACV in the late 1990s and early 2000s, 
in addition to a rapid shift from ptxP1 to ptxP3 in the 1980s 
and early 1990s. a) Shows the shift from ptxP1 to ptxP3 also 
occurred in New Zealand, but ptxP1 alleles continued to 
circulate in New Zealand until the 2000s. b) and c) show that, 
in New Zealand, one allele each is circulating for ptxA and 
fim2.  d) Shows a brief increase in the frequencies of non-
fim3-1 alleles. Finally, e) shows a rapid increase in the 
prevalence of prn2 since the 1990s; no other prn alleles 
appear to be present in the population anymore. 
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35% of all strains, and 89% of strains isolated since 2012, were predicted to be pertactin 
deficient 
The closed genome sequences were annotated using Prokka, and the resulting annotations were 
screened for the presence/absence of prn, fhaB and ptxA-E, as well as for the insertion of IS 481, IS 
1002 or IS 1663 into the same genes. 
34.8% (23/66) of all strains were found to have a copy of IS 481 within their prn gene, which is known 
to cause pertactin deficiency. No strain was found to have this insertion prior to 2012, whilst 85.2% 
(23/27) of all strains isolated between 2012 and 2018 had it. There are three potential IS 481 insertion 
sites within the prn gene, at 240 bp, 1,613 bp, and 2,735 bp (Pawloski et al., 2014). In other studies, 
such as Weigand et al. (2017), the site most commonly seen to have an IS 481 inserted was at 1,613 
bp, appearing in 95 of 114 IS 481 insertion strains in that study, followed by the insertion site at 240 
bp, seen in 16 of the 114 strains. Insertion at the 2,735 is rare, appearing in only 3 of the 114 strains 
in Weigand et al. (2017). Likewise, in the majority (22/23) of the New Zealand strains with an IS 481 
insertion in prn, it was inserted at position 1,613. The remaining strain had IS 481 inserted at position 
240.  
One additional strain (NZ63) from 2017 was found to have a mutation previously identified in Weigand 
et al. (2017) as causing deficiency, a change from C to T at position 223, resulting in a premature stop 
codon. In total, therefore, 88.9% (24/27) of strains isolated in 2012 or later are predicted to be 
pertactin-deficient. This suggests that pertactin deficiency was uncommon in New Zealand B. pertussis 
strains until 2012, and has rapidly increased in prevalence since then.  
No FHA or PT deficiency caused by IS insertion was predicted in any strain.  
New Zealand isolates cluster phylogenetically with global strains according to allelic 
profile, but isolates circulating during outbreak years appear more closely related than 
outbreak strains in other countries 
A phylogeny was inferred using 325 core SNPs for the 63 New Zealand isolates for which Illumina data 
was available (Figure 3.12). The ptxP1 strains clustered separately from the ptxP3 strains. All non-prn2 
strains were included in the ptxP1 cluster, and all predicted PRN-deficient strains were included in the 
ptxP3 cluster. All but one of the predicted PRN-deficient strains were contained on the same sub-
branch within the ptxP3 cluster. The different deficiency-related prn2 mutations did not cluster 
together, suggesting PRN deficiency has arisen on multiple different occasions.  
Most arrangement types were spread relatively evenly throughout the phylogeny; however, strains 
with the NZ002 arrangement type clustered together, including the three highly similar strains from 
the 2004-2006 outbreak. These strains (NZ35, NZ36 and NZ37) were identical in terms of core genome 
SNPs. Likewise, strains with the arrangement type CDC237 clustered together, and were all isolated 
during the most recent (2017-2018) outbreak, representing 40% (n=10) of all strains sequenced from 
that outbreak. These four strains also shared the same mutation in their prn2 gene (IS 481-1613fwd), 
and three of them (NZ57, NZ64 and NZ65) were identical in terms of core genome SNPs. Two of the 
strains (NZ57 and NZ58) were isolated in the Southern region within the same two week period, whilst 
the other two strains (NZ64 and NZ65) were isolated in the South Canterbury region several months 
later, but again within two weeks of each other. 70% (n=10) of the strains isolated during the 2017-
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2018 outbreak period clustered together, regardless of genomic arrangement, suggesting that the 
strains circulating during that outbreak tended to be closely related. 
Figure 3.12 Phylogenetic tree showing the evolutionary relationships of the New Zealand strains sequenced here, in the context of allele 
type, Prn deficiency, genomic arrangement and period of isolation. Snippy was used to identify variants between the NZ strains and the 
reference, Tohama I, as well as defining a core genome. IQ-Tree2 was used to infer a maximum-likelihood phylogeny, which was then 
displayed using iTOL (interactive Microreact tree also available at https://microreact.org/project/JG7I7MBBV).  
Bootstrap values varied from 10 to 100, and are represented by line thickness (thicker line=higher bootstrap value). 
Key branches are highlighted. All ptxP3 strains are contained within one major branch, whilst a slightly smaller sub-branch contains all 
but one of the predicted Prn-deficient strains. 
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Other than the 2004-2006 and 2017-2018 outbreaks, strains did not tend to cluster together according 
to the outbreak or year in which they were isolated. On the whole, many New Zealand strains appear 
to be very closely related, including a large group of eight strains (NZ51, NZ52, NZ55, NZ27, NZ56, 
NZ59, NZ50 and NZ53) from throughout the 2000s/2010s, including the 2012 and 2017-2018 
outbreaks, which were either identical or separated by only one or two SNPs in their core genome. 
To determine whether the New Zealand strains are genetically distinct from those circulating 
elsewhere in the world during the 1982-2018 period, a further phylogeny was inferred from the 63 
New Zealand strains and 73 global strains from the same period, using 511 core SNPs (Figure 3.13). 
Again, all ptxP1 strains clustered on the same branch, and all ptxP3 strains clustered on a separate, 
larger branch. In general, strains isolated earlier (for example, in the 1980s) clustered at one end of 
the tree, whilst strains isolated later (for example, the 2010s) clustered at the other end.  
During periods for which sequencing data was available from many countries, little geographical 
clustering was seen. For recent years (since 2014), most of the available sequencing data was for 
strains isolated in the USA and sequenced by the CDC; this gives the impression of geographical 
clustering, but is more likely simply due to undersampling of strains from other countries.  
Certain New Zealand strains do appear to be clustered separately from the majority of the global 
strains. Group A (Figure 3.13) contains ten New Zealand strains (NZ14, NZ43, NZ42, NZ21, NZ38, NZ30, 
NZ33, NZ31 and NZ34) and one Asian strain (B281), clustered on their own sub-branch, distinct from 
the closest global neighbours. These nine strains all have the allelic profile ptxP3-ptxA1-prn2-fim2-1-
fim3-1, all have the RD4 deletion and the CDC010 genomic arrangement type, and none possesses a 
known prn2 deficiency mutation. Where serotyping data was available (n=8), the strains were all 
serotype 1,3 (or 1,2,3).  They were isolated between 1999 (NZ14) and 2010 (NZ43), in a variety of 
different regions around New Zealand (Auckland, Nelson Marlborough, Northland, Southern and 
Waikato). Four of the strains were isolated during the 2004-2006 outbreak, and three were isolated 
during the 2008-2011 outbreak. 
Group B contains another ten strains clustered on their own branch, including one which was isolated 
in Australia (L2264). The nine New Zealand strains (NZ62, NZ61, NZ24, NZ47, NZ22, NZ60, NZ25, NZ54 
and NZ23) also all have the ptxP3-ptxA1-prn2-fim2-1-fim3-1 genotype and the RD4 deletion. They all 
possess a prn2 mutation: five have the IS 481-1613fwd mutation, and four have the IS 481-1613rev 
mutation. All but one have the CDC010 arrangement type; the remaining strain (NZ60) has the NZ008 
arrangement type. Where serotyping data was available (n=6), the strains were all serotype 1,2 (or 
1,2,3). The strains were all isolated since 2011, and five of them were isolated during outbreaks (2008-
2011, 2012 and 2017-2018).  
Group C is another group of ten strains, containing nine New Zealand strains (NZ56, NZ27, NZ55, NZ53, 
NZ59, NZ52, NZ51, NZ50 and NZ44) and one Australian strain (L2239). Like the other groups, and most 
recent strains, this group has the ptxP3-ptxA1-prn2-fim2-1-fim3-1 genotype and the RD4 deletion. All 
but one of the strains (NZ44) has a prn2 mutation, with five instances of IS 481-1613fwd and four of 
IS 481-1613rev. Like Group B, eight of the New Zealand strains share the CDC010 arrangement type 
and the ninth (NZ44) has the NZ008 type. All were isolated since 2010, and eight were isolated during 
outbreaks (one from 2008-2011, six from 2012, and one from 2017-2018). Where tested (n=8), the 
strains all had the serotype 1,3. 
Finally, Group D contains four New Zealand strains (NZ65, NZ57, NZ64 and NZ58). Three are identical 
in terms of core genome SNPs, and the fourth (NZ58) differs by only a single SNP. These are the same 





Figure 3.13 Phylogenetic tree 
showing the evolutionary 
relationships of the New Zealand 
strains compared with a 
selection of global strains from 
the same time period. Variants 
between the selection strains 
and the Tohama I reference 
were called, and a core genome 
was defined, using Snippy. A 
maximum-likelihood phylogeny 
was inferred using IQ-Tree2, and 
iTOL was used to display the 
resulting tree.  
Like the New Zealand strains 
alone, all strains carrying the 
ptxP3 allele* are found on the 
same major branch, separate 
from the ptxP1 strains. 
Several groups containing highly 
similar strains, almost all from 
New Zealand, are indicated. 
Bootstrap values varied from 1 
to 100, and are represented by 
line thickness (thicker 
line=higher bootstrap value). 
*Allele information was not available 






(ptxP3-ptxA1-prn2-fim2-1-fim3-1) allelic profile. Serotype was not tested for any of them, but they all 
have the RD4 deletion and the IS 481-1613fwd prn2 mutation. As previously mentioned, they all have 
the CDC237 arrangement type, and were isolated in two geographically contemporaneous pairs. 
Groups A-D in the global phylogeny suggest that certain strains circulating in New Zealand in the 2000s 
and 2010s are more closely related than those circulating in other countries, particularly during New 
Zealand whooping cough outbreak periods. To investigate whether this effect was simply due to 
oversampling of New Zealand strains in the global phylogeny, smaller phylogenies were inferred for 
each of the four post-2000 New Zealand whooping cough outbreaks, with additional global strains 
included for each outbreak period. 
Figure 3.14 shows the focussed phylogenies for a) the 2004-2006 outbreak and b) the 2008-2011 
outbreak. The New Zealand strains are spread across several different branches in the 2004-2006 
phylogeny, which was constructed from 378 core SNPs.  Nonetheless certain strains are closely 
related; NZ35, NZ36 and NZ37, as mentioned previously, are identical in terms of core SNPs, and were 
not all isolated at the same time or location. However, on the same branch as these three New Zealand 
strains are two Australian strains. The Australian strains are not identical to the New Zealand strains 
(although they are identical to each other), but differ from the New Zealand strains by only two SNPs.  
Similarly, NZ32 and L508 (also from Australia) are identical to each other, as are two other Australian 
strains, B048 and L518.  Overall, this phylogeny suggests that certain strains circulating during the 
2004-2006 outbreak were relatively clonal in both New Zealand and Australia, but the outbreak was 
not caused by a single strain in either country.  
The picture is less clear for the 2008-2011 phylogeny, which was inferred from 408 core SNPs. Again, 
some of the New Zealand and Australian strains have clustered separately from the strains from 
elsewhere in the world. Three Australian strains (L1214, L1423 and L1419) have identical core genome 
SNPs, and one New Zealand strain (NZ46) differs by only one SNP. Likewise, there are three New 
Zealand strains from different regions (NZ38, NZ43 and NZ42) which are, at most, only one SNP apart. 
However, on the whole, the New Zealand strains from the 2008-2011 outbreak are less closely related 
to each other than those from the 2004-2006 outbreak, and there is less of a clear similarity with the 
Australian strains. 
Figure 3.15 shows the focussed phylogenies for the a) 2012 outbreak and b) the 2017-2018 outbreak. 
The 2012 phylogeny, inferred from 320 core SNPs, shows 60% (n=10) of the New Zealand strains 
(NZ52, NZ50, NZ53, NZ51, NZ55 and NZ56) form a clear group, again with some Australian strains 
(L1661, L1779 and L1780). Four of the New Zealand strains have identical core genome SNPs, and the 
others are one SNP different each. The Australian strains are not identical to each other, but each is 
only two SNPs different from the New Zealand strains. The remaining New Zealand strains cluster 
throughout the rest of the phylogeny, with strains isolated in the UK or USA. 
Finally, the phylogeny showing strains from the most recent outbreak, which was constructed from 
323 core genome SNPs, indicates a slightly different picture again. As previously mentioned, four of 
the New Zealand strains (NZ57, NZ65, NZ64 and NZ58) have identical core genomes; these strains 
cluster on their own branch. The remaining New Zealand strains, however are less similar to each 
other, and cluster on branches with strains from Australia and/or the USA. At the same time, several 
USA strains (J733, J811, J878, K256 and K298) isolated over the same period are identical or only a 





Figure 3.14 Phylogenetic trees showing the evolutionary relationships between strains isolated in New Zealand during the a) 2004-2006 whooping cough outbreak and b) 2008-2011 whooping 
cough outbreak, compared with global strains isolated during the same time periods. Variants were called and core genomes defined using Snippy, then phylogenies were inferred using IQ-
Tree2 and visualised using IToL and Microreact (interactive trees available at https://microreact.org/project/8F3Ilz2Bi and https://microreact.org/project/UWL4KNRaN). Bootstrap values are 
shown for major branches. Branches containing only single strains tended to have lower bootstrap values. 
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Figure 3.15 Phylogenetic trees showing the evolutionary relationships between strains isolated in New Zealand during the a) 2012 whooping cough outbreak and b) 2017-2018 whooping 
cough outbreak, compared with global strains isolated during the same time periods. Variants were called and core genomes defined using Snippy, then phylogenies were inferred using IQ-
Tree2 and visualised using Microreact (interactive trees available at https://microreact.org/project/yR6WukJhF and https://microreact.org/project/tbl0zUnck). Bootstrap values are shown for 





New Zealand strains were investigated for a number of reasons. Historically, vaccine uptake in New 
Zealand was lower than in many other countries although, thanks to efforts to monitor and increase 
rates of uptake since 2008, vaccine coverage is now comparable to that in the UK. However, despite 
the increasing vaccine coverage, whooping cough incidence has remained higher in New Zealand than 
in most other countries, including the USA and England (Figure 3.2). An outbreak occurred in New 
Zealand from 2017 to 2019, for example, a period when no other countries noted a similar increase in 
cases. Although isolates have been collected and stored by New Zealand’s ESR since the 1980s, no 
sequencing of any B. pertussis from New Zealand had previously been conducted. Therefore, the 
genomes of 66 isolates from between 1982 and 2018 were sequenced here, using the hybrid nanopore 
and Illumina pipeline developed in Chapter 2, to determine the following: whether vaccine-driven 
global genomic trends observed in B. pertussis had been delayed by New Zealand’s slower vaccine 
uptake; whether the strains circulating during whooping cough outbreaks were polyclonal, as seen in 
recent outbreaks in the UK and USA; and whether the consistently higher incidence of whooping cough 
in New Zealand could be explained by the circulation of a unique hyper-virulent strain. 
Allelic profile, genome size and antigen deficiency trends in New Zealand generally match 
those seen elsewhere in the world 
King et al. (2010) surveyed the genomes of global strains for a 60-year period, between 1949 and 2008. 
Overall, they found a downward linear trend in both genome size and number of genes, suggesting 
that B. pertussis is a species which is seeing ongoing genome reduction (Ring et al., 2019). Applying a 
linear trend-line to Figure 3.9a reveals a similar trend in the genome size of the 66 strains isolated in 
New Zealand between 1982 and 2018. The largest genome observed by King et al. was 4.124 Mb, and 
the smallest was 3.937 Mb. Amongst the New Zealand genomes analysed here, the largest was 4.134 
Mb and the smallest was 4.101 Mb; at face value, the New Zealand strains would therefore appear to 
be larger. However, King et al. used a genome size approximation method, estimating the length of 
each genome based on gene content from CGH data and extrapolating from the length of the Tohama 
I genome. It is likely that this method produced genome size estimates which were less accurate than 
the assembly of complete, closed genome sequences. The main difference in sizes was likely due to 
numbers of repetitive elements like IS elements being underestimated by the CGH estimation method. 
The grouping of genome sizes observed here was also seen in King et al. (2010), with a small group of 
larger genomes and a large group of smaller genomes. The size difference is not explained by a single 
large deletion or insertion, by the larger genomes clearly containing more copies of IS 481, IS 1002 or 
IS 1663, or by the larger genomes all belonging to the same phylogenetic family.  A brief review of the 
lengths of all closed B. pertussis genomes available from the NCBI’s RefSeq database (downloaded for 
Chapter 5, see Supplementary Table S5.1) reveals the same pattern: most genomes are no longer than 
around 4.115 Mb and a small group have genomes between 4.125 and 4.135 Mb, but no genomes 
have been seen with a length between the two groups. This genome size grouping trend may be due 
to undersampling (only 524 closed genomes from RefSeq had the required year of isolation metadata 
available), or may be a previously unstudied B. pertussis genomic phenomenon. 
Genome reduction in B. pertussis, like genome rearrangement, is largely mediated by recombination 
between IS elements. Indeed, the speciation of B. pertussis from its B. bronchiseptica-like ancestor is 
thought to have resulted from the very large increase in IS 481 copy number in the B. pertussis 
genome. However, no trend in numbers of IS elements was observed here (Figure 3.9b); the number 
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of copies of IS 481 has remained stable at around 250, numbers of IS 1002 remain around 6 copies, 
and numbers of IS 1663 copies are still around 16/17, suggesting that despite extensive recombination 
between IS elements, copy number is not currently undergoing increase or decrease, or is changing 
too slowly for any change to be apparent over the 40-year period studied here.  
Just as the trend in genome size of New Zealand strains matches the trend seen in other global strains, 
analysis of the allelic profile of the ACV-related genes also reveals a similar pattern in the New Zealand 
strains to that seen in Bart, Harris, et al. (2014)’s landmark study of global strains throughout the 20th 
and early 21st century, as well as other studies of how B. pertussis populations have changed over 
recent years, such as Sealey et al. (2015), Xu, Y. et al. (2015), Zomer et al. (2018). The most common 
global allelic profile during the “WCV era” in Bart, Harris et al. (defined as 1960-1995) was found to be 
ptxP1-ptxA1-prn1-fim2-1-fim3-1. The most common allelic profile of the New Zealand strains from 
1982-1995 was the same, and was present in 50% (n=12) of the strains screened; the other 50% of 
strains were split between those carrying ptxP3, and different prn alleles. In the Bart, Harris et al. 
“WCV/ACV era” and “ACV era” (post-1995), the most prevalent allelic profile shifted to ptxP3-ptxA1-
prn2-fim2-1-fim3-1. An increased frequency of strains carrying the newer fim3-2 allele was also noted 
(from <1% frequency in the WCV era to 37% in the ACV era), with ptxP3-ptxA1-prn2-fim2-1-fim3-2 
being observed as the dominant profile in the late 2010s (Kallonen and He, 2009). Again, the most 
common allelic profile seen in the New Zealand strains throughout the period matched that seen 
elsewhere in the world.  
Noted shifts, such as ptxP1 to ptxP3 and prn1 to prn2, appear to have happened in New Zealand along 
similar timescales as the rest of the world. Additionally, the noted increase in the prevalence of the 
deletion of RD4 (Figure 3.7) has happened over the same timescale as it was detected in Caro et al. 
(2006) and Bouchez et al. (2008).  Interestingly, although the progression of fim3-2 in the New Zealand 
strains reflects that seen in Bart, Harris et al. (2014) throughout the WCV and early ACV eras, from 0% 
of strains in the 1980s and 1990s to 30.4% (7/23 strains) in the 2000s, a noticeable decline in the 
frequency of this allele can be seen in the strains from the 2010s (to 9.7%, 3/31 strains, Figure 3.11). 
The most recent strains in the Bart, Harris et al. screen were isolated in 2010; it is therefore possible 
that a similar decrease in prevalence would be seen in more recent global strains, rather than being a 
New Zealand-specific phenomenon.  
Another shift observed globally in the ACV era has been the rapid increase in strains which do not 
express functional pertactin protein. In Australia, for example, the percentage of PRN-deficient strains 
increased from 5% to 78% over the four year period between 2008 and 2012 (Lam et al., 2014). A 
study of strains from European countries isolated between 1998 and 2015 showed a clear correlation 
between how early each country introduced the ACV and the current proportion of PRN-deficient 
strains (Barkoff et al., 2019). The ACV was introduced in New Zealand in 2000, several years before 
some European countries, including the UK. Although the first PRN-deficient strains did not appear in 
the New Zealand cohort studied here until 2012, later than in some other countries, the proportion of 
PRN-deficient strains rapidly increased; 88.9% of strains since 2012 are PRN-deficient, including 90% 
of those isolated in 2017 and 2018. This frequency is higher than any of the European strains included 
in Barkoff et al.’s study, although it is similar to the frequencies observed in Australia (78%) and the 
USA (85%) (Lam et al., 2014; Martin et al., 2015). The majority of the predicted PRN-deficient New 
Zealand strains (95.8%, n=24) have a copy of IS 481 in their prn gene, and one (NZ63) possesses a SNP 
which results in a premature stop codon. Other mechanisms for PRN-deficiency have been observed 
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in other studies (for example, Pawloski et al., 2014), such as a commonly seen inversion of 22 kb 
containing the prn promoter, but were not seen here. These other mechanisms for PRN-deficiency 
may not have been identified from sequence alone; the percentage of PRN-deficient strains in New 
Zealand may therefore be even higher than predicted. Expression or non-expression of antigens such 
as PRN, PT and FHA can usually be tested in vitro, for example by western blot, but only heat-killed 
cells were available here. Nonetheless, it should be noted that the use of hybrid genome assembly 
allowed the prediction of PRN-deficiency caused by the most common deficiency mutations from 
sequence alone. 
Overall, New Zealand’s historically slower uptake of the whooping cough vaccine does not seem to 
have significantly delayed the most commonly observed recent genomic changes, unlike other slow-
uptake countries such as China (Xu, Y. et al., 2015). 
Are the B. pertussis strains circulating in New Zealand more clonal than in most other 
countries? 
Over the last decade, a variety of global B. pertussis phylogenies have been produced, including the 
landmark Bart, Harris et al. (2014) study. Some of the key patterns from these phylogenies, for 
example the clear branching of ptxP1 from the ptxP3 strains, were also observed in the global 
phylogeny here (Figure 3.13), with the New Zealand isolates clustering in the same way as the 
sequences from the rest of the world. Another discovery of Bart, Harris, et al. (2014) was that there 
was very little geographic clustering of strains; strains from all around the world were spread 
throughout the phylogeny. Likewise, Sealey (2015)’s investigation of UK strains showed little 
geographic specificity. In addition, studies of outbreaks such as those by Sealey et al. (2015) and 
Bowden et al. (2014) showed that strains circulating during outbreaks were polyclonal, and not 
characterised by a single hypervirulent outbreak strain. Conversely, an outbreak in Australia in the late 
2000s and early 2010s was found to be caused primarily by the circulation of a group of highly related 
strains (Octavia et al., 2012). 
Although some of the New Zealand isolates cluster throughout the global phylogeny along with strains 
from other countries, some notable groups (labelled Groups A-D) of highly similar New Zealand 
isolates stand apart. Groups A-C each contain nine New Zealand strains and one strain each from 
either Australia (Groups B and C) or Asia (Group A), all of which are identical in terms of core genome, 
or only one or two SNPs different. No other groups of this size, containing such similar strains, are 
seen in strains from any other country in the global phylogeny. Interestingly, the highly similar strains 
were not always isolated during the same year, and often not even during the same outbreak, 
although usually the majority of them were from outbreak periods (70% of Group A were isolated 
during the 2004-2006 or 2008-2011 outbreaks, 50% of Group B were isolated during the 2008-2011, 
2012 or 2017-2018 outbreaks, and 80% of Group C were isolated during the 2008-2011, 2012 or 2017-
2018 outbreaks), and all are from the post-2000 era. In each group, the strains are not only similar in 
terms of core genome SNPs, but also in serotype (where tested), RD4 presence or absence, PRN-
deficiency and, almost always, genomic arrangement. This suggests that it is not just a coincidence 
that the core genome SNPs are congruent, but that the genomic features of these strains are highly 
similar or identical as a whole.  
Group D contains four identical New Zealand strains, all from the 2017-2018 outbreak. The four strains 
can be separated into two pairs which were isolated in the same region and within the same 
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timeframe. Although this suggests that the similarities seen in this cluster could be explained by 
transmission of the same strain between patients, the fact that the two pairs were isolated in different 
regions from each other, and several months apart, could also indicate that the 2017-2019 outbreak, 
which was only observed in New Zealand, may have in part been the result of the circulation of a 
particularly virulent strain around the country. This theory is challenged by the fact that the other six 
isolates sequenced from the outbreak did not cluster with Group D; however, sequencing of more 
strains from the currently undersampled outbreak could be worthwhile.  
In case the clustering of New Zealand strains on the global tree was due to overrepresentation of New 
Zealand compared to any other country, further phylogenies were constructed for the four major 
outbreaks since 2000, each including a greater number of global strains from the outbreak period. As 
New Zealand’s closest neighbour, it seemed possible that strains from Australia would show most 
similarity to the strains from New Zealand, so extra Australian strains were included where possible. 
Indeed, in each of the outbreak trees, strains from Australia clustered most closely with the New 
Zealand strains, particularly during the 2004-2006 and 2012 outbreaks; as seen in the global tree, 
some of the Australian strains had highly similar or identical genetic characteristics to some of the 
New Zealand strains. This similarity with Australian strains supports the theory that outbreaks in New 
Zealand tend to be less polyclonal than those in the USA or UK, but simultaneously disagrees with the 
idea that New Zealand outbreaks are caused by hypervirulent strains which are unique to the country. 
Overall, the phylogenies suggest that, whilst the outbreaks in New Zealand are not caused by a single 
hypervirulent strain, there may be a higher than usual proportion of very similar or identical strains 
circulating in the country. These strains have been isolated during non-outbreak periods, although 
more often during outbreaks. It is possible that these groups of strains are more virulent than most B. 
pertussis, as hinted at by their overrepresentation during outbreak periods. Their circulation during 
non-outbreak years could therefore help to explain New Zealand’s seemingly permanent higher 
incidence of whooping cough than elsewhere in the world. However, such a phenomenon has not 
been observed in B. pertussis before, and there is no evidence in genetic screen here for enhanced 
virulence, with the clusters all showing allelic profiles and other characteristics which are in line with 
the global trends.  
The apparent trend for strain clusters seen here could be due to the small sample size, with only 63 
New Zealand strains, spanning nearly 40 years, included in the phylogenies. The phylogenies are based 
on shared core genome SNPs, and thus do not include all of the SNPs in each strain. It is therefore 
possible that the clustered strains look identical in their core genome, but are relatively dissimilar in 
the parts of the genome not included in the core phylogeny, although the other similarities identified 
here, such as genome arrangement, serotype and prn mutation, do suggest these strains are still 
closely related. Whether the clustered strains are identical or not, the global and outbreak trees show 
evidence that the New Zealand strains are more similar to each other than to strains from other 
countries, which is unusual. Not all New Zealand strains fall into clusters, however; some cluster 
throughout the phylogeny with strains from other countries, as seen with the UK strains in Sealey 
(2015). With sequencing of additional strains from New Zealand, it is possible that a different picture 
will emerge, with the majority of strains falling into the global spread and only a minority forming 
clusters. More strains have been collected and are stored by the ESR, but cost and other practical 




Further improvements to nanopore sequencing and data analysis 
One of the key findings from Chapter 2 was that, as nanopore sequencing library preparation kits, flow 
cells and data analysis tools continue to improve, sequencing pipelines will need to remain flexible. 
The sequencing here took place approximately 2 years after the sequencing runs in Chapter 2; in that 
time, flow cell yield had improved further, new library preparation kits had become available, and 
new, more accurate, data analysis tools had been developed. With that in mind, the rapid barcoding 
library preparation kit (SQK-RBK004) was used here, in place of the native barcoding ligation kit (SQK-
LSK109 with EXP-NBD104) used in Chapter 2.  
The rapid barcoding library preparation process takes a fraction of the time of the ligation library 
preparation, and does not require most of the third-party reagents used in the ligation protocol (for 
example, NEB’s end-repair enzymes), thus is also a fraction of the cost. In turn, the rapid kit tends to 
produce a lower sequencing yield; without the thorough DNA clean-up and repair steps of the ligation 
kit, fewer DNA strands make it to and through the nanopore intact. Additionally, the rapid kit uses a 
transposon-based mechanism to attach the sequencing adaptors and barcodes to the DNA strands, 
which can result in much shorter read lengths than the ligation kit (Heron, 2018). However, word-of-
mouth communication at nanopore community conferences suggested that yields of >10 Gb per flow 
cell were common with the rapid kit, if a high starting mass of DNA was used, and that read lengths 
could be maximised by skipping any DNA-shearing steps (Personal Communication, Nanopore 
Community Meeting 2018/London Calling 2019). Consequently, the rapid kit was trialled for the first 
sequencing run here, using 10 barcodes. Unsheared DNA was barcoded, and the entire pooled library 
was cleaned up and concentrated into the final sequencing mix using Promega ProNex SPRI beads, 
which were recommended as a cheaper and potentially more efficient alternative to the Agencourt 
AMPure XP beads used previously (P. Kover, Personal Communication). The yield of this run was over 
20 Gb, and the N50 was 14 kbp, both higher than the values achieved in Chapter 2. This method was 
therefore repeated for the remaining 56 strains, increasing the number of barcodes used to 12 for 
most of the runs. 
Similarly, some new data analysis tools were also used here. The Albacore basecaller used in Chapter 
2 was officially retired by ONT at the Nanopore Community Meeting in November 2018 (Oxford 
Nanopore Technologies, 2018b). Its reportedly more accurate successor, Guppy, was used here 
instead. Likewise, the demultiplexing tool used in Chapter 2, Porechop, became “officially 
unsupported” and was replaced with Deepbinner in October 2018 (Wick, 2017; Wick, Judd and Holt, 
2018b). Guppy and Deepbinner were therefore used in tandem to demultiplex the barcoded runs 
here, as Albacore and Porechop were in Chapter 2. Porechop was still used here, after basecalling and 
demultiplexing, to trim the adaptor and barcode sequences from the final read sets. The newer 
basecalling tools mean that the consensus accuracy of de novo assemblies has continued to improve, 
even since the analysis in Chapter 2. 41 of the hybrid assemblies here had a higher percentage identity 
than the most accurate assembly from Chapter 2 (99.69%), and 17 had the same percentage identity; 
in total, 92.1% (n=63) of the hybrid New Zealand assemblies were therefore at least as accurate, or 
more accurate, as the best UK hybrid assembly from Chapter 2.  
Summary 
The results of this chapter contribute to a growing body of knowledge surrounding the genomics of B. 
pertussis, particularly during whooping cough outbreaks, and how changes have occurred over time, 
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influenced by the introduction and alteration of vaccines. Whilst concrete conclusions cannot be 
drawn about the genetics of the circulating B. pertussis population in New Zealand from the sample 
of 66 strains, the isolates sequenced here represent the first from New Zealand to be sequenced and 
may help to understand the country’s ongoing unusually high incidence of whooping cough. In 
addition, this study demonstrates for the first time the utility of nanopore sequencing in conducting 
rapid and affordable B. pertussis strain screens, in combination with Illumina sequencing, particularly 
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- Neil Gaiman, Stardust 
(AKA, the negative results chapter) 
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4.1 Data summary 
1. Ultra-long nanopore reads are available from Figshare: 
https://figshare.com/s/ceef04fc644025a4638f  




Some UK Bordetella pertussis strains have unusual read mapping coverage 
Two of the B. pertussis strains sequenced during the initial nanopore pipeline development described 
in Chapter 2 were found to have unusual genomic features. A nanopore read set with a mean read 
length of over 5,000 bp was insufficient to produce a closed genome sequence for UK48. Instead, two 
contigs were produced: one 3.9 Mbp long and one 0.2 Mbp long. Further investigation revealed that 
this genome appears to contain a duplication of a region around 0.2 Mbp long, an “ultra-long” 
duplication. Surprisingly, we also found that the genome of UK76, which was closed using our standard 
nanopore reads, seemed to contain a potential duplication around the same region, around 0.3 Mbp 
long. These duplications were identified through mapping sequencing reads to the B. pertussis 
reference sequence, Tohama I, and calculating the depth of coverage at each base position. The 
expected result was relatively level coverage across the entire reference sequence, whereas the 
duplications appeared as enhanced coverage, as seen for UK36 in Figure 4.1. We also noted that 
duplications at the same region, which contains many motility-related genes, had previously been 
noted in a small number of other studies (Caro et al., 2006; Heikkinen et al., 2007; Weigand et al., 
2016; Weigand et al., 2018). 
Figure 4.1  Illumina short reads for Bordetella pertussis UK36 mapped to the Tohama I reference genome. 
Coverage is steady across the whole genome, apart from one small section around 2.6 Mb (this section 
represents two genes which are found in duplication in a large number of non-Tohama strains (Abrahams et 




Figure 4.2 The five UK B. pertussis strains which 
show unusual coverage features when 
sequencing reads are mapped to the Tohama I or 
B1917 reference genome, visualised using a 
rolling-window of 400 bp. Further details were 
also generated using CNVnator; these are shown 
in Table 4.1 
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Work by Abrahams et al. (In review) aiming to catalogue duplications in all Illumina-sequenced B. 
pertussis strains available from the NCBI database showed that almost one hundred other strains from 
around the world also had a genomic duplication at the same locus as UK48 and UK76. In Abrahams 
et al., a pipeline is developed which uses CNVnator (Abyzov et al., 2011) to identify copy number 
variants by mapping Illumina reads to a more recent clinical reference strain, B1917. The application 
of this pipeline to all available high-quality B. pertussis lllumina sequencing data from the NCBI 
database showed that 94 strains share copy number anomalies around the same locus, with a shared 
core duplicated region of 71,000 bp, centred around the Bordetella motility locus (BP1366-BP1411). 
Five of these strains were isolated during the UK 2012 whooping cough outbreak, including UK48 and 
UK76 (Figure 4.2). Table 4.1 shows further details for all five strains, including CNVnator-predicted start 
and end bases of the CNV compared to the Tohama I reference genome, length of the predicted CNV, 
and the depth of the coverage enhancement seen. 119 genes are common to all five strains, from 
BP1308 to BP1450, spanning 148 kbp. Supplementary table S4.1 shows the full details of the genes in 
the shared region. 
The enhanced coverage for UK48 and UK92 is a clear 1.9x and 1.7x higher respectively than for the 
rest of the reference genome, suggesting that this portion of the genome is duplicated in these strains. 
The remaining strains, however, have less clear coverage enhancements. CNVnator shows the 
coverage of the potentially duplicated sections in UK65, UK76 and UK90 as a range; the range is 
centred around 2.0 in UK65 and UK90, and around 1.5 in UK76. This unusual distribution may be 
caused by the second copy of the region containing variants such as SNPs, thus preventing the  
mapping of reads to this region. Alternatively, and more likely in the case of UK76, the duplication may 
not be carried by all cells in the population: in UK76, half the cells carrying and half the cells not 
carrying the duplication would explain the observed 1.5x enhancement in coverage. It should be noted 
that CNVnator indicates a higher coverage enrichment in the UK76 reads than a simple visual review 
of the coverage graphs in Figure 4.2; the UK76 coverage graph suggests an enrichment of 1.25x 
compared to the 1.5x enrichment assigned by CNVnator. CNVnator’s more thorough method of 
identifying CNVs, which includes optimisation of rolling-window size to ensure cleaner estimations of 
start and end bases, means that the true level of coverage enrichment is more likely to be closer to 
1.5x than 1.25x. 
Short (150 bp) Illumina sequencing reads are not able to resolve the duplications in either UK48 or 
UK76 during de novo assembly, and nor were nanopore sequencing reads with a mean length of 5,000 
bp. Theoretically, to resolve a long repetitive region, reads longer than the longest repeat will likely 
be required (Chin et al., 2013; Conlan et al., 2014; Koren and Phillippy, 2015; Loman, Quick and 
Simpson, 2015; Wick et al., 2017a; Jain, Koren, et al., 2018; Jain, Olsen, et al., 2018; Schmid et al., 
2018). This chapter details attempts to characterise the ultra-long duplication shared by these five UK 
B. pertussis strains, via assembly of fully resolved genome sequences, followed by investigation of 
likely phenotypic consequences of the duplication. 
Table 4.1 Five UK B. pertussis strains identified as having unusual reference genome coverage 
Strain SRA accession Start / bp* End / bp* Length / kbp Depth 
UK48 ERR212388 1351001 1525000 174 1.9 
UK65 ERR304786 1342201 1562400 220 1.9 - 2.3 
UK76 ERR316415 1377076 1681400 304 1.4 - 1.5 
UK90 ERR305956 1376401 1524800 148 1.6 - 1.9 
UK92 ERR305958 1242151 1673490 431 1.7 
*The start and end position of the duplication in the reference genome was estimated here using by 




4.3 Research questions 
Research question 1: Can ultra-long reads, longer than the predicted duplications observed in 
several UK B. pertussis strains, be used to assemble closed genome sequences which contain two full 
copies of the duplicated region? 
Research question 2:  Does the commonly observed duplication centred around the Bordetella 
motility locus result in observable phenotypic changes to duplication-carrying B. pertussis strains? 
 
4.4 Methods 
Bacterial strains and culture conditions 
The strains used in this chapter are shown in Table 4.2. Strains were stored at -80oC in PBS/20% glycerol 
prior to growth. Unless otherwise stated, B. pertussis strains were grown on charcoal agar (Oxoid) for 
72 hours at 37oC or cultured in Stainer-Scholte (SS) broth with supplement (recipes shown in Tables 
4.3 and 4.4) at 37oC with shaking at 180 rpm. B. bronchiseptica strains were grown on charcoal agar 
for 24 hours at 37oC or cultured in SS broth with supplement at 37oC with shaking.  
Ultra-long nanopore sequencing 
Prior to gDNA extraction, B. pertussis isolate UK48 was stored at -80oC in PBS/20% glycerol at the 
University of Bath. Cells were grown for 72 hours at 37oC on charcoal agar (Oxoid) plates. Harvested 
cells were resuspended in 10 ml SS broth with supplement, to an OD600 of 0.1 and grown overnight. At 
approximately OD600 1.0, cultures were further resuspended in 50 ml SS broth with supplement, to an 
OD600 of 0.1 and grown again overnight. Ultra-long gDNA was then extracted from UK48 using the 
standard ultra-long extraction protocol developed by Josh Quick (Quick, 2018). 
After growth to OD600 1.0, all 50 ml of culture was pelleted by centrifugation at 13 000 g for 5 minutes 
and taken forward to ultra-long gDNA extraction. The full protocol is available from 
dx.doi.org/10.17504/protocols.io.mrxc57n (Quick, 2018), but is essentially a phenol-chloroform gDNA 
extraction which aims to avoid pipetting and/or vigorous mixing where possible. Briefly, the pellet was 
resuspended in 200 µl PBS and 10 ml TLB (100 mM NaCl, 10 mM Tris-HCl pH 8.0, 25 mM EDTA pH 8.0,  
Table 4.2 Strains used in this work 
Strain Description Reference 
B. pertussis Tohama I WT Parkhill et al. (2003) 
B. pertussis UK48 Duplication-carrying Sealey et al. (2015) 
B. pertussis UK65 Duplication-carrying Sealey et al. (2015) 
B. pertussis UK71 Non-duplication-carrying control, 
similar to UK48 
Sealey et al. (2015) 
B. pertussis UK76 Duplication-carrying Sealey et al. (2015) 
B. pertussis UK90 Duplication-carrying Sealey et al. (2015) 
B. pertussis UK92 Duplication-carrying Sealey et al. (2015) 
B. bronchiseptica RB50 WT Cotter and Miller (1994) 
B. bronchiseptica RB53 Phase-locked Bvg(+) derivative of 
RB50 
Cotter and Miller (1994) 
B. bronchiseptica RB54 Phase-locked Bvg(-) derivative of 
RB50 
Cotter and Miller (1994) 
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Table 4.3 Stainer-Scholte Broth. Chemicals were dissolved in 900 ml distilled H2O, adjusted to pH 7.6 with 
NaOH and/or HCl, topped up to the final volume (1 L) with distilled H2O, and filter-sterilised. SS broth was 
stored at 4oC or room temperature. 
Reagent Molecular weight / g 
mol -1 
Final concentration / mM Mass / g 
Casamino acids    10 
L-glutamic Acid (Na salt)  187.7 57  10.70 
L-proline  115.1 2.1 0.24 
NaCl  58.44 43  2.5 
KH2PO4  136.1 31  0.5 
KCl 74.56 2.7  0.2 
MgCl2.6H2O 203.3 0.49  0.1 
CaCl2.2H2O 147.0 0.18  0.0265 
Tris base 121.14 50 6.1 
Heptakis (if required, for 
B. pertussis only) 
  1 
 
Table 4.4 Stainer-Scholte supplement. 10 ml of 100X supplements were used per 1 L SS broth, adding 
immediately prior to use. Chemicals were dissolved in distilled H2O and filter-sterilised. SS supplement was 
stored at -20oC. 
Chemical Molecular weight / g mol -1 Final concentration (in 1x) g in 10 ml 
L-Cysteine 121.2 0.33 mM 0.04 
FeSO4.7H2O 278.0 36 M 0.01 
Niacin 123.1 33 M 0.004 
Glutathione 307.3 0.49 mM 0.15 
Ascorbic acid 176.1 2.3 mM 0.40 
 
0.5% w/v SDS, 20 µg ml-1 Qiagen RNase A), vortexed for 5 seconds at full speed and incubated for 1 h 
at 37oC to lyse the cells.  
After lysis, 100 µl proteinase K (Qiagen) was added (final concentration of 200 µg ml-1), mixed by slowly 
rotating three times, and incubated for 2 h at 50oC, with gentle mixing by rotation every 30 minutes. 
The lysate was split between two 15 ml Falcon tubes containing light phase-lock gel (VWR), 5 ml TE-
saturated phenol (Sigma Aldrich) was added, and the tubes were mixed for 10 minutes at 20 rpm on 
a HulaMixer (Invitrogen) followed by centrifugation for 10 minutes at 4500 rpm. The top, aqueous 
phase, was then poured into two new 15 ml Falcon tubes also containing phase-lock gel, avoiding the 
transfer of any protein layer. A further 2.5 ml TE-saturated phenol and 2.5 ml chloroform-isoamyl 
alcohol (Sigma Aldrich) were added, and the tubes were mixed on a HulaMixer for 10 minutes at 20 
rpm followed by centrifugation for 10 minutes at 2,400 g. The aqueous phases from both tubes were 
collected by pouring slowly into a 50 ml Falcon tube. 
4 ml 5 M ammonium acetate (Sigma Aldrich) was added, followed by 30 ml ice-cold ethanol to 
precipitate the DNA. After the DNA floated to the top of the tube, it was spooled out gently, using a 
hook crafted from a melted glass rod. The spooled DNA was submerged in 70% ethanol to wash and 
tighten the pellet whilst still on the hook, then worked off the hook into a 1.5 ml Eppendorf tube. Two 
washes were performed as follows: 1 ml 70% ethanol was added to the Eppendorf, the tube was spun 
for 1 minute at 10,000 g, and the ethanol was removed. The remaining ethanol was allowed to 
evaporate for 15 minutes at room temperature with the lid open, 100 µl buffer EB (10 mM Tris-HCl pH 
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8.0, 0.02% Triton-X100) was added, and the DNA was left at 4oC for at least a week to resuspend. The 
resuspended DNA was then quantified via Qubit and taken forward to rapid (SQK-RAD004) library 
preparation. 
The concentration of the ultra-long gDNA was adjusted to 1 µg µl-1 and left overnight at 4OC to 
resuspend. 1.5 µl fragmentation mix (FRA, ONT) and 3.5 µl EB were added, and mixed by very slowly 
pipetting up and down 8 times using P20 pipette set to 18 µl and P20 tip with the end cut off to reduce 
shearing. After mixing, the mixture was incubated for 1 minute at 30OC and 1 minute at 80OC. 1 µl 
rapid adaptor (RAP, ONT) was added, and mixed by very slowly pipetting up and down 8 times using 
a P20 pipette set to 19 µl and the cut-off tip from before. 
The library was incubated at room temperature whilst a flow cell was prepared as per ONT’s 
instructions. To load the library, 34 µl sequencing tether (SQT, ONT) and 20 µl nuclease-free H2O were 
added, and the library was mixed by very slowly pipetting up and down 5 times using a P200 set to 75 
µl and P200 tip with the end cut off. On the final mix, the library was slowly pipetted drop-wise onto 
the flow cell.  
Ultra-long gDNA nanopore sequencing libraries were sequenced for 48 hours on a GridION sequencer 
using R9.4 flow cells. Reads were basecalled with Nanopore’s Guppy basecaller (V2.1.3), using the 
“fast” Flip-flop model.    
De novo assembly of ultra-long reads 
A variety of de novo assembly tools optimised for long reads were trialled with different combinations 
of the ultra-long reads produced for UK48, alone, in combination with the standard nanopore long 
reads from Chapter 2, and in hybrid with the Illumina reads from Chapter 2. The tools trialled were 
Canu (v1.7.1), Flye (v2.3.5), MaSuRCA (v3.2.7), SPAdes (v3.12.0), Unicycler (v0.4.6) and 
Wtdbg2/Redbean (v2.0) (Bankevich et al., 2012; Koren et al., 2017; Wick et al., 2017b; Zimin et al., 
2017; Kolmogorov et al., 2019; Ruan and Li, 2019). Read sets trialled included the full set of ultra-long 
UK48 reads, 40X coverage of the UK48 genome in ultra-long reads corrected by Canu and ultra-long 
reads longer than 100 kbp, 174 kbp and 348 kbp (the latter being the predicted length of a single copy 
and tandem copies of the duplicated region, respectively). See Table 4.5 for full set of trials.   
Each assembly was assessed for contiguity. If a single closed sequence had been assembled, copy 
number of several genes predicted to be located throughout the duplicated region (shown in Table 
4.6) was checked using blastn.  
Validating the duplication without de novo assembly 
In addition to validating the presence of the UK48 duplication through de novo assembly of the ultra-
long nanopore sequencing reads, an alternative strategy was developed for in silico assembly of closed 
genomes. This strategy, shown in Figure 4.3, requires a single contig assembly of the genome to have 
been achieved, albeit with only a single copy of the duplicated region, such as the hybrid UK48 
assembly produced in Chapter 2. It assumes that the duplications occur in tandem. First, CNVnator 
was used to predict the start and end bases of the duplicated region, allowing the whole sequence of 
the duplicated region to be extracted from the reference genome using SAMtools faidx (Li et al., 2009). 
Due to the ongoing inter-strain genome rearrangements in B. pertussis, the duplication was unlikely 
to be in the same genomic position in UK48 as in the reference genome. Thus, the location of the 
duplicated region in UK48 was found using blastn to search for the duplication sequence in the draft,   
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Table 4.5 Assembly strategies trialled using UK48 ultra-long reads 
Read correction Assembly Hybrid? Read subset 
None Canu No All ultra-long 
None Flye No All ultra-long 
None MaSuRCA No All ultra-long 
None Unicycler No All ultra-long 
None Wtdbg2 No All ultra-long 
None Canu No All ultra-long plus standard long reads from Chapter 2 
None Flye No All ultra-long plus standard long reads from Chapter 2 
None MaSuRCA No All ultra-long plus standard long reads from Chapter 2 
None Unicycler No All ultra-long plus standard long reads from Chapter 2 
None Wtdbg2 No All ultra-long plus standard long reads from Chapter 2 
Canu  Canu No Ultra-long, 40X Canu-corrected 
Canu  Flye No Ultra-long, 40X Canu-corrected 
Canu  MaSuRCA No Ultra-long, 40X Canu-corrected 
Canu  Unicycler No Ultra-long, 40X Canu-corrected 
Canu  Wtdbg2 No Ultra-long, 40X Canu-corrected 
None Canu No Ultra-longs longer than 100 kbp 
None Flye No Ultra-longs longer than 100 kbp 
None MaSuRCA No Ultra-longs longer than 100 kbp 
None Unicycler No Ultra-longs longer than 100 kbp 
None Wtdbg2 No Ultra-longs longer than 100 kbp 
None Canu No Ultra-longs longer than 174 kbp (predicted duplication length, 
one copy) 
None Flye No Ultra-longs longer than 174 kbp (predicted duplication length, 
one copy) 
None MaSuRCA No Ultra-longs longer than 174 kbp (predicted duplication length, 
one copy) 
None Unicycler No Ultra-longs longer than 174 kbp (predicted duplication length, 
one copy) 
None Wtdbg2 No Ultra-longs longer than 174 kbp (predicted duplication length, 
one copy) 
None Canu No Ultra-longs longer than 348 kbp (predicted duplication length, 
both copies in tandem) 
None Flye No Ultra-longs longer than 348 kbp (predicted duplication length, 
both copies in tandem) 
None MaSuRCA No Ultra-longs longer than 348 kbp (predicted duplication length, 
both copies in tandem) 
None Unicycler No Ultra-longs longer than 348 kbp (predicted duplication length, 
both copies in tandem) 
None Wtdbg2 No Ultra-longs longer than 348 kbp (predicted duplication length, 
both copies in tandem) 
Canu  SPAdes Yes All ultra-longs plus Illumina from Chapter 2 
Canu  Unicycler Yes All ultra-longs plus Illumina from Chapter 2 
Canu  SPAdes Yes 40X Canu-corrected ultra-longs plus Illumina from Chapter 2 
Canu  Unicycler Yes 40X Canu-corrected ultra-longs plus Illumina from Chapter 2 
None SPAdes Yes Ultra-longs longer than 174 kbp (predicted duplication length, 
one copy) plus Illumina from Chapter 2 
None Unicycler Yes Ultra-longs longer than 174 kbp (predicted duplication length, 
one copy) plus Illumina from Chapter 2 
None Canu No Only ultra-longs spanning the duplicated region 
None Flye No Only ultra-longs spanning the duplicated region 
None MaSuRCA No Only ultra-longs spanning the duplicated region 
None Unicycler No Only ultra-longs spanning the duplicated region 
None Wtdbg2 No Only ultra-longs spanning the duplicated region 
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non-duplication-resolved, assembly sequence. This also allowed the exact sequence of the duplicated 
region in UK48 to be identified, in case of SNPs between UK48 and the reference. Using the sequence 
and locus of the duplicated region, a second copy of the region was inserted immediately after the 
original, creating an “in silico resolved” genome containing both copies of the duplication. To check 
that the artificially resolved genome was correct, the ultra-long reads were mapped to it. If reads 
mapped to the entire genome sequence, including the unique junction that would only exist if two 
copies of the same region were present in tandem, the sequence was accepted as correct.  
Throughout the following phenotyping tests, two strains were compared: UK48 and UK71. The UK48 
genome contains the common duplication, and the UK71 genome does not. This pair of strains was 
chosen as they are part of the PERISCOPE strain panel which will undergo thorough testing in the 
future (Diavatopoulos et al., 2018). To select the strains to be included in this panel, a B. pertussis core 
genome was constructed, and UK48 and UK71 were estimated to differ by only 6 SNPs within this core 
genome (Personal Communication, J. Abrahams, 2019). This was validated by adding UK48 and UK71 
Table 4.6 Genes used to assess copy number of the duplicated region in assembly drafts 
Gene Identifier  Gene name 
BP1280 pyrroline-5-carboxylate reductase 
BP1301 glutathione S-transferase 
BP1339 cardiolipin synthase 
BP1373 Flagellar basel body rod protein, flgB 
BP1425 1-deoxy-D-xylulose 5-phosphate reductoisomerase  
Figure 4.3 Steps in alternative in silico assembly strategy 
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to the global phylogeny from Chapter 3; of 508 core SNPs in this phylogeny, all but 6 were indeed 
shared by UK48 and UK71. UK71 was therefore used as a no-duplication control for UK48.  
Motility assays 
The motility of selected B. pertussis and B. bronchiseptica strains was tested using a method described 
by Hoffman et al. (2019).  Strains were grown on charcoal agar with (Bvg(-)) or without (Bvg(+)) 50 
mM MgSO4 for 24 (B. bronchiseptica) or 96 (B. pertussis) hours.  This growth was used to inoculate 10 
ml SS broth plus supplement plus 1 g/l heptakis (Sigma) with (Bvg(-)) or without (Bvg(+)) 50 mM MgSO4 
to OD600 0.25. The cultures were grown for 20 hours at 37oC. At 18 hours, fresh soft agar motility plates 
were prepared from 15 ml SS broth with supplement and 1 g/l heptakis (with or without 50 mM 
MgSO4) plus 0.4% agar and 1% fetal bovine serum and left to set with lids open in a safety cabinet. At 
20 hours, the cultures were diluted to OD600 = 0.80. 2 µl of the diluted culture was stabbed into the 
middle of the motility agar. The motility plates were grown lid-up at 37oC for 24 (B. bronchiseptica) or 
72 (B. pertussis) hours, after which any growth was measured in mm from the centre of the stab-point. 
 
4.5 Results 
Ultra-long sequencing reads did not facilitate de novo assembly  
There is no theoretical upper limit to the length of DNA strand that can be sequenced using Oxford 
Nanopore Technology sequencers. A phenol-chloroform DNA extraction method alongside modified 
nanopore library preparation, both with as little pipetting as possible, was used to maximise DNA 
fragment length. A preliminary run employing this ultra-long read approach yielded 1.2 Gb, 300x 
coverage of the UK48 genome. Although the mean read length was only 31,000 bp, over 100x 
coverage was produced in reads longer than 100,000 bp.  
Assuming the length of the duplication in UK48 to be 174 kbp (Table 4.1), reads longer than 174, 000 
bp will be required to span each copy of the duplicated section or, if the duplication is in tandem, 
longer than 348,000 bp to span the entire region. The ultra-long read sequencing yielded 30x coverage 
of the UK48 genome in reads longer than 174,000 bp, but only 2.5x coverage in reads longer than 
348,000 bp. The optimal coverage required for de novo assembly has previously been shown to be 
around 50x (Desai et al., 2013), hence the 30x or 2.5x coverage produced was unlikely to be sufficient, 
particularly for so complex a region. 
Nevertheless, a variety of de novo assembly strategies was trialled, as detailed in the Section 4.5, and 
Supplementary table S4.4. None of these strategies produced an error-free, closed UK48 contig. The 
two best assemblies were produced by Unicycler with the ultra-long reads and Illumina reads, and by 
Wtdbg using Canu-corrected ultra-long reads. The Unicycler assembly consisted of two contigs: one 
was 3.9 Mb (the majority of the genome), whilst the other was 178 kbp (around the predicted size of 
the duplicated region). In fact, the hybrid Unicycler assembly produced using ultra-long and Illumina 
reads together was almost exactly the same as a Unicycler hybrid assembly produced using regular 
barcoded nanopore reads together with Illumina reads in Chapter 2. Seemingly, Unicycler recognises 
the existence of the duplication in the nanopore reads but has not yet been given enough information 
to fully resolve its layout. The Wtdbg2 assembly was a single contig but, on closer inspection, did not 
contain full duplicated copies of the genes predicted to occur in the region of interest, and had sections 
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to which none of the ultra-long reads aligned; it was thus concluded that this contig was 
misassembled. As expected, the yield of ultra-long UK48 reads was not sufficient to resolve the 
duplication; an extra ~160 Mb of reads longer than 300 kbp may be required.  
After none of the de novo assembly tools produced an error-free closed UK48 contig which included 
two copies of the duplicated region, de novo assembly was attempted just for the region of the 
duplication, using reads which mapped to the region alone, with Canu, Flye, MaSuRCA, Unicycler and 
Wtdbg2. These trials were also unsuccessful. 
In silico duplication resolution is possible for some strains 
An alternative resolution strategy does seem to work with the current set of ultra-long reads, 
however. The steps of this alternative method are shown in Figure 4.3, and involve creating an 
artificially resolved copy of the genome in silico, using the output from CNVnator and the nanopore-
only Flye genome assembled using reads with a mean length of 5,000 bp, followed by polishing with 
Illumina short reads using Pilon. This strategy involves two major assumptions: that the two copies of 
the duplicated section occur in tandem, and that the copies of the duplication are identical. However, 
both assumptions can be validated by aligning the ultra-long reads to the in silico draft; if the 
Figure 4.4  a) An artificially resolved draft of the whole UK48 genome was generated using CNVnator output. b) Ultra-long 
reads were mapped to the in silico draft assembly using Minimap2 and SAMtools, then visualised using Tablet. This 
visualisation shows that the junction between the two copies of the region is present in the ultra-long reads; this junction 
would only exist if the duplication was correctly assembled 
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assumptions are correct, the artificial genome will have been correctly assembled, and the ultra-long 
reads will correctly align, using Minimap2 (Li, 2017),  to every base along the whole genome, as 
visualised using SAMtools (Li et al., 2009) and Tablet (Milne et al., 2013). Figure 4.4 shows that this 
strategy was successful for UK48: multiple reads existed which spanned both copies of the duplicated 
region, including the junction between the two, the sequence at which would be present in the reads 
only if the in silico genome was assembled perfectly. There were no obvious differences, such as SNPs 
or indels, between the reads which aligned to the two copies of the duplicated region. However, the 
in silico assembly strategy shown in Figure 4.3 was unsuccessful for the UK76 reads; no reads mapped 
to the predicted junction between the two copies of the region, suggesting the start or end point of 
the duplication was mispredicted by CNVnator. 
No recent UK B. pertussis strains appear to be motile in the conditions tested here 
All five UK strains carrying the ultra-long duplication (UK48, UK65, UK76, UK90 and UK92) were tested 
for motility, using a motility assay developed by Hoffman et al. (2019). In addition, UK71 was tested; 
UK71 has a SNP profile very similar to UK48, but UK48 has the duplication and UK71 does not. B. 
bronchiseptica strain RB54, which is a Bvg(-) phase-locked mutant, was used as a positive control for 
both Bvg conditions.  
As expected, the Bvg(-)-locked B. bronchiseptica mutant was positive for motility in both 0 mM MgSO4 
and 50 mM MgSO4. However, none of the B. pertussis strains tested were positive for motility in either 
Bvg condition. In both conditions, some cells grew out of the hole into which they had been stabbed, 
as shown in Figure 4.5. This was particularly noticeable for the 50 mM MgSO4 plates, likely because B. 
pertussis cells grow more quickly in Bvg(-) conditions (Belcher, 2017).  
2 µl overnight culture for each strain was also viewed on a microscope slide: B. bronchiseptica RB54 
cells could be observed to move across the field of view, but no such movement was observed for any 
B. pertussis cells. Because motility was not observed for any B. pertussis strains in the conditions used 
here, no further comparisons of motility phenotype between duplication-carrying and non-
duplication-carrying strains were possible.  
4.6 Discussion 
Resolving ultra-long duplications is not an easy task 
Ultra-long reads were unable to resolve the duplication in UK48. Perhaps 30X coverage is insufficient 
for de novo assembly of such long duplications, or longer reads still are required. Phenol-chloroform 
methods to extract ultra-long gDNA have continued to be refined, commonly producing data sets with 
an N50 greater than 100 kbp, and read lengths approaching 1 Mb (Jain, Koren, et al., 2018). More 
recently, agarose plug-based extraction methods have been developed, which can achieve read 
lengths upwards of 2 Mb (Payne et al., 2019). These methods may produce longer UK48 reads, or a 
higher coverage of the genome in reads as long as the duplication, potentially permitting resolution 
of the ultra-long repetitive region.  
Ultra-long reads were also used to attempt to resolve a high copy number CNV in a different UK strain, 
UK54, in Abrahams et al. (In review). Although this CNV was much shorter at around 15 kbp, full 
resolution of the repetitive region did not prove to be possible. In the case of UK54, however, there 
existed a highly mixed population in which cells could contain between one and five (or more) copies 
of the region in question. If different reads contain different numbers of the region, no matter how  
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ultra-long they are, embly tool will be able to correctly resolve the genome. Such a mixed                           
Figure 4.5 Motility assays showed no motility phenotype in any UK B. pertussis strains test. Bacteria edwere grown on charcoal agar 
plates with (Bvg(-)) or without (Bvg(+)) 50 mM MgSO4 for 24 (B. bronchiseptica) or 96 (B. pertussis) hours. Growth from each plate 
was used to inoculate 10 ml SS plus supplement (with or without MgSO4) to 0.25 OD600. This was then incubated at 37 oC with shaking 
until 0.9 ± 0.1 OD600. 2 µl of growth was stabbed in triplicate into 15 ml motility agar (0.4% agar, SS plus supplement (with or without 
50mM MgSO4), 10% FBS) and the motility plates were grown at 37 oC for 24 (B. bronchiseptica) or 96 (B. pertussis) hours.  
A phase-locked Bvg(-) B. bronchiseptica mutant, RB54, was used as a positive control for motility in both growth conditions, and all 
repeats showed motile behaviour. None of the B. pertussis samples appeared to be motile in either Bvg(+) or Bvg(-) conditions, 
although some cells grew out of the stab-hole onto the surface of the agar (particularly in the Bvg(-) conditions), as shown here for 
UK48 and UK71.  
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ultra-ultra-long they are, no assembly tool will be able to correctly resolve the genome. Such a mixed 
population has not been observed in UK48, but could be an alternative explanation for the inability 
using ultra-long reads to resolve the “motility” duplication.  
In contrast, the “in silico resolved” UK48 genome was ostensibly assembled correctly. However, this 
in silico assembly method requires a level of manual intervention which would preclude high-
throughput genome assembly, as well as being based on a number of assumptions, most notably that 
the duplication occurred in tandem and that neither copy was inverted. It also required CNVnator to 
predict the exact start and end bases of the duplicated region correctly. When tested on UK76, the 
method was not successful in producing an artificially resolved genome; the UK76 ultra-long reads did 
not map to the junction between the two copies of the duplicated region. This was probably due to 
the numerous different versions of the duplication which existed in different cells in the UK76 
population (Abrahams et al., In review). If all non-integer CNV predictions are due to the presence of 
a mixed population within the strain, where some cells carry the duplication and others do not, and 
where some cells can carry slightly different versions of the duplication, as noted in Abrahams et al., 
this in silico assembly method is unlikely to be effective for resolving the genomes of most duplication-
carrying strains, including UK65, UK90 and UK92. Given the equal failure of ultra-long reads to produce 
de novo assembled resolved genomes, the most effective method of resolving these ultra-long 
duplications remains the optical genome mapping method technique used by the CDC, despite the 
additional cost this technique presents. Nonetheless, ongoing improvements to ultra-long sequencing 
protocols towards single read sequencing of entire microbial genomes may enable easy resolution of 
ultra-long duplications and in depth investigation of any intra-strain genomic variations (Payne et al., 
2018b; Long Read Club, 2019).  
Does duplication of the flagellar locus result in extra-motile Bordetella pertussis? 
B. pertussis has traditionally been described as a non-motile bacterium which is unable to produce 
flagella, despite its genome containing the 24 core flagella genes observed across all motile bacteria 
(Liu and Ochman, 2007). The ancestor of B. pertussis, Bordetella bronchiseptica, has the same set of 
core flagellar genes, and has been shown to both produce flagella and display motile behaviour when 
in the Bvg(-) phase (Akerley et al., 1992). In the B. pertussis genome, however, the flagella biosynthesis 
gene flhA contains a premature stop, 1313 codons into the 2119-codon gene (Parkhill et al., 2003). In 
other bacteria, including B. bronchiseptica, the flagella also play a role in biofilm formation (Klausen 
et al., 2003; Diaz et al., 2011; Nicholson, Conover and Deora, 2012; Fong and Yildiz, 2015). However, 
over the last decade, it has been shown repeatedly that B. pertussis is still able to form biofilm, in spite 
of its supposedly truncated FlhA protein (Irie, Mattoo and Yuk, 2004; Serra, D. et al., 2007; Serra, D.O. 
et al., 2011; Nicholson, Conover and Deora, 2012; Burns, Meade and Messionnier, 2014; Cattelan et 
al., 2016).  
The unexpected ability of B. pertussis to form biofilm led Hoffman et al. (2019) to question whether 
B. pertussis could potentially by motile after all, under the right conditions. They discovered that the 
“B. pertussis is a non-motile bacterium” dogma essentially dated back to a single experiment in the 
1980s, during which Dr. Jeffrey Miller tested the motility of both B. pertussis and B. bronchiseptica 
using the standard clinical motility agar, which contained pancreatic digest of gelatin, sodium chloride, 
beef extract and agar (Stiles and Ng, 1981). It has subsequently been discovered that B. pertussis 
cannot grow in the presence of gelatin; however, the non-growth of B. pertussis during this original 
motility test, combined with the premature stop codon in flhA, has generally been taken as evidence 
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that B. pertussis is both non-motile and non-flagellated, despite the later discovery regarding the 
motility and flagellation of B. bronchiseptica when grown in a different medium in Bvg(-) conditions. 
Hoffman et al. therefore re-tested the motility and flagellation of B. pertussis in a variety of strains 
and conditions, using the standard Bordetella in vitro growth media, Bordet-Gengou agar 
supplemented with 15% sheep blood for initial growth, and soft agar comprised of Stainer-Scholte 
broth plus 0.4% agar for the motility test (Bordet and Gengou, 1906; Stainer and Scholte, 1970).   
Hoffman et al. found that certain strains of B. pertussis were motile in Bvg(-) conditions, including a 
mutant phase-locked Bvg(-) B. pertussis strain, BP347, several lab-adapted strains, such as BP338, 
Bpe60 and BPSM, and several clinical strains, such as V015, UVA010 and UVA052. At the same time, 
nearly half of the isolates tested (9/22) did not display motile behaviour in Bvg(-) conditions. The 
motility displayed by the “motile” strains was also not consistently seen in every trial. Hoffman et al. 
concluded that some unknown other genetic or environmental factor may contribute to B. pertussis 
motility, alongside the BvgAS two-component system. The duplication of motility genes seen in UK48 
and other UK strains here could be one such genetic factor. However, no motility was observed in any 
of the UK strains tested, although the B. bronchiseptica reference strains RB50, RB53 and RB54 all 
displayed the expected motile behaviour. If the duplication of the flagellar locus in these strains does 
influence motile behaviour, there may be an additional factor involved which was not discovered here. 
What other phenotypes could result from the duplication seen in the UK strains studied 
here? 
As shown in Supplementary Table S4.1, the duplicated region differs in length in each of the five UK 
strains studied here. However, a set of 119 genes is duplicated in all of them. The flagella locus, 
BP1366-1411, includes almost 40 genes, thus representing around 33% of all of the genes duplicated 
in the UK strains. Extending to all of the strains in which a duplication was found at the same locus in 
Abrahams et al. (In review), the core shared region decreases in size, and the portion of the duplication 
consisting of flagellar and motility-related genes therefore increases to almost a half. If any phenotype 
results from this duplication, it therefore seemed likely that it might be related to motility. As already 
discussed, however, no motility has yet been observed in any strain carrying this duplication. Could 
the duplication result in a different phenotype instead? 
No other such obvious groups of related genes are present in the duplicated locus. Indeed, many of 
the other genes in the core duplication are not well characterised, being labelled simply as “membrane 
protein” or “hypothetical protein”. Nonetheless, a few genes of interest include those involved in 
metabolism, such as acyl-CoA dehydrogenase, enoly-CoA hydratase, and 3-hydroxyisobutyrate 
dehydrogenase (BP1445-1447), or membrane biosynthesis, such as lpxA and lpxB (BP1431-BP1432). It 
is possible, therefore, that the duplication may result in a phenotype which could be observed in the 
growth behaviour of the duplication-carrying bacteria.  
A number of growth assays were undertaken (data not shown) to compare the growth dynamics of 
UK48 with those of UK71, which does not possess the duplication. Unfortunately, these clinical strains 
are not lab-adapted, and do not grow well in vitro. Growth rates in SS media in 24-well plates, 96-well 
plates, and 250 ml acid-washed flasks, were unpredictable. No growth was seen in Bvg(+) or Bvg(-) 
conditions on either type of plate, and growth in acid-washed flasks was irreproducible, with each 
repeat behaving differently. Even the addition of heptakis, a cyclodextrin which sequesters molecules 
released by the bacteria as they grow, and which can hence often help unstable B. pertussis 
populations to grow in the absence of blood media (MacArthur et al., 2019), was unsuccessful for 
these strains. Unfortunately, this irreproducible growth meant that planned comparisons of the 
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expression of duplicated genes by qPCR was not possible here. It is feasible that, with time, conditions 
under which the strains grow predictably and reproducibly could be identified. However, this kind of 
growth optimisation was beyond the scope of this study. Additionally, the benefit conveyed by the 
duplication (if any) may be masked by any growth conditions which allow even the least lab-adapted 
bacteria to grow well in vitro.  
Ultimately, although no phenotype relating to the commonly seen ultra-long duplication could be 
identified here, the existence of such a large duplicated region in so many seemingly unrelated B. 
pertussis isolates suggests that there could indeed be a benefit to carrying more than one copy of one 
or more of the genes in the region. This benefit could be in the form of enhanced motility, or might 
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“One thing I have learned is that humans cling to their first knowledge of you, particularly if they 
have no experience of you once you’ve changed.” 




A picture of accelerated genetic changes and increasing antigen-deficiency in the Bordetella pertussis 
acellular vaccine component proteins has recently emerged from a number of large longitudinal strain 
screens, although the phenotypic consequences of many of the observed changes with regards to 
infection are unclear. In light of the clear changes observed in the other ACV-encoding genes, it 
seemed likely that the genes involved in producing the final ACV component, FHA, would also be 
undergoing allelic changes. However, due to the complexity of the gene which codes for FHA, fhaB, 
assembly of the full gene using short-reads sequencing is difficult, so analyses of any changes over 
time have been lacking.  
Here, long-read-closed B. pertussis genomes were mined, and the fully-assembled fhaB sequences 
within were screened for any ongoing changes. This revealed that a specific 10-base homopolymeric 
tract, 1,078 bp into most fhaB alleles, appears to be susceptible to slippage, resulting in some strains 
carrying an indel at this locus which has previously been linked to FHA-deficiency. However, further 
investigation showed that the mutation is present in almost all strains ever sequenced, but rarely 
present in all reads in a sample: instead, there tends to be a mixed population of sequences at the 
tract locus, like those observed in previous chapters. In addition, Illumina reads were used to identify 
the insertion of any IS elements into fhaB in the same strains, revealing that mixed populations of cells 
with and without IS insertion may also be present. There do not seem to be any significant longitudinal 
trends in either phenomenon; nonetheless, this work adds to a growing body of evidence that the 
genotypic characteristics of intra-strain B. pertussis populations are highly fluid. 
 
5.2 Data Summary 
1. A full list of accession numbers for closed genome sequences, and raw Illumina reads, as well as 
full results, is available in Supplementary table S5.1 (https://figshare.com/s/e0585f38926b02239be9)  




Bordetella pertussis causes most cases of whooping cough, a respiratory disease which has been 
resurgent in many countries since the late 1980s and early 1990s (Clark, 2014). This resurgence follows 
several decades of reduced whooping cough incidence, largely due to the introduction and 
widespread uptake of a whooping cough vaccine in the 1940s and 1950s (Jakinovich and Sood, 2014). 
The original whole-cell vaccine (WCV) contained whole killed B. pertussis cells. However, the WCV was 
perceived to cause some mild-to-severe side-effects, leading to a decrease in vaccine uptake by the 
1980s (Cherry, 1996, 2019). Consequently, a new acellular vaccine (ACV) was developed, containing 
one to five of the following B. pertussis antigens: pertactin (PRN), pertussis toxin (PT), filamentous 
haemagglutinin (FHA), fimbrial 2 (Fim2) and fimbrial 3 (fim3). The ACV was introduced in most 
developed countries by the late 1990s and early 2000s, leading to renewed high levels of vaccination 
coverage (WHO, 2018). Nonetheless, the resurgence in whooping cough incidence has continued, with 
numerous large outbreaks in the 2000s and 2010s, in countries including Australia, Japan, the United 
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States and the United Kingdom (Octavia et al., 2012; Miyaji et al., 2013; Bowden et al., 2014; Sealey 
et al., 2015). 
The most likely cause of the ongoing resurgence of whooping cough is a combination of factors, 
including improved awareness and introduction of more sensitive diagnosis methods such as PCR 
(Cherry, 2015), waning immunity conveyed by the ACV compared to the WCV (Koepke et al., 2014), 
and the genetic divergence of circulating B. pertussis strains away from the vaccine strains (Bart, 
Harris, et al., 2014). The widespread availability of whole genome sequencing has enabled the 
monitoring of allelic shifts in B. pertussis genes. Bart el al.’s landmark strain screen in 2014, including 
343 samples spanning between 1920 and 2010, showed ongoing allelic changes in key B. pertussis 
genes since the introduction of vaccination, particularly in ptxA, ptxP, prn, fim2 and fim3, all of which 
code for, or promote the transcription of,  the antigens now included in the ACV (Bart, Harris, et al., 
2014). Sealey et al.’s 2015 study of 100 strains isolated during the UK’s  2012 whooping cough 
outbreak further showed that,  since the switch to the ACV from the WCV, these same genes have 
been evolving more quickly than genes encoding other cell-surface proteins (Sealey et al., 2015). In 
addition to these allelic changes, a seemingly increasing number of strains isolated since 2008 do not 
express pertactin (Hegerle et al., 2012; Queenan, Cassiday and Evangelista, 2013; Lam et al., 2014; 
Pawloski et al., 2014; Williams, M.M. et al., 2016; Barkoff et al., 2019). 
In many of these large strain screens, however, the gene which codes for the final ACV component 
FHA has not been investigated.  The length of fhaB (over 10 kbp), repeat regions within it, and 
presence of paralogues all mean that accurate assembly and identification of SNPs using short-read 
sequencing is difficult (Bart, Harris, et al., 2014; Belcher and Preston, 2015), so it is often left out of 
analyses of allelic shifts in the ACV genes. In Bordetella, FHA has a number of different roles, including 
as a vital adhesin during early infection, contributing to immune evasion, and playing a part in biofilm 
formation (Urisu, Cowell and Manclark, 1986; Relman et al., 1989; Cotter et al., 1998; Serra, D.O. et 
al., 2011; Melvin et al., 2015). The FHA protein is coded for by fhaB, which first results in the 
production of the 370 kDa precursor protein FhaB. FhaB is then sequentially processed by FhaC, CtpA 
and SphB1 to produce the  final 220 kDa FHA protein (Nash and Cotter, 2019). Mutations in any of 
these genes could therefore lead to FHA-deficiency, just as mutations in prn and other related genes 
lead to the deficiency of PRN seen in an apparently increasing number of strains. 
Given the changes seen in the other ACV genes since the introduction of vaccination, and particularly 
since the switch from WCV to ACV, we might expect to see similar allelic changes in fhaB. Indeed, 
some recent and older strains have been identified by Western Blot or other protein-based methods 
as having severely reduced or absent FHA expression, often in tandem with PRN deficiency, and 
Etskovitz et al. (2019) showed that multiple sites relating to the antigenic epitopes in FHA are under 
diversifying selection (Bart et al., 2015; Weigand et al., 2018; Etskovitz et al., 2019; Xu, Z., Octavia, et 
al., 2019). Investigation of fhaB and its partner genes may therefore reveal previously hidden ACV-
driven mutations. 
Long-read sequencing offers the opportunity to produce closed B. pertussis genome sequences, 
including closed fhaB sequences. The genomes of several hundred B. pertussis genomes have now 
been sequenced using either Pacific Biosciences (PacBio) or Oxford Nanopore Technologies (ONT) 
sequencing platforms, and many are available from the NCBI RefSeq or GenBank databases (Bart, 
Zeddeman, et al., 2014; Bouchez et al., 2018; Ring et al., 2018). Here, RefSeq was mined for all 
available closed B. pertussis genome sequences and global genetic trends in FHA between 1935 and 
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2019 were investigated, considering any shifts in the context of recent changes to the other B. 
pertussis ACV genes. 
 
5.4 Research questions 
Research question 1: Can closed genome sequences reveal previously unnoticed changes in FHA and, 
if so, how do these changes relate to the emerging picture of allelic shifts and increasing deficiency 
seen in the other ACV components? 
 
5.5 Methods 
All data analysis was conducted using the Medical Research Council’s Cloud Infrastructure for 
Microbial Bioinformatics (CLIMB) (Connor et al., 2016). 
Mining of closed genome sequences 
The assemblies for all available B. pertussis genomes were downloaded in fasta format from the NCBI’s 
RefSeq database, filtering for “complete” genomes only. Accompanying strain metadata was 
downloaded from the NCBI’s Sequence Read Archive (SRA) Run Selector. 
Allele typing 
Allele type was assigned to the genes coding for the ACV proteins, and the promoter for pertussis 
toxin  (ptxA-E, prn, fim2, fim3, fhaB and ptxP) in the closed genomes using MLST (v2.17.6; Seemann, 
2019) with the method described in Chapter 3. 
Strains with fhaB alleles which were assigned by MLST as non-exact matches were investigated 
manually using PubMLST’s sequence query tool and blastn (Zhang, Z. et al., 2000; Morgulis et al., 2008) 
to identify sequence differences between the strain’s sequence and the closest allele’s sequence. 
Potential new alleles were validated using raw Illumina reads from the SRA for each strain (where 
available). The SRA accession numbers for each strain validated are shown in Supplementary table S5.1. 
The Illumina reads were mapped to the assembled closed genome sequence, and Tablet (Milne et al., 
2013) was used to manually validate that the reads contained the new allele sequence.  
Mining and processing of raw reads for all available sequenced strains  
The raw Illumina short reads for all sequenced strains available on the NCBI’s SRA were downloaded  
using prefetch and fastq-dump, both from the SRA toolkit (https://github.com/ncbi/sra-tools.git). 
First, the entire list of available data was downloaded from the SRA’s Run Selector by searching for 
“Bordetella pertussis”. The list was then filtered by “Assay Type” for WGS, “Platform” for Illumina, and 
by “Collection date” and “geo_loc_name_country” to exclude missing/blank values. Some manual 
intervention was required to standardise the strain names, as these had sometimes been submitted 
in the “Sample Name” column, sometimes in the “Isolate” column, and sometimes in the “Strain” 
column, whilst some had spaces in their strain names, which could have confounded command line-
based processing. Likewise, locations were sometimes submitted in the “geo_loc_name_country” 
column, and sometimes in the “geographic_location_(country_and/or_sea)” column. Finally, 
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“Collection date” values were processed to show year alone, as some entries included only the year 
of isolation, whilst others also included a day and/or month. The full metadata for all strains accessed 
is shown in Supplementary table S5.2 and is summarised in Figure 5.1. Briefly, the data set included 278 
pre-2000 (ostensibly the “WCV” strains) strains, and 2660 post-2000 (the “ACV” strains) strains. All 
continents (excluding Antarctica) were represented by at least 12 strains; likewise, all three 
vaccination eras (pre-vaccine, WCV, ACV) were represented by at least 17 strains. However, strains 
from North America were over-represented, as were strains from the 2010s. This is largely due to 
sequencing of large numbers of B .pertussis isolates by the USA’s CDC in recent years (Weigand et al., 
2017; Weigand et al., 2018; Centers for Disease Control, 2019a). 
Characterisation of fhaB polyG tract in Illumina read sets 
The 2938 paired-end global B. pertussis read sets downloaded from the SRA as described above were 
mapped using bwa mem (v0.7.17; Li, 2013) to an fhaB sequence which had been manually edited to 
remove all 10 Gs from the polyG tract (https://figshare.com/s/0b437c10f552f1e55972). The resulting 
sam file was processed using SAMtools view and sort to produce a sorted bam alignment file, which 
was parsed using SAMtools mpileup. By mapping to an fhaB sequence with no Gs at position 1078 bp, 
Figure 5.1 Location and year of isolation of the 2938 strains screened for FHA deficiency using Illumina short reads from the 
NCBI SRA. Strains were filtered from all sequence data on the SRA according to the availability of information regarding 
collection date and location. A) shows the countries from which strains were isolated; the darker the colour, the more strains 
were included (grey represents no strains). B) groups the strains into continents; all continents were represented by at least 
10 strains (excluding Antarctica). C) shows the year of isolation of the screened strains; all three vaccination eras were 
represented (pre-vaccine, WCV, ACV). The USA’s CDC has run a large clinical isolate screening project throughout the 2010s, 
resulting in the over-representation of USA strains and strains from the 2010s in this sample. The New Zealand strains 
investigated in Chapter 3 are not represented here. 
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the mpileup showed an insertion at position 1077 for each read, for example: “C+10GGGGGGGGGG” 
non-mutated polyG tract. The code is available from GitHub: 
 https://github.com/nataliering/FHA_screening/blob/master/fhaB_checker. This output a single file 
with one line per strain, showing the mpileup string for all reads at position 1077. The output was 
processed (https://github.com/nataliering/FHA_screening/blob/master/number_extractor.vba) to 
extract each of the numbers from the string (for example: 10, 10, 9, 9, 9, etc.) and count the number 
of occurrences of each number from 5 to 15. This method assumed that the inserted bases were all 
Gs, hence each string was also processed to count reads with bases other than G inserted at this locus 
(https://github.com/nataliering/FHA_screening/blob/master/nonG_read_counter.vba). 
 
The percentage of reads containing each potential length of homopolymeric tract was calculated for 
each strain. These percentages were then used to calculate mean proportions of each tract length for 
different groupings of strains based on their time period and country of isolation. Differences within 
each grouping were tested statistically for significance using one-way ANOVA (for normally distributed 
values) or Kruskal-Wallis (for non-normally distributed values) tests (Fisher, 1921; Kruskal and Wallis, 
1952). A group of 100 strains from 2014 sequenced with either the HiSeq 2500 or MiSeq were used to 
test whether different Illumina sequencers produced significantly different results, using the Mann-
Witney U test for non-normally distributed values (Wilcoxon, 1945; Mann and Whitney, 1947). 
The percentage of reads which contained a base other than a G in this tract was calculated for each 
strain, and this percentage was used to calculate a mean number of reads with non-Gs across the 
whole dataset (excluding the four Minnesota strains): 
∑ (
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑜𝑛𝐺 𝑟𝑒𝑎𝑑𝑠 𝑝𝑒𝑟 𝑠𝑡𝑟𝑎𝑖𝑛
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑟𝑒𝑎𝑑𝑠 𝑝𝑒𝑟 𝑠𝑡𝑟𝑎𝑖𝑛
 × 100)
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑡𝑟𝑎𝑖𝑛𝑠
 
Spearman’s rank correlation coefficient was calculated to determine whether any correlation existed 
between the percentage of reads with 10 bases at the tract and the percentage of reads which 
contained non-G bases. 
Identification of IS insertion into FHA 
There are several potential IS recognition sites within the fhaB sequence, as shown in Figure 5.2. 
ISMapper (v2.0, Hawkey et al., 2015) was used to predict strains with FHA or PRN deficiency as 
described in Chapter 3, using the Illumina paired-end short reads downloaded from the SRA as the 
input sequences for each strain.  
The results tables were parsed to extract rows which had identified hits for any of the IS elements 
within the fhaB gene (BP1879). In addition, tables were parsed for hits within fhaC, ctpA or sphB1 
(BP1884, BP0609, BP0216), all of which are important during the processing of the mature FHA protein 








fhaB2 remains the most prevalent fhaB allele globally, but a potential deficiency-causing 
mutation may be on the rise 
On 11 June 2019, 538 closed B. pertussis genomes were downloaded from NCBI’s RefSeq database 
(Supplementary table S5.1). 10 of these genomes had “unknown” year of isolation, so were excluded. 
The allelic profiles for each of the remaining 528 genomes were assigned using MLST (v2.16.2) 
(Seemann, 2019), with a custom MLST scheme to assign alleles to the ACV protein-encoding genes 
(ptxP, ptxA-E, prn, fim2, fim3, fhaB). All known alleles for each of these genes were downloaded from 
PubMLST to produce the custom scheme; this included 22 recorded allele sequences for fhaB, 
although most literature cites only the two fhaB alleles defined by van Loo et al. (2002) in their 
investigation of MLST for the B. pertussis cell surface protein-encoding genes (for example: Bouchez 
et al., 2015; Xu, Z., Wang, et al., 2019). MLST assigns an allele to each genome, if the gene is present. 
If a match is non-exact, MLST assigns the closest match, for example “2?”. The non-exact matches 
were investigated further here by using blastn to align the relevant genome against the allele 
sequence of the closest match and thus identify any differences. 
In the 528 closed genomes, the most commonly seen fhaB allele was fhaB2 (512 genomes, including 
124 non-exact matches which contained SNPs or indels). A smaller number of strains was observed 
with fhaB21, fhaB4, fhaB5, fhaB6 and fhaB17 (five strains possessed fhaB21, all with the same two 
SNPs compared to the PubMLST definition, and one strain each possessed fhaB4, fhaB5, fhaB6 and 
fhaB17). One genome (H321) was not assigned any known alleles for any of the genes included in the 
custom MLST scheme. The reasons for this were unknown, hence this genome was excluded from 
further analysis, leaving 527 closed genomes. Because many of the gene sequences identified here 
varied consistently from the alleles defined by PubMLST, altered allele names were assigned for the 
purposes of this work (Table 5.1).  
Figure 5.2 fhaB and the FHA precursor protein, FhaB. The most commonly observed fhaB allele, fhaB2, is 10,773 base 
pairs, coding for a preprotein which is almost 3,600 amino acids long. The preprotein contains several domains: the signal 
peptide (SP), two-partner secretion (TPS), a long β-helical shaft, a mature C-terminal domain (MCD), N-terminal predomain 
(PNT), proline-rich region (PRR) and extreme C-terminal domain (ECT). The preprotein is processed to become the final FHA 
protein, containing the domains indicated. A polyG tract 1,078 bases into fhaB is a common site for mutation. The wild type 
tract contains 10 Gs, whilst mutants containing 9 or 11 Gs have been observed, each of which results in a premature stop 
codon and subsequently truncated FHA protein. The fhaB sequence also contains three predicted insertion sites for IS 481 
and IS 1002 (NCTAGN), at 2,785, 3,124 and 9,865 bases respectively (indicated by red arrows), although insertions at the 
9,865 bp site do not seem to cause FHA deficiency. Insertion sites for IS 1663 may also be present, but the recognition 
sequence for IS 1663 is not currently known.                 
 Figure adapted from Weigand et al. (2018). 
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The frequency of each of the redefined fhaB alleles over time was then analysed, and placed in the 
global ACV context established by Bart, Harris, et al. (2014)’s landmark strain screen, Figure 5.3. Due 
to the availability of strains from certain years, the time period groupings were altered slightly. In 
addition, many more strains from 2012 onwards were available for this study than were available to 
Bart et al., hence this was added as a new time period. This analysis shows that, since the introduction 
of the WCV, the prevalence of non-fhaB2 alleles has greatly decreased, with fhaB2 remaining by far 
the most common allele. In addition, the prevalence of one particular mutation, defined here as 
fhaB2b, appears to be increasing. The indel seen in fhaB2b is an indel at a homopolymeric tract starting 
at bp 1,078 in fhaB2. In the wild type fhaB2 allele (and all other fhaB alleles defined on PubMLST 
except fhaB3 and fhaB22), the tract contains 10 Gs. The 115 variants classed as fhaB2b here contain 
an insertion or deletion at this tract, resulting in an assembled fhaB sequence containing 9 or 11 Gs. 
Both versions of this indel have been noted in single strains in previous studies and have been 
predicted to lead to a frame-shift resulting in a premature stop codon, thus are linked with FHA 
deficiency (Bart et al., 2015; Weigand et al., 2018; Xu, Z., Octavia, et al., 2019).  
However, the closed genomes used to screen fhaB sequences here were produced using PacBio long 
reads. PacBio, like nanopore and many other sequencing technologies, is prone to errors when 
sequencing homopolymeric regions. Most of the closed genomes were assembled using PacBio and 
Illumina reads in hybrid; the raw Illumina reads were available for 62 strains from the NCBI SRA 
(accession numbers are given in Supplementary table S5.1). To validate that the fhaB sequence in the 
fhaB2b strains did indeed contain an indel, the raw Illumina reads for each strain were downloaded 
and mapped back to their relevant closed genome sequence using bwa mem, and the number of Gs 
in the fhaB homopolymeric tract at 1078 bp was checked manually. This revealed a mixed population 
in most of the strains whereby Illumina reads were observed with 8 to 12 Gs in the tract, as shown in 
Figure 5.4. In many strains, the highest percentage of reads still contained 10 Gs, suggesting that the 
mutant fhaB2 allele present in some closed genome sequences may indeed have been due to 
homopolymeric error in the PacBio long reads. A notable exception is J199, for which 64% of the 
Illumina reads contained a truncated polyG tract (62% G9, 2% G8). This mutation was also noted by 
Weigand et al. (2018), who had seen reduced FHA production in J199. A key observation here was 
that, although most reads in most strains still contained 10 Gs, almost every strain possessed a mixed 
population of homopolymer lengths, suggesting that slippage may be common at this locus on a wider 
Table 5.1 Redefined fhaB alleles for this study  
fhaB allele Sequence description Number of genomes  
2 As per PubMLST 396 
4 As per PubMLST 1 
5 As per PubMLST 1 
6 As per PubMLST 1 
17 As per PubMLST 1 
21 As per PubMLST 0 
21b fhaB21 with 2 SNPs: C7341T, G7778A 3 
23 fhaB20 with 6 SNPs and indels: AA1039--, G1047-, 
C1088G, G6995-, -7532G, C10314- 
1 
2b fhaB2 with 1 indel: G1078- or G1078GG 115 
2c fhaB2 with 1 SNP: A4432G 4 
2d fhaB2 with 1 SNP: G3347A 2 
2e fhaB2 with 1 SNP: C4497T 2 
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scale. In light of this, and the apparently increasing percentage of fhaB2 in the hybrid closed genomes, 
the phenomenon was therefore investigated further, using the raw Illumina data available for a larger 
number of strains from the NCBI’s SRA. 
Figure 5.3 fhaB alleles over time, placed in the same global context as the other ACV antigen-coding genes in Bart, Harris, et 
al. (2014). Alleles were assigned by MLST, using closed genome sequences downloaded from the NCBI’s RefSeq database. 
Certain mutations were commonly observed, hence allele names were redefined for the purposes of this study, as shown in 
Table 5.1. Like the other ACV-encoding genes, some alleles which were prevalent in the pre-vaccine era disappeared after the 
introduction of the WCV. As seen with fim3 (B), prn (E) and ptxP (D), a new fhaB (F) allele seems to be becoming increasingly 
prevalent. This “allele”, coined fhaB2b, is identical to the most common allele, fhaB2, but has an indel at a homopolymeric 
(polyG) tract 1078 base pairs into the gene sequence. 










Figure 5.4 fhaB:G1078 characteristics of Illumina read sets for 62 “fhaB2b” genomes for which data was available. The number of Gs seen in the homopolymeric tract at 1078 bp in the fhaB2 sequence 
varied from 8 to 12 in the strains investigated here. However, despite the assembled genome of each of the 62 strains containing a mutated fhaB2 1078 homopolymer sequence (i.e. more or less than 10 




Many strains contain a mixed population of fhaB sequences, but there may not be any 
trends towards deficiency 
As a result of the discovery that raw Illumina reads could reveal mixed populations at the fhaB:1078 
polyG tract in some of the 528 strains with long-read-closed genomes studied here, a wider screen 
was conducted of all strains available from the NCBI’s SRA which had associated country and year 
metadata, as listed in Supplementary table S5.2. Paired-end reads were mapped to a manually edited 
fhaB2 sequence with the polyG tract removed, then processed with SAMtools view, sort and mpileup 
to identify how many Gs were present at the tract locus in each of the mapped reads within each read 
set (raw results in Supplementary table S5.3). 
Some strains have been sequenced more than once, and some strain names may have been used more 
than once globally, to represent different strains. To account for this, 325 duplicate strain names were 
removed at random from the processed results using Excel’s “remove duplicates” function, leaving 
results for 2,613 strains (Supplementary table S5.4). For 860 of the remaining strains, fewer than 10 
reads mapped to the locus of interest, so these strains were also discarded. This left usable data for 
1,753 strains (Supplementary table S5.5). 
Of the 1,753 strains with usable data, 1,638 had a mixed population; the datasets for all but 115 strains 
contained a mixture of reads with between G6 and G12 at the polyG tract in fhaB. Overall, the mean 
percentage of reads containing only G10 was 87.23%. Only 10 strains contained less than 50% of G10 
reads (including the aforementioned J199, with 36% G10), suggesting that the vast majority of the 
strains in the dataset would not be fully FHA-deficient. To determine whether the frequency of non-
Figure 5.5 Kruskal-Wallis test for significant differences between the mean percentage of G10 reads in each time period.  
The percentage of G10 reads per strain was calculated, and a mean percentage of G10 reads was calculated for all strains in 
each time period. There were no significant differences between the means of the four groups. Although the boxplots suggest 
that the percentage of G10 reads has fallen slightly since the year 2001, both of the pre-2001 groupings contained a small 
number of strains (8 pre-1966, and 34 1955-2000), which would have meant that finding a significant p-value would have 
been unlikely, unless the difference between the means was very large. The means of the two post-2000 groupings were not 
significantly different, but the post-2011 group contained many more strains outside of one standard deviation from the 
mean, as indicated by stars.  
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G10 reads has changed over time, the strains were separated into the same period groupings as shown 
in Figure 5.3, and an independent-samples Kruskal-Wallis test was used to assess the significance of 
any differences between the means (Figure 5.5). No significant differences were found between the 
means of the four groups (p=0.817).  
After removing those strains for which fewer than 10 reads mapped to the tract of interest, too few 
strains remained for most countries to conduct meaningful comparisons. The vast majority of the 
remaining strains (1,675) were isolated in the USA, reflecting the predominance of USA strains in the 
pre-filtered data set. However, 35 strains remained for China, which was potentially enough to reveal 
a statistically significant difference in mean G10 percentages. The mean G10 percentage for all reads for 
all strains was calculated for both countries, and a Mann-Whitney U test was used to test for 
significance. This showed that significantly fewer reads from the Chinese strains contained non-G10  
tracts than from the USA strains (means 90.38 and 87.10% respectively, p=0.006).  
Different Illumina sequencers do not appear to produce statistically different results 
The data downloaded from the SRA was produced by a variety of different Illumina sequencers, as 
illustrated in Figure 5.6. Consequently, there was a chance that any differences observed between 
strains were a result of different error profiles of different sequencers. As shown in Figure 5.6, the 
majority of the dataset was evenly split between the HiSeq 2500 and the MiSeq. Data was available 
for 100 strains from 2014 and, fortuitously, around half of the strains (54) were sequenced using the 
HiSeq 2500 and the other half (46) were sequenced using the MiSeq. This dataset was therefore ideal 
to determine whether different sequencers produced statistically different percentages of reads with 
10 bases in the polyG tract. Any differences between the two groups would not be due to their year 
of isolation, which would indicate they were due purely to the different sequencers and were thus 
Figure 5.6 Numbers of strains sequenced by each type of Illumina sequencer in the downloaded dataset 
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likely to be sequencing error. A Mann-Whitney U test determined that the means of the two groups 
(HiSeq 2500 vs MiSeq) were not significantly different, with a p-value of 0.549 (see Figure 5.7). This 
suggests that any differences observed within the larger dataset were also not due to differences 
between the Illumina sequencers used to produce the data. 
Some strains do not contain a polyG tract in every read at the fhaB 1,078 bp locus 
Four strains (K059, K060, K062 and K063) contained a very different sequence at the 1078 bp locus 
compared to all other strains. Instead of a polyG tract, these strains had the sequence GGTGGCG at 
the locus in every read. As mentioned above, all of the 22 fhaB alleles defined by PubMLST contain 
the polyG tract at the 1,078 bp locus except two. The sequence found in the remaining two alleles, 
fhaB3 and fhaB22, is the sequence found in K059, K060, K062 and K063. Thus, these four strains 
contain either fhaB3 or fhaB22, and were the only four strains of the 1,753 tested to contain a 
sequence other than the polyG tract at this locus. According to the SRA’s metadata for these strains, 
all four were isolated in 2018 in Minnesota; it therefore seems likely that they were isolated from 
patients who had been in close contact with each other.  
In addition to the obvious outlier strains from Minnesota, the reads from every other strain were 
processed to determine if any read contained bases other than G in their “polyG” tract. It emerged 
that, in a small number of reads, other bases were sometimes substituted for one of the Gs in the 
middle of the tract (never at the beginning or end). In most cases, only a single G was substituted.  
Across the whole dataset, 2.15% of the 53,782 total reads for all strains contained bases in the tract 
which were not G. 1,045 strains had 0% reads containing non-Gs in this tract, 406 strains had between 
0 and 5% of reads with non-Gs, 231 strains had between 5 and 10% of reads with non-Gs, and 73 
strains had non-Gs in more than 10% of reads. The strains with the highest percentage of reads 
containing non-Gs at this tract tended to be those with lower coverage, suggesting that perhaps the 
higher percentage was a result of lower sequencing quality overall; this is supported by the fact that 
the non-G base in the affected reads was not always the same within these strains. Overall, there did 
not appear to be any correlation between percentage of non-G reads and percentage of reads which 
Figure 5.7 A Mann-Whitney U test revealed no significant difference between the mean % of G10 reads for the 2014 strains 
sequenced with the HiSeq 2500 and those sequenced with the MiSeq, with a p-value of 0.549 
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had an indel at the tract; the Spearman’s rank correlation coefficient between the two factors was 
determined to be -0.026, as shown in Figure 5.8.  
Insertion of IS 481 into fhaB likely causes deficiency in a number of strains 
Illumina short-read data (from Genome Analyzer, MiSeq, HiSeq and NextSeq machines) was 
downloaded from the SRA for 277 pre-vaccine and WCV-era strains, and 2660 ACV-era strains. Poor 
quality data or lack of paired end reads meant that 124 pre-vaccine/WCV-era strains and 403 ACV-era 
strains were discarded, leaving 153 pre-vaccine/WCV-era and 2257 ACV-era strains. Of the 2410 
strains tested, 14 were found to have an IS 481 inserted into fhaB, including 11 from the ACV cohort 
(0.49% of those tested) and three from the WCV cohort (1.96% of those tested). Table 5.2 shows the 
strains found to have an IS 481 within their fhaB gene, along with the ISMapper-predicted insertion 
site. One strain, B290 (UK1), appeared to have IS 481 inserted at two of the three potential insertion 
sites, 3,124 and 9,865 bp into the gene, in forward and reverse orientation respectively. 
No strains were found to have disruption by either IS 1002 or IS 1663 in fhaB. Likewise, no disruption 
of fhaC, ctpA or sphB1 was seen in any strain. Neither does there seem to be any link between PRN-
deficiency and likelihood of IS 481 insertion into fhaB: of the 14 strains identified here as having IS 481 
inserted into fhaB, seven also had an IS 481 insertion in prn, whilst seven did not. 
Figure 5.8 There seems to be no correlation between % of reads with a non-G base and % of reads with 10 bases at the 





Table 5.2 Strains containing a copy of IS 481 in their fhaB gene  










J043 1947 USA SRR5829785 9,865 F Weigand et al. 
(2018) 
N 
B290/UK1 1920 UK ERR037420 3,124 & 
9,865 




B199 1935 USA SRR5829828 3,124 F Weigand et al. 
(2018) 
N 
B066 2004 Canada ERR037426 3,124 R Novel? N 
J365 2014 USA SRR5829857 9,865 F Weigand et al. 
(2018) 
Y 
J198 2014 USA SRR5070733 3,124 F Novel? N 
H777 2011 USA SRR9123597 3,124 F Novel? Y 
H971 2012 USA SRR9123520 9,865 F Novel? Y 
I262 2012 USA SRR9131342 9,865 F Novel? N 
I317 2012 USA SRR9131477 2,785 F Novel? Y 
I333 2012 USA SRR9131367 9,865 R Novel? Y 
J014 2014 USA SRR5829804 3,124 F Weigand et al. 
(2018) 
Y 
J199 2014 USA SRR5829751 3,124 R Weigand et al. 
(2018) 
Y 
TN0003 2014 Tunisia ERR2658138 3,124 R Novel?* N 






Does Illumina have a homopolymer problem?  
The main body of work for this chapter was centred around the precept that, whilst PacBio reads may 
have errors around homopolymeric sequences, Illumina reads would likely not; that any indels 
observed in Illumina reads were real, rather than sequencing error. Indeed, comparisons between 
different sequencing technologies have often concluded that most technologies (including Ion 
Torrent, 454, PacBio and nanopore) make more mistakes in homopolymeric tracts than Illumina (for 
example: Salipante et al., 2014). However, the exact frequency with which Illumina makes any 
mistakes at all in these regions is unclear. One comparison of sequencing bias and error showed that, 
the longer a homopolymer, the higher the chance of erroneous insertions and deletions, but that 
assuming all such indels to be erroneous resulted in false negative calls (Ross et al., 2013). Another 
analysis of error profiles in Illumina sequencing found a substantial bias for motifs which ended in 
GGG, like the variable tract here identified in fhaB (Schirmer et al., 2016). However, the same 
fluctuations in the fhaB:1078 polyG tract were also observed in reads which represented sequencing 
of the complementary strand, where the homopolymer was Cs instead of Gs, suggesting that the 
fluctuations were not necessarily due to this type of sequencing bias.  
In addition, a 2012 analysis conducted by Ion Torrent suggested that Illumina MiSeq sequencing has a 
tendency to miscall the first base after a homopolymeric tract (Robison, 2012). Discounting the 
obvious conflict of interest in this finding by Ion Torrent about their primary competitor, the method 
used in this chapter would likely have not been affected by this kind of error in any case, as it simply 
counted how many Gs occurred after base 1,077, and would not therefore have been influenced by 
any difference in the base which occurred after the Gs. In addition, the most common error observed 
during the Ion Torrent analysis was one more call of the homopolymer, thus a single-base insertion 
extending the tract, whereas the most common variant seen in fhaB here was a single-base deletion, 
resulting in a shortening of the homopolymer (on average, 8.72% of reads contained G9, compared to 
only 3.76% of reads containing G11).  
Nonetheless, there remains a chance that the fhaB:1078 indel phenomenon observed here is an 
artefact of sequencing bias, and that the majority of this chapter is simply a detailed description of the 
resulting error rates. However, several factors indicate the phenomenon may be real. The same indel 
at the same fhaB polyG tract  has been observed several times by chance in other, peer-reviewed and 
published, studies. Xu, Z., Octavia, et al. (2019) observed a single-base insertion at fhaB:1078, thus 11 
Gs in the tract, in a strain which they had found to have lowered expression of FHA (L2228). They 
validated this finding with both Illumina and Sanger Sequencing reads, and found the same mixture of 
G10 and G11 reads from both types of sequencing. It has been suggested that Sanger Sequencing is an 
appropriate method for validating variants called by NGS in low complexity regions, including 
homopolymers, so indels observed in this tract in the Sanger Sequencing reads are likely to be real 
(Mu et al., 2016).  
Meanwhile, both Weigand et al. (2018) and Bart et al. (2015) observed strains which included a 
deletion or insertion at the fhaB:1,078 polyG tract respectively, although in both cases they validated 
solely using Illumina reads (J199 and B3582, respectively). Weigand et al. also noticed a mixed 
population of G9 and G10 reads. In all three cases, the fhaB:1,078 mutation was identified due to the 
strains in question having been observed as FHA-deficient or FHA-impaired; no other mutations to any 
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of the FHA or FHA-processing genes were present, suggesting that the frameshift resulting from the 
expansion or contraction of the fhaB:1,078 polyG tract was indeed real, and responsible for the 
observed reduction in FHA expression. However, only one of the strains (J199) in which this mutation 
has previously been observed was included in the usable dataset here.  
Additionally, 115 of the strains analysed here, including some with relatively high (45x) coverage, 
contained 100% reads with 10 Gs at the tract. If Illumina sequencing does produce systematic error in 
around 13% of reads at this tract (based on the average G10 percentage of 87.23%), probability 
suggests that at least one erroneous read should be produced per 10 reads in the data set. The 
comparison here between 54 strains sequenced with the HiSeq 2500 and 46 sequenced with the 
MiSeq also showed that there was no significant difference in the percentage of reads found to contain 
an indel (Figure 5.7). This suggests that, either the error profiles of the two different sequencers are 
identical, or the indels detected are real. The reads containing non-G bases within the tract at 1,078 
bp may have been caused by sequencing error, or may indicate that the tract is prone to substitutions 
as well as indels. Determining which answer is correct was beyond the scope of this work, but Figure 
5.8 shows that, even if the substitutions were caused by error, there was no correlation between this 
kind of error, and the identification of indels in the same tract.  
Overall, without further wet-lab investigation, it is difficult to know for sure whether the indels 
observed here are truly real, or whether they are a remnant of sequencing error at a low complexity 
region. PCR could potentially determine whether different reads contained different numbers of bases 
at this locus, using primers designed to flank the homopolymeric tract in fhaB. However, the difference 
in product lengths may only be a single base in either direction, meaning capillary electrophoresis, as 
used in Sanger Sequencing, may be required to resolve the different band lengths. In addition, the 
predicted mixed populations in almost every strain would mean that products of different lengths 
would be present in the same sample. As most of the evidence here suggests that the observed indel 
phenomenon is likely to be real, designing a wet-lab experiment to validate the findings may be 
worthwhile. 
A number of potential FHA deficiency-causing mutations exist in highly mixed B. pertussis 
populations 
Using purely informatics methods, various potential fhaB mutations in large numbers of strains have 
been identified here, more quickly and cheaply than possible by wet-lab methods. In a matter of 
weeks, 1,753 strains were screened for a potential FHA deficiency-causing indel in the homopolymeric 
tract 1,078 bp into the sequence of most fhaB alleles. This revealed the existence of highly mixed 
populations of cells and suggested that, at any given time, individual cells could develop mutations at 
this locus which could eventually lead to deficiency.  
At face value, the lack of statistically significant temporal trends illustrated in Figure 5.5 indicates that 
these mixed populations of cells have always been present, and the proportions of cells with and 
without a deficiency-causing indel have not changed in response to either the introduction of the 
vaccination, or the switch to the acellular vaccine. The boxplots in Figure 5.5 do appear to show that 
the percentage of G10 reads may have decreased slightly between the 1966-2000 and 2001-2011 
groups, which would correspond with the introduction of the ACV in many countries; however, usable 
data was available for only 34 strains from the 1966-2000 group (n=34), compared to usable data for 
192 strains for the 2001-2011 group (n=192). Combined with a large standard deviation in G10 
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percentage between strains, this small sample means that finding a significant difference between the 
groups in terms of p-value was very unlikely, unless the difference itself was so large as to be obvious 
even prior to statistical testing. Likewise, there is no statistically significant difference between the 
mean percentage of G10 reads for the 2001-2011 (n=192) and post-2011 (n=1519) groups. In this case, 
the boxplot shows no difference between the means, but does show a large difference in the range: 
many more strains have a G10 percentage lower than one standard deviation less than the mean, as 
indicated by the stars in Figure 5.5. This suggests that, while overall there is no significant trend towards 
most strains gaining more non-G10 reads, the number of individual strains with lower G10 percentages 
is increasing; that is, the number of strains in which a reduced production of FHA could be detected 
using methods such as that described by Weigand et al. (2018) may be increasing. It is therefore 
possible that, if the same analysis were performed in ten years’ time, a significant difference would 
be detected between the 2019-2029 group and those preceding it, although there is of course no way 
of knowing if this is true.  
In contrast to the lack of significant temporal trends observed, a statistically significant difference was 
observed between the percentage of reads with G10 in Chinese strains compared to USA strains (means 
90.38 and 87.10% respectively, p=0.006). The USA strains therefore appear to have a higher 
proportion of cells carrying an indel than the Chinese. If the ACV-induced trend hinted at in the 
temporal data was true, this finding would make sense: the WCV is still in use in China, whereas the 
USA switched to an FHA-containing ACV as early as 1996. However, there was a large difference in the 
sample sizes, with usable data for 1,675 strains from the USA, and only 35 from China. Data from 
additional recent Chinese strains would help to determine if this observed difference is an ongoing 
phenomenon, and also to investigate whether the difference is caused by the ACV or some other, as 
yet unknown, factor.  
The strains possessing an indel at the 1,078 bp homopolymeric tract were termed “fhaB2b” for the 
purposes of categorisation here. As shown in Figure 5.3, the most prevalent fhaB allele is fhaB2; 
however, all but two (fhaB3 and fhaB22) of the 22 alleles definitions available on PubMLST possess 
the same polyG tract 1078 bp into the fhaB sequence. This means that strains carrying alleles other 
than fhaB2 could be affected by the slippage at the polyG tract and, in light of the prevalence of fhaB2 
in the currently circulating population, a large majority of strains not yet sequenced could also contain 
a mixed population of cells for this locus. 
An informatics method to identify strains potentially FHA-deficient due to IS insertion into fhaB was 
also successful here. ISMapper showed IS 481 insertion into fhaB in several strains previously 
investigated in Weigand et al.’s detailed 2018 characterisation of FHA-deficient strains. Weigand et al. 
screened 787 recent and historic strains for FHA expression using their electrochemiluminescent 
antibody capture (ECL) assay, and identified five strains with absent or “severely reduced” FHA 
expression. Importantly, however, Weigand et al. did not find any obvious FHA deficiency-causing 
mutations in their assembled genome of J014, which was shown by the ECL assays to be FHA-deficient. 
By contrast, ISMapper, which uses raw Illumina reads rather than an assembled genome to identify IS 
insertions into genes, identified a copy of IS 481 at the insertion site 3,124 bp into fhaB. Likewise, 
Weigand et al. attributed their observed reduction in FHA expression in J199 solely to the presence of 
the homopolymeric slippage mutation thoroughly detailed here, whereas ISMapper also identified a 
copy of IS 481 at the 3,124 bp insertion site.  
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Given the picture of highly mixed intra-strain B. pertussis populations which has emerged throughout 
this, and previous chapters, it seems likely that the cell populations of both J014 and J199 contained 
a portion of cells with the IS 481 insertion within fhaB, and a portion of wild type cells. When the 
genomes for these strains were assembled by Weigand et al., the assembly tool may or may not have 
included the insertion, according to which sub-population the assembled reads came from. The 
opposite phenomenon could also be true for those strains identified here as having IS 481 within their 
fhaB but which had not been previously found to be FHA-deficient: enough of their cells may contain 
wild type fhaB that FHA expression is not yet severely reduced, but ISMapper was still able to detect 
those cells which contained the mutant. The same could be true for any of the other novel IS-
containing strains identified here.  
Wet- and dry-lab techniques are both required to fully explore FHA deficiency 
Weigand et al. (2018) found one strain, J365, which appeared to have an IS 481 inserted at the last 
insertion site within the fhaB gene, at 9,865 bp (see Figure 5.2), yet was not FHA-deficient, indicating 
that IS 481 insertion late in the fhaB sequence does not prevent expression of the FHA protein. Three 
more of the strains identified here (Table 5.2) also appear to have an IS 481 at the 9,865 bp insertion 
site, suggesting these strains are likely not FHA-deficient.  
The informatics approach, therefore, may be able to detect mutations in finer detail than the wet-lab 
approach, and certainly before they have begun to result in full FHA deficiency, but the evidence here 
suggests that both methods will be required for full resolution. The use of ISMapper alone would 
predict FHA deficiency in strains with IS 481 at the 9,865 bp fhaB insertion site, but Weigand et al.’s 
ECL assay shows that insertion at this site likely does not cause FHA deficiency. The ECL assay could 
also be used to validate the fhaB:1,078 indel results seen here as, to some extent, the results are non-
binary, and can show a range of expression between fully deficient and fully normal expression 
(although the level of resolution possible is limited (Personal Communication, Michael Weigand, 
2019)). In theory, mixed populations should result in a range of different FHA expressions, according 
to how many cells in the population have the non-mutated copy of fhaB. For example, J199, which has 
a mixed population (64% non-G10 reads), was found to have a low level of FHA expression in the ECL 
assay, which is in keeping with 36% of cells still possessing the non-mutated version of fhaB (Weigand 
et al. 2018). A variety of strains could be selected from the 1,753 screened here, with a range of G10 
percentages, and predictions of relative FHA expression or deficiency tested.  
Short- and long-read sequencing are required to fully explore FHA deficiency 
Most of the analysis conducted here utilised Illumina short reads, primarily because of their high 
accuracy and potentially lower tendency to produce errors in homopolymeric tracts. However, the  
fhaB:1,078 indel phenomenon was originally observed in closed genome sequences produced using 
PacBio long reads, both here and in every other study which has observed the same mutation (Bart et 
al., 2015; Weigand et al., 2018; Xu, Z., Octavia, et al., 2019). Whilst short reads were required to 
investigate the mutation in detail, the mutation was only discovered because long reads enabled the 
assembly of closed genomes. On the other hand, ISMapper was also able to provide a likely cause for 
Weigand et al.’s observed FHA deficiency in J014, which was not apparent from the closed genome 
sequence alone. It seems therefore that, like hybrid de novo assembly, there remains a place for both 




The implications of mutations in fhaB 
Increasing incidence of PRN deficiency has been well documented (for example: Hegerle et al., 2012; 
Queenan, Cassiday and Evangelista, 2013; Barkoff et al., 2019; Lam et al., 2014; Martin et al., 2015). 
Small numbers of strains deficient in FHA or PT have also been identified, often in tandem with PRN 
deficiency (for example: Bouchez et al., 2009; Bart et al., 2015; Williams, M.M. et al., 2016; Weigand 
et al., 2018). Here, a potential mutation which could lead to FHA deficiency was found to be common 
in intra-strain B. pertussis populations. However, the prevalence of the mutation within these 
populations was not 100%. This could lead to populations which have decreased, but not absent, 
expression of FHA. FHA is thought to have roles as a secreted protein, as well as a membrane-bound 
adhesin (Urisu, Cowell and Manclark, 1986; Relman et al., 1989; Cotter et al., 1998; Melvin et al., 
2015). In culture, membrane-bound FHA alone is sufficient for the adhesion of B. pertussis to 
eukaryotic cells, whilst the secreted protein is involved with immune evasion. Mammalian studies 
have shown that FHA expression is vital,  but not sufficient alone, to establish B. pertussis infection in 
the respiratory tract (Inatsuka, Julio and Cotter, 2005; Julio et al., 2009; Henderson, M.W. et al., 2012; 
Melvin et al., 2015). Strains which are fully FHA-deficient should therefore be less able, or completely 
unable, to establish infection in the respiratory tract. Nevertheless, the previous detection of FHA-
deficient strains in patients suggests that, rarely, deficient strains may still be able to establish 
infection. This could be explained by the mixed populations of FHA mutations seen here: many cells 
could indeed be FHA deficient, but a small number of cells in the population remain able to express 
FHA. As a secreted protein, the FHA produced by the non-deficient cells could compensate for the 
deficient cells enough for successful immune evasion. Alternatively, infection could be established by 
populations of B. pertussis cells in which a majority are not yet FHA deficient, after which the pressure 
applied by a host immune system (particularly in a vaccinated host) could lead to a shift in population 
frequencies, and the eventual dominance of deficient cells. Although this would aid the cells in the 
current infection, the shifted population would then be less able to infect future hosts. Perhaps the 
mixed populations observed here are the result of a balance between the benefits of immune evasion 
in the current host and the ability to infect future hosts. 
Although deficiency of FHA and PT appear to be more rare than deficiency of PRN, and seem unlikely 
to proliferate in the same way as PRN deficiency has due to their more vital roles during infection 
compared to PRN, the selective pressure applied by the ACV on the five component antigens means 
that increasing defiency in PT, FHA or Fim2/Fim3 is possible, particularly if the bacteria are able to 
develop ways to compensate for the absence of the seemingly vital proteins, as may have happened 
in the deficient strains previously isolated from whooping cough patients. The implications of antigen 
deficiency are clear. The ACV causes the immune system to recognise B. pertussis infection due to the 
presence of the ACV antigens on the B. pertussis cells; if one or more of these antigens are no longer 
present on the surface of the cell, the immune system may be less able to recognise the infection. 
Screening for increasing deficiency in all five antigens is therefore valuable. Given the complexities of 
fhaB, methods to screen for FHA deficiency could be particularly useful .  
Finally, it should also be noted that Bart et al. (2015) observed an additional FHA-deficient strain in 
which they could not identify any mutations in any of the FHA-related genes, indicating that FHA 
deficiency may also arise by some as yet unidentified mechanism. The emerging picture of highly 
mixed B. pertussis intra-strain populations means that many genomic phenomena may exist, which 




























“Your future hasn’t been written yet, no one’s has! Your future is whatever you make it, so 
make it a good one!” 
- Doc Brown, Back to the Future, Part III 
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The aims of this project were to understand how long-read sequencing, and particularly nanopore 
sequencing, could be usefully applied to the study of Bordetella pertussis, and to elucidate what this 
application may reveal about the B. pertussis genome. Prominent in achieving these aims, and a theme 
that permeates throughout this thesis, has been the ongoing development and improvement of 
nanopore sequencing and its associated data analysis tools. 
Ongoing development and improvement of long-read sequencing technologies and their 
associated data analysis tools 
Before the major work for this thesis was begun, several attempts had been made (in 2014 and 2015) 
to sequence B. pertussis at the University of Bath using Oxford Nanopore Technologies’ MinION 
sequencer. This sequencing was conducted as part of the “MinION Access Programme (MAP)”, and 
used the earliest publicly available sequencers and sequencing chemistry, the MinION Mk1 and R7.3, 
respectively.  Although these attempts did produce longer read lengths (5-6 kbp) than possible using 
most other NGS technologies, the tests were largely unsuccessful due to the poor yield and poor 
accuracy of the data produced: a 48-hour sequencing run on an R7.3 flow cell did not produce high 
enough coverage of the 4.1 Mb B. pertussis genome to assemble a closed sequence for even a single 
strain (see Figure 1.16). The performance of each flow cell was unpredictable, often having few pores 
available for sequencing, or rapidly losing available pores as sequencing progressed. These issues 
appear to have been common throughout the MAP community (Robison, 2017; Stack Exchange, 2017; 
van der Helm, 2017).  
As this project began in 2016, however, a new sequencing chemistry was released, along with updated 
and improved basecalling and data analysis tools. The R9.4 flow cells were developed to increase the 
throughput and accuracy of each MinION sequencing run, and required a new version of the MinION: 
the Mk1b (Oxford Nanopore Technologies, 2016; Clarke, 2018). A sample of B. pertussis UK76 was 
sent to the University of California Santa Cruz, to test the throughput of the new sequencing 
chemistry. This yielded around 9.3 Gb over a 48-hour sequencing run, an order of magnitude higher 
than produced by the previous R7.3 runs over the same time period. Combined with the newer data 
analysis tools, this data could be used to assemble a closed UK76 genome; however, assembly with 
one of the more accurate assembly tools, Canu, took many days due to the extremely high coverage 
(Koren et al., 2017). Tests of smaller subsets of the data showed that equally accurate closed genome 
sequences could be assembled using just a twentieth of the data, indicating that multiple strains could 
now be sequenced during each sequencing run. This led directly into the work of Chapter 2, during 
which a barcoding protocol was tested, and five B. pertussis strains were sequenced on the same flow 
cell. As expected, this produced more than enough coverage (between 200 and 400x) for each of the 
five strains. 
Many different de novo assembly and polishing tools have been, and continue to be, developed for 
long reads produced by nanopore (or PacBio) sequencing. The data produced in Chapter 2, combined 
with Illumina data previously produced for the five sequenced strains, was an ideal set to test the 
various different de novo assembly strategies available. This revealed that pre-correction with Canu, 
assembly with Flye, and polishing with Nanopolish produced the most accurate nanopore-only 
assemblies but, as could be expected, hybrid assemblies with both pre-corrected nanopore and 
Illumina data, produced with Unicycler, were the most accurate (on average, 99.48% accuracy for 
nanopore-only assemblies vs 99.69% for hybrids) (Loman, Quick and Simpson, 2015; Wick et al., 
2017b; Kolmogorov et al., 2019).  One of the major observations during these tests was how quickly 
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the field was changing: new tools were rapidly becoming available and, in fact, the whole testing 
process had to be repeated from scratch when a new and more accurate basecalling tool (Albacore) 
replaced the MinKNOW basecaller used originally (Oxford Nanopore Technologies, 2017).  
The trend of rapid development continued into the work of Chapter 3, where a new, quicker and 
cheaper library preparation kit could be used to produce 200x coverage for 12 strains (instead of five) 
per flow cell. In addition, the most accurate basecaller had changed again (the current favourite 
basecaller for the community is Guppy), and several of the tools identified as optimal in Chapter 2 had 
been replaced with newer versions (Wick, Judd and Holt, 2019). For example, Deepbinner replaced 
the demultiplexing tool Porechop, which resulted in fewer reads being discarded as having no 
recognisable barcode, whilst Medaka largely replaced the older, slower, and harder-to-use Nanopolish 
(Wick, 2017; Wick, Judd and Holt, 2018b; Luo et al., 2020). Using these newer tools, the accuracy of 
assemblies produced using nanopore reads increased to 99.63% - 0.15% higher than Chapter 2, and 
only 0.06% lower than the average hybrid accuracy in Chapter 2. In turn, the average accuracy of the 
hybrid assemblies also increased, though less dramatically, to 99.71%. The ability of MinION 
sequencing to consistently produce enough data to assemble closed genome sequences for multiple 
B. pertussis strains per flow cell is now well established. The remaining raw error present in MinION 
data, however, means that variant calling has remained a challenge.  
Greig et al. (2019) conducted a thorough comparison of single-nucleotide variants identified in two 
Shiga toxin-producing E. coli isolates using raw, uncorrected Illumina and ONT reads. This work used 
GATK with some options customised for the more error-prone ONT reads, along with Minimap2 to 
map the long reads to a reference sequence (McKenna et al., 2010; Li, 2018). Many discrepancies 
between the variants called with the different reads were in repeat regions, likely because the Illumina 
reads could be mis-mapped whereas the ONT could not. When variants in repeat regions were 
masked, the vast majority of the remaining discrepancies were found to be “false positives” in the 
ONT data. These false positives usually occurred in the same motif (CC(A/T)GG), which has been 
associated with cytosine methylation. Greig et al. therefore used Nanopolish’s methylation-calling 
script on their raw Fast5 data, which showed that these “false positives” were indeed miscalled due 
to the influence of cytosine methylation in the raw ONT signal (Loman, Quick and Simpson, 2015).   In 
some regards, ONT reads therefore outperform Illumina reads, as they do not result in false positive 
variant calls due to mis-mapping around repeat regions, and because epigenetic markers like 
methylation are detectable. However, the methylated bases still resulted in false positive variant calls, 
meaning it was necessary to mask them from the variant analysis. After they were masked, up to ten 
remaining discrepancies were noted between the variants called using the two types of sequencing 
reads in the two isolates; most of these were bases called as variant in the ONT data but not the 
Illumina. It is likely these discrepancies were indeed false positives in the ONT data, due to its higher 
raw non-random error profile. In addition, to achieve almost the same variant calls with the ONT data 
as with the Illumina data, lengthy extra steps (i.e. Nanopolish methylation calling) were required.  
Variant calling with ONT data is therefore possible, and the results are almost as accurate as those 
made with Illumina data are assumed to be. At the moment, however, Illumina data remains optimal 
for this process, although repeat regions should be masked from any analysis, as they are prone to 
false positive variant calls. Nonetheless, if only ONT data was available, or if variant calls were required 
rapidly, ONT data produced with the most recent flow cells and data tools may now be sufficient.  In 
addition, the “high accuracy” mode of the Guppy basecaller, combined with the nanopore-specific 
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variant calling tools such as Clair, Longshot, NanoCaller or even Medaka, have recently been used to 
produce accurate variant calls at the single base level (Edge and Bansal, 2019; Ahsan et al., 2020; 
Gilpatrick et al., 2020; Luo et al., 2020). Future work for the B. pertussis nanopore field will therefore 
include testing these newer and more accurate tools, to establish whether single nucleotide variants 
can be called as accurately with nanopore data as with Illumina data. At the moment, the CPU-usage 
requirements of Guppy’s high accuracy mode are prohibitive, with some reports of a single MinION 
run taking several months to basecall (P. Kover, personal communication, 2020). However, high 
powered computer clusters, particularly those with GPU capabilities, should be able to basecall a 
single run in little more than a day.  
How we can use long-read sequencing to study B. pertussis, and what that can reveal 
about the genome and evolution of the bacteria 
As discussed, and as demonstrated in Chapters 2 and 3, the assembly of closed B. pertussis genomes 
using nanopore sequencing is now easily achievable. In addition, PacBio sequencing has been capable 
of the same since the mid-2010s, although this usually requires sending DNA to a sequencing service 
so could be more time-consuming or expensive (Bart, Zeddeman, et al., 2014). The vast increase in 
numbers of available closed B. pertussis sequences is allowing the investigation of genome-level 
variation in B. pertussis in a way which was not previously possible. 
The first trait to have become apparent from the study of closed B. pertussis genomes is large-scale 
genomic rearrangements. This has been thoroughly investigated and characterised at the Centers for 
Disease Control (CDC) in the USA, and it is now clear that major rearrangements, mediated by 
homologous recombination between copies of IS 481 and centred around the origin of replication, are 
occurring frequently (Weigand et al., 2017; Weigand et al., 2019). Although the existence of different 
genome structures in B. pertussis has been hypothesised for decades, based on pulsed field gel 
electrophoresis (PFGE) data, the assembly of closed genome sequences has, for the first time, 
confirmed the variety of arrangements seen, and allowed the documentation of these arrangements 
in a reproducible manner. For example, in Chapter 3 here, it was possible to compare the 
arrangements of the New Zealand isolates’ genomes with the arrangement types defined by the CDC’s 
work. This was possible because closed genome sequences can be shared far more easily than isolates, 
which would have been required for such comparisons using PFGE. Chapter 3, as well as the work by 
the CDC, raises a few questions about genomic rearrangement in B. pertussis. For example, given the 
number and location of copies of IS 481 throughout the genome, not every potential genome 
arrangement type has so far been observed, despite the study of hundreds of isolates (Weigand et al., 
2017). Additionally, certain arrangement types appear more frequently than others: in the (mainly 
USA) isolates studied by Weigand et al., the most commonly seen arrangement types were CDC237 
and CDC002, whilst amongst the Chapter 3 New Zealand isolates, the most commonly seen 
arrangement type was CDC010. This suggests rearrangement may not be an entirely random process, 
and that certain arrangement types may have a selective advantage over others. As yet, little in vivo 
work has been conducted to demonstrate any correlation between B. pertussis genome arrangement 
and phenotype. Future work may therefore address this knowledge gap although, as seen in Chapter 
4, observing and comparing phenotypes in B. pertussis is not always a straightforward task. 
Another emerging genome-level trait in B. pertussis is the duplication of relatively large regions of 
DNA. In Chapter 2, a duplication of several hundred thousand base pairs was seen in two of the five 
UK strains sequenced. In Chapter 3, a 15 kbp duplication was seen in two New Zealand strains. Both 
132 
 
of these duplications have been investigated further elsewhere, and shown to appear in a number of 
other, unrelated, strains (Abrahams et al., 2020). Duplications in the B. pertussis genome, like 
rearrangement, are the result of homologous recombination between copies of IS 481, and could 
therefore occur at random. Nonetheless, like arrangement types, certain duplications appear to be 
more frequent than others, suggesting they may convey some selective advantage. This is another 
trait which would benefit from in vivo work to investigate the phenotypes resulting from duplications; 
indeed, Chapter 4 covers attempts to investigate the phenotypes resulting from the ultra-long 
duplication identified in Chapter 2. However, one of the other observations from Abrahams et al. 
(2020), identified through the use of ultra-long nanopore reads produced for UK54 (not discussed 
here), was that both duplications and arrangements are present as mixed populations in B. pertussis. 
Within populations of cells from the same strain, some cells can contain no duplication, versions of 
the duplication starting at slightly different points in the genome, or even greater copy number 
variants (the “duplication” seen in the New Zealand strains and in UK54 appeared 60+ times in some 
cells in the UK54 population). Likewise, different cells in the population can contain different genomic 
arrangements. These fluctuating, seemingly highly dynamic, populations may help to explain why 
observing phenotypes in B. pertussis is so difficult: populations of cells from the same strain may not 
behave in exactly the same way every time they are grown, due to ongoing changes in CNVs and 
genome arrangements in individual cells in the population. Going forward, methods will need to be 
developed to account for these potential differences in populations when strains are observed in vivo. 
This may involve producing ultra-long nanopore reads for each population observed in vivo, in order 
to characterise the CNV and arrangement landscape at the time of testing, although this would 
currently be very expensive, as each ultra-long sequencing run uses a whole flow cell per strain. 
Finally, Chapter 5 adds to this emerging “mixed population” story in a slightly different way. Closed 
genome sequences allowed the identification of variation at the single base level in fhaB. Having 
observed the variation in closed sequences, a method could then be developed to screen the 
unassembled short read data for every B. pertussis strain currently available from public databases. 
The mixed populations of fhaB in B. pertussis are likely not unique: similar mixed populations of cells 
with mutations or no mutations are probably present in many other genes, particularly in regions 
prone to mutations such as homopolymeric slippage. For a bacterium once described as being “clonal” 
and having little variation between different strains, long-read sequencing is increasingly revealing 
































“Until I feared I would lose it, I never loved to read. One does not love breathing.” 
- Harper Lee, To Kill a Mockingbird 
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NZ1 SAMN12385760 NA SRR9849540 NA 
NZ2 SAMN12385761 SRR11855999 SRR9849539 CP054126 
NZ3 SAMN12385762 SRR11855998 SRR9849542 CP054125 
NZ4 SAMN12385763 SRR11855987 SRR9849541 CP054124 
NZ5 SAMN12385764 NA SRR9849536 NA 
NZ6 SAMN12385765 SRR11855976 SRR9849535 CP054123 
NZ7 SAMN12385766 SRR11855965 SRR9849538 CP054122 
NZ8 SAMN12385767 SRR11855954 SRR9849537 CP054121 
NZ9 SAMN12385768 SRR11855943 SRR9849534 CP054120 
NZ10 SAMN12385769 SRR11855939 SRR9849533 CP054119 
NZ11 SAMN12385770 SRR11855938 SRR9849531 CP054118 
NZ12 SAMN12385771 SRR11855937 SRR9849530 CP054127 
NZ13 SAMN12385772 SRR11855997 SRR9849529 CP054117 
NZ14 SAMN12385773 SRR11855996 SRR9849528 CP054116 
NZ15 SAMN12385774 SRR11855995 SRR9849573 CP054115 
NZ16 SAMN12385775 SRR11855994 SRR9849572 CP054114 
NZ17 SAMN12385776 SRR11855993 SRR9849571 CP054113 
NZ18 SAMN12385777 SRR11855992 SRR9849570 CP054112 
NZ19 SAMN12385778 SRR11855991 SRR9849569 CP054111 
NZ20 SAMN12385779 SRR11855990 SRR9849568 CP054110 
NZ21 SAMN12385780 SRR11855989 SRR9849555 CP054109 
NZ22 SAMN12385781 SRR11855988 SRR9849556 CP054108 
NZ23 SAMN12385782 SRR11855986 SRR9849553 CP054107 
NZ24 SAMN12385783 SRR11855985 SRR9849554 CP054106 
NZ25 SAMN12385784 SRR11855984 SRR9849551 CP054105 
NZ26 SAMN12385785 SRR11855983 SRR9849552 CP054104 
NZ27 SAMN12385786 SRR11855982 SRR9849549 CP054103 
NZ28 SAMN12385787 SRR11855981 SRR9849550 CP054102 
NZ29 SAMN12385788 NA SRR9849557 NA 
NZ30 SAMN12385789 SRR11855980 SRR9849558 CP054101 
NZ31 SAMN12385790 SRR11855979 SRR9849567 CP054100 
NZ32 SAMN12385791 SRR11855978 SRR9849566 CP054099 
NZ33 SAMN12385792 SRR11855977 SRR9849560 CP054098 
NZ34 SAMN12385793 SRR11855975 SRR9849559 CP054097 
NZ35 SAMN12385794 SRR11855974 SRR9849563 CP054096 
NZ36 SAMN12385795 SRR11855973 SRR9849562 CP054095 
NZ37 SAMN12385796 SRR11855972 SRR9849565 CP054094 
NZ38 SAMN12385797 SRR11855971 SRR9849564 CP054093 
NZ39 SAMN12385798 SRR11855970 SRR9849532 CP054092 
NZ40 SAMN12385799 SRR11855969 SRR9849561 CP054091 
NZ41 SAMN12385800 SRR11855968 SRR9849545 CP054090 
NZ42 SAMN12385801 SRR11855967 SRR9849546 CP054089 
NZ43 SAMN12385802 SRR11855966 SRR9849547 CP054088 
NZ44 SAMN12385803 SRR11855964 SRR9849548 CP054087 
NZ45 SAMN12585513 SRR11855963 SRR9974535 CP054086 
NZ46 SAMN12585514 SRR11855962 SRR9974536 CP054085 
NZ47 SAMN12385804 SRR11855961 SRR9849543 CP054084 
NZ48 SAMN12585515 SRR11855960 SRR9974533 CP054083 
NZ49 SAMN12585516 SRR11855959 SRR9974534 CP054082 
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NZ50 SAMN12585517 SRR11855958 SRR9974531 CP054081 
NZ51 SAMN12585518 SRR11855957 SRR9974532 CP054080 
NZ52 SAMN12585519 SRR11855956 SRR9974529 CP054079 
NZ53 SAMN12585520 SRR11855955 SRR9974530 CP054078 
NZ54 SAMN12585521 SRR11855953 SRR9974527 CP054077 
NZ55 SAMN12585522 SRR11855952 SRR9974528 CP054076 
NZ56 SAMN12585523 SRR11855951 SRR9974523 CP054075 
NZ57 SAMN12385805 SRR11855950 SRR9849544 CP054074 
NZ58 SAMN12585524 SRR11855949 SRR9974524 CP054073 
NZ59 SAMN12585525 SRR11855948 SRR9974521 CP054072 
NZ60 SAMN12585526 SRR11855947 SRR9974522 CP054071 
NZ61 SAMN12585527 SRR11855946 SRR9974519 CP054070 
NZ62 SAMN12585528 SRR11855945 SRR9974520 CP054069 
NZ63 SAMN12585529 SRR11855944 SRR9974517 CP054068 
NZ64 SAMN12585530 SRR11855942 SRR9974518 CP054067 
NZ65 SAMN12585531 SRR11855941 SRR9974525 CP054066 







Table S3.2: Immunisation coverage for New Zealand children aged 6 months to 5 years, from 2009 to 2017 
 % fully immunised for age*  
Year 6 months 12 months 18 months 24 months 5 years 
2009  67 85 74 83 - 
2010 70 92 82 90 72 
2011 71 90 82 91 79 
2012 74 91 81 91 81 
2013 77 93 84 92 77 
2014 79 94 85 93 81 
2015 80.4 94.1 85.7 92.8 82.8 
2016 80.6 94.2 85.8 92.8 87 
2017 78.7 94.1 87.8 92.4 88.6 















Table S3.3: Whooping cough incidence in NZ, England and Wales, and the USA, from 2000-2019 
Year Cases per 100,000 
(NZ)1 
Cases per 100,000  
(England and Wales)2,3 
Cases per 100,000 
(USA)2,3 
2000* 110.8 1.4 2.8 
2001 35.7 1.7 2.8 
2002 28.7 1.7 3.4 
2003 15.7 0.8 4 
2004* 93.4 0.9 8.8 
2005* 66.3 1.1 8.7 
2006* 27.1 1.1 5.3 
2007 7.9 2.1 3.5 
2008 10.1 2.8 4.4 
2009 32.4 2.2 5.5 
2010 20 0.7 8.9 
2011* 45.3 1.5 6 
2012* 133.1 11.6 15.2 
2013* 79.7 5.5 9 
2014 25.1 4.2 10.3 
2015 25.4 4.9 6.5 
2016 23.4 7.5 5.6 
2017 44.8 5.4 5.8 
2018† 61.4 4.3 4.8 
2019 24.5 6.6 4.8 
* denotes an epidemic period in New Zealand 
† preliminary data available from the ESR, but not for England/Wales or USA 
1 Annual notifiable disease summaries (ESR):    https://surv.esr.cri.nz/surveillance/annual_surveillance.php  
2 Laboratory confirmed cases of pertussis in England (PHE): 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_da
ta/file/881410/Laboratory_confirmed_cases_of_pertussis_in_England_2019.pdf 
3 England mid-year population estimate: 
https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/population
estimates/timeseries/enpop/pop 
4 USA whooping cough surveillance reports 2012-2019 (CDC):   https://www.cdc.gov/pertussis/surv-
reporting.html 
Incidence 2000-2011 estimated from Pertussis cases by year (1922-2016), using Google population stats for 
each year: 
https://www.cdc.gov/pertussis/surv-reporting/cases-by-year.html   
  
 
Table S3.4: Incidence across different age groups in New Zealand in three different time periods 
 Age group  
<1 year 1-4 years 5-9 years 10-14 years 15-19 years 20+ years 
1999-2000 460 180 190 90 20 10 
2008-2009 176.4 58.9 48.7 31.8 37.2 24.37 






Figure S3.1 Coverage plots for New Zealand strains 2, 3, 4, 6, 7, 8, 9, 10. Produced by aligning Illumina 




Figure S3.2 Coverage plots for New Zealand strains 11, 12, 13, 14, 15, 16, 17 and 18. Produced by aligning 




Figure S3.3 Coverage plots for New Zealand strains 19, 20, 21, 22, 23, 24, 25 and 26. Produced by aligning 




Figure S3.4 Coverage plots for New Zealand strains 27, 28, 30, 31, 32, 33, 34 and 35. Produced by aligning 




Figure S3.5 Coverage plots for New Zealand strains 36, 37, 38, 39, 40, 41, 42 and 43. Produced by aligning 




Figure S3.6 Coverage plots for New Zealand strains 44, 45, 46, 47, 48, 49, 50 and 51. Produced by aligning 




Figure S3.7 Coverage plots for New Zealand strains 52, 53, 54, 55, 56, 57, 58 and 59. Produced by aligning 




Figure S3.8 Coverage plots for New Zealand strains 60, 61, 62, 63, 64, 65 and 66. Produced by aligning 
Illumina reads to the Tohama I reference genome 
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Table S3.5 Full details of the “RD3” region which has been deleted from the genomes of all New Zealand 
strains 
Locus in Reference Locus tag Gene 
947116-948066 BP0910 Transposase for IS481 
948154-948141 BP0911 decarboxylase 
948879-949878 BP0912 pseudogene 
949983-950957 BP0913 exported protein 
950977-951849 BP0914 
binding-protein-dependent transport system inner 
membrane protein 
951846-952673 BP0915 
binding-protein-dependent transport system inner 
membrane protein 
952697-953476 BP0916 pseudogene 
953576-954997 BP0918 hypothetical protein 
955102-956556 BP0919 gabD 
956606-958009 BP0920 tricarballylate dehydrogenase 
958030-959214 BP0921 citB 
959257-960432 BP0922 hypothetical protein 
960603-961418 BP0923 hypothetical protein 
961460-962356 BP0924 transcriptional regulator 
962411-963271 BP0925 fumarylacetoacetate family hydrolase 
963349-964422 BP0926 hypothetical protein 
964548-965522 BP0927 exported protein 
965661-966650 BP0928 LysR family transcriptional regulator 
966675-967250 BP0929 membrane protein 
967344-969002 BP0930 CoA ligase 
969014-969997 BP0931 exported protein 
970002-970424 BP0932 hypothetical protein 
970428-971616 BP0933 pseudogene 
971671-972030 BP0934 hypothetical protein 
972065-973039 BP0935 exported protein 
973185-974075 BP0936 LysR family transcriptional regulator 
974352-974744 BP0937 phage-like protein 
974874-975824 BP0938 Transposase for IS481 
 
 Table S3.5 Full details of the “RD2” region which has been deleted from the genomes of all New Zealand 
strains 
Locus in Reference Locus tag Gene 
1196854-1197804 BP1134 Transposase for IS481 
1197773-1197804 BP1135 tauD 
1198526-1199059 BP1136 fecI 
1199052-1200014 BP1137 fecR 
1200108-1202585 BP1138 bfrH 
1202702-1203010 BP1139 iron uptake protein 
1203007-1204650 BP1140 pseudogene 
1204655-1204981 BP1141 iron uptake protein 




Table S3.7 Full details of the “RD4” region which has been deleted from the genomes of many B. pertussis 
isolates since the late 1990s. 
Locus in Reference Locus tag Gene 
2049605-2050555 BP1947 Transposase for IS 481 element 
2050602-2051810 BP1948 Branched-chain amino acid-binding protein 
2051902-2053851 BP1949 branched-chain amino acid transport system permease 
2053848-2054624 BP1950 ABC transporter ATP-binding protein 
2054621-2055391 BP1951 ABC transporter ATP-binding protein 
2055546-2057838 BP1952 pseudogene 
2057835-2058356 BP1953 oxidoreductase 
2058433-2059584 BP1954 monooxygenase 
2059885-2060637 BP1955 maiA 
2060657-2061476 BP1956 pseudogene 
2061504-2062535 BP1957 hypothetical protein 
2062551-2063168 BP1958 isochorismatase 
2063175-2064405 BP1959 Transposase for IS 1663 element 
2064490-2066393 BP1960 pseudogene 
2066515-2067855 BP1961 flavocytochrome 
2067866-2069974 BP1962 bfrI 
2070108-2070635 BP1963 pseudogene 
2070729-2071694 BP1965 exported protein 
2071711-2073276 BP1966 pseudogene 
2073298-2074349 BP1968 Transposase for IS 481 element 
 
Table S3.8 Full details of the 14.3 kbp region found to be duplicated in the genomes of NZ35 and NZ36 
Locus in Reference Locus tag Gene 
1818813-1819763 BP1735 Transposase for IS481 
1819912-1820250 BP1736 exported protein 
1820308-1820469 BP1737 membrane protein 
1820501-1820701 BP1738 hypothetical protein 
1820967-1823540 BP1739 cphA 
1823611-1826184 BP1740 cphA 
1826575-1828714 BP1741 pseudogene 
1828711-1829199 BP1743 hypothetical protein 
1829291-1839421 BP1744 hypothetical protein 
1830496-1831317 BP1745 exported protein 
1831356-1832585 BP1746 peptidoglycan-binding protein 
1832714-1833154 BP1747 hypothetical protein 
1833265-1834215 BP1748 Transposase for IS481 
 
Supplementary tables S3.9, S3.10, S3.11, S3.12 and S3.13  
The remaining supplementary data from Chapter 3, “Comparative genomics of Bordetella pertussis 
isolates from New Zealand, a country with uncommonly high incidence of whooping cough”, can be 





Supplementary table S4.1  
Supplementary data from Chapter 4, “Chapter 4:  Investigating potential phenotypes resulting from 
a common, ultra-long, genomic duplication”, can be downloaded from:  





Supplementary tables S5.1, S5.2, S5.3, S5.4 and S5.5  
Supplementary data from Chapter 5, “Closed Bordetella pertussis genomes uncover changes to 
Filamentous Haemagglutinin gene”, can be downloaded from:  
https://figshare.com/s/e0585f38926b02239be9  
 
 
 
 
